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I Abstract 
Carbonyl reduction of aldehydes, ketones and quinones to their corresponding hydroxy de-
rivatives plays an important role in the phase-I metabolism of many endogenous (biogenic 
aldehydes, steroids, prostaglandins, reactive lipid peroxidation products) and xenobiotic 
(pharmacologic drugs, carcinogens, toxicants) compounds. Carbonyl-reducing enzymes are 
grouped into two large protein superfamilies, the aldo-keto reductases (AKR) and the short-
chain dehydrogenases/reductases (SDR). Whereas aldehyde reductase and aldose reductase 
are AKRs, several forms of carbonyl reductase belong to the SDRs. In addition, there exist a 
variety of pluripotent hydroxysteroid dehydrogenases (HSDs) of both superfamilies which 
specifically catalyze the oxidoreduction at different positions of the steroid nucleus, and 
which also catalyze rather non-specifically the reductive metabolism of a great number of 
non-steroidal carbonyl compounds. The present review summarizes recent findings on car-
bonyl reductases and pluripotent HSDs of the SDR protein superfamily. 
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II Introduction 
II.1  Carbonyl Reduction 
Metabolic reduction is the counterpart to oxidative pathways and plays an important role in 
the phase-I metabolism of carbonyl group bearing substances. Carbonyl reduction means the 
formation of a hydroxy group from a reactive aldehyde or ketone moiety and is generally re-
garded as an inactivation or detoxification step since the resulting alcohol is easier to conju-
gate and to eliminate. Not only are these carbonyl-containing compounds widespread in the 
environment and enter the body as xenobiotics and environmental pollutants, but they can 
also be generated endogenously through normal catabolic oxidation and deamination reac-
tions. Many endogenous compounds such as biogenic amines, steroids, prostaglandins and 
other hormones are metabolized through carbonyl intermediates (Felsted and Bachur, 1980; 
Forrest and Gonzalez, 2000). In addition, lipid peroxidation within the cell results in the pro-
duction of reactive carbonyls such as acrolein, 4-hydroxynonenal, 4-oxononenal and malon-
dialdehyde, while oxidative damage to DNA generates base propenals (Esterbauer et al., 
1982). Dietary sources of carbonyl-containing compounds are diverse and include aldehydes 
found in fruits as well as the breakdown product of ethanol, acetaldehyde  (Ellis and Hayes, 
1995; Maser and Oppermann, 1997). Pharmacologic drugs represent further sources of expo-
sure to carbonyl-containing compounds (Maser, 1995; Rosemond and Walsh, 2004) (cf. chap-
ter 4.5).  
 
From the pharmacologist’s point of view, carbonyl reduction has been shown to be of signifi-
cance in various inactivation processes of drugs bearing a carbonyl group. On the other hand, 
the carbinols formed may retain therapeutic potency, thus prolonging the pharmacodynamic 
effect of the parent drug, or, in some instances, a compound gains activity through carbonyl 
reduction. 
 
From the toxicologist’s point of view, carbonyl reduction plays an important role in the toxi-
fication of drugs such as daunorubicin and doxorubicin (cf. chapter 4), whereas numerous 
reports corroborate the concept of carbonyl-reducing enzymes being involved in detoxifica-
tion processes of endogenous and xenobiotic reactive carbonyl compounds. 
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Compared with the oxidative cytochrome P450 (CYP) system, carbonyl-reducing enzymes 
had, for a long time, received considerably less attention. However, the advancement of car-
bonyl reductase molecular biology has allowed the identification and characterization of sev-
eral carbonyl-reducing enzymes, including pluripotent hydroxysteroid dehydrogenases that 
are involved in xenobiotic carbonyl compound metabolism, in addition to catalyzing the oxi-
doreduction of their physiologic steroid substrates [reviewed in (Maser, 1995)]. 
 
II.2  Enzymes Mediating Carbonyl Reduction 
Enzymes catalyzing the reductive metabolism of carbonyl compounds are ubiquitous in na-
ture, but the majority of the research work was performed in mammalian cells and tissues. 
Carbonyl-reducing enzymes have been reported in a variety of non-mammalian organisms, 
such as plants (Baker and Agard, 1994), bacteria (Zelinski et al., 1994; Oppermann and Ma-
ser, 1996; Oppermann et al., 1998), yeast (Peters et al., 1993; Wada et al., 1998), fish and 
insects (Oppermann et al., 1998). In mammals, these enzymes have been analyzed in more 
detail, amongst others, in rabbit (Ahmed et al., 1978; Ahmed et al., 1979; Sawada et al., 
1979; Felsted and Bachur, 1980; Imamura et al., 1993), rat (Ahmed et al., 1978; Hara et al., 
1987), mouse (Ahmed et al., 1978; Nakayama et al., 1986; Iwata et al., 1990a), guinea pig 
(Sawada et al., 1979; Nakayama et al., 1986), monkey (Lee and Levine, 1974a; Iwata et al., 
1990a), chicken (Lee and Levine, 1974b; Cagen et al., 1979), pig (Tanaka et al., 1992), dog 
(Hara et al., 1986b; Iwata et al., 1990a) and  bovine species (Iwata et al., 1990a). 
 
Human carbonyl-reducing enzymes occur in many different tissues like liver (Ahmed et al., 
1979; Sawada and Hara, 1979; Sawada et al., 1979; Felsted and Bachur, 1980; Hara et al., 
1986b), lung (Nakayama et al., 1986; Nakanishi et al., 1995), heart (Imamura et al., 1999a; 
Imamura et al., 1999b), kidney (Higuchi et al., 1993; Imamura et al., 1993), brain (Wermuth, 
1981; Cromlish et al., 1985; Iwata et al., 1989; Iwata et al., 1990b; Inazu et al., 1992b; 
Wermuth et al., 1995), ovary (Iwata et al., 1989; Aoki et al., 1997; Guan et al., 1999), and 
adrenal (Oppermann et al., 1991; Maser et al., 1992) and are known to exhibit broad substrate 
specificities for xenobiotic aldehydes and ketones as well as for physiological carbonyl com-
pounds such as biogenic aldehydes (Smolen and Anderson, 1976), prostaglandins (Hayashi et 
al., 1989; Inazu and Satoh, 1994), and steroid hormones (Pietruszko and Chen, 1976; Ikeda et 
al., 1984; Maser, 1995).  
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The difference in tissue and intracellular distribution suggests that several enzymes may be 
involved in the enzymatic reduction of carbonyl compounds and that the intracellular multi-
plicity of the enzymes may have some relation to their physiological function. Since the early 
seventies, a multitude of carbonyl-reducing enzymes has been purified and characterized in 
terms of substrate specificity and kinetic constants (Fig.1). While lots of data on these en-
zymes were accumulating, it was speculated that several of these enzymes are in fact identical 
to one another. On the basis of their primary structure, three of these enzymes were classified 
as aldehyde reductase (EC 1.1.1.2), aldose reductase (EC 1.1.1.21) (Bohren et al., 1989) and 
carbonyl reductase (EC 1.1.1.184) (Wermuth et al., 1988) (Fig. II-1) . As proposed by the 
scientific community working in this field, these enzyme names were adopted in the Interna-
tional Enzyme Nomenclature System and received their respective EC number. In addition, it 
turned out that there exist several isoforms of dihydrodiol dehydrogenase, which, initially, 
were summarized under EC 1.3.1.20. An interesting observation was that several hydroxys-
teroid dehydrogenases (HSDs) specifically catalyze the oxidoreduction at different positions 
of the steroid nucleus on the one hand, but on the other hand rather non-specifically catalyze 
the reductive metabolism of a great variety of non-steroidal xenobiotic carbonyl compounds. 
This was also true for the dihydrodiol dehydrogenases which were later shown to be HSDs 
(cf. chapter 1.2.2 of this review) (Ratnam et al., 1999). 
 
 alcohol: NADP+-oxidoreductase
 high Km aldehyde reductase
 mevaldate reductase
 daunorubicin-pH 8.5 reductase
 hexonate dehydrogenase
 lactaldehyde reductase
 glucuronate reductase
 ALR 1
 alditol: NADP+-oxidoreductase
 low Km aldehyde reductase
 ALR 2
 NADPH: sec.-alcohol oxidoreductase
 prostaglandin 9-ketoreductase
 daunorubicin-pH 6.0 reductase
 ALR 3
 several isoforms of dihydrodiol
dehydrogenases and/or
 several HSDs specified according to
carbon atom involved in catalysis
aldehyde reductase
(EC 1.1.1.2)
carbonyl reductase
(EC 1.1.1.184)
hydroxysteroid dehydrogenases
(AKR1C family)
hydroxysteroid dehydrogenases
(EC 1.1.1.xx)
aldose reductase
(EC 1.1.1.21)
AKR
AKR
AKR
SDR
SDR
 
Fig. II-1: Multiplicity of enzymes involved in carbonyl reduction 
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Sequence comparisons and data base searches revealed that the enzymes mediating carbonyl 
reduction obviously belong to two large protein superfamilies. Whereas aldehyde reductase 
and aldose reductase belong to the aldo-keto reductases (AKR) (Jez et al., 1997a), carbonyl 
reductase turned out to be a member of the short-chain dehydrogenases/reductases (SDR) 
(Jornvall et al., 1995). The situation is not so clear-cut with the HSDs, since they were shown 
to belong to either the AKR or SDR superfamily. Until now, several of these pluripotent 
HSDs have been described. The coincident ability of these pluripotent enzymes to metabolize 
endogenous steroids and to reduce xenobiotic carbonyl compounds has evidently been in-
vented twice and subsequently been conserved during evolution in these two different protein 
superfamilies, corresponding to the principle of convergent evolution (reviewed in (Maser, 
1995)). At present, 12  different pluripotent carbonyl-reducing enzymes belonging to the 
AKR and SDR protein superfamilies are known in humans (Matsunaga et al., 2006). 
 
Sequence comparison, chemical modification and site-directed mutagenesis studies, combined 
with crystallographic analyses and bioinformatic data, led to the identification of important 
structural features and consensus sequences of these enzymes (see below). 
 
 
1.1 The Aldo-Keto Reductase (AKR) Superfamily  
The aldo-keto reductase (AKR) superfamily represents a growing superfamily of NADP(H)-
dependent oxidoreductases, which accept many structurally different substrates of endoge-
nous and exogenous origin. This protein superfamily includes, amongst others, aldose reduc-
tase (EC 1.1.1.21), aldehyde reductase (EC 1.1.1.2) and several HSDs (EC 1.1.1.x), some of 
which have previously been designated dihydrodiol dehydrogenases (EC 1.3.1.20) (Jez et al., 
1997b). These enzymes are monomeric (/)8-barrel proteins, about 320 amino acids in 
length, which bind their cosubstrate without a Rossmann-fold motif (Jez et al., 1997b). The 
active site of the AKR members contains a conserved tetrad of the amino acids Tyr, His, Asp 
and Lys. Found in almost every living organism, the AKRs metabolize steroids, sugars, pros-
taglandins, polycyclic aromatic hydrocarbons, and a great variety of non-steroidal aldehydes 
and ketones. 
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The broad substrate specificity of some AKR proteins has led to some ambiguities, e.g. the 
indomethacin-sensitive cytosolic rat liver 3-HSD has previously also been described as di-
hydrodiol dehydrogenase, chlordecone reductase, or bile acid binding protein. To address 
these issues, a new nomenclature system for the AKR superfamily has been established (Jez 
et al., 1997b). Based on amino acid sequence identities of the different AKR members, the 
superfamily currently comprises 14 families: AKR1 – AKR14. Mammalian AKRs are found 
predominantly in the AKR1 and AKR7 families, whereas members of the AKR2 – AKR5 and 
AKR8 – AKR14 families have been identified in plants, yeast and bacteria. The AKR6 family 
is formed by the β-subunit of the Shaker-related voltage-gated K+-channel. An excellent 
source of more information is available on the AKR superfamily homepage 
(www.med.upenn.edu/akr) which has been created by TM Penning and coworkers. Many of 
the mammalian AKRs are potential therapeutic targets, and structure-based drug design may 
lead to compounds with the desired specificity and clinical efficacy.  
 
 
1.2 Short-Chain Dehydrogenase/Reductase (SDR) Superfamily 
The second superfamily to which carbonyl-reducing enzymes belong, the short-chain dehy-
drogenases/reductases (SDR), comprises a wide range of procaryotic and eukaryotic enzymes 
involved in functions as diverse as the metabolism of steroids, sugars, aromatic hydrocarbons 
and prostaglandins, the fixation of nitrogen and the synthesis of antibiotics (Persson et al., 
1991; Jornvall et al., 1995). The superfamily is made up of enzymes averaging 250 – 350 
amino acids in length which function independently of metal cofactors, and its members are 
readily distinguishable from those of the medium-chain and long-chain alcohol dehydro-
genase superfamilies (Persson et al., 1991; Jornvall et al., 1995). Among the members of the 
various families and subfamilies of the SDRs, there are no structural similarities to the AKR 
proteins in spite of overlapping substrate specificities (Flynn and Green, 1993; Maser, 1995). 
 
They exist as soluble or, in some cases, membrane-bound proteins, mostly homodimers or 
homotetramers (Ghosh et al., 1994b; Ghosh et al., 1995; Tanaka et al., 1996a; Tanaka et al., 
1996b; Benach et al., 1998). All SDR proteins share well-conserved primary structure ele-
ments that are restricted to certain segments in the sequence, indicating a possibly common 
fold, active site, reaction mechanism, and cosubstrate and substrate binding regions (Persson 
et al., 1991; Jornvall et al., 1995). Analysis of the three-dimensional structure of the SDRs 
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characterized so far shows that both NAD(H) and NADP(H) bind to the classical βαβ motif of 
the Rossmann fold which is characteristic of the coenzyme-binding domain of many other 
dehydrogenases (Duax et al., 2000). It depends on their predominant function as a dehydro-
genase or reductase whether they use either NAD(P) or NAD(P)H as cosubstrate (cf. chap-
ter 2.3.3 of this review).  
 
The SDRs comprise a large and highly divergent superfamily with about 3000 known forms, 
including species variants (Persson et al., 2003). They share a residue identity of typically 15-
30% in pairwise comparison (Kallberg et al., 2002a), indicating early duplicatory origins and 
extensive divergence (Jornvall et al., 1995). Nevertheless, the folding pattern of the members 
whose structures have been solved so far is conserved with largely superimposable peptide 
backbones (Krook et al., 1993b; Ghosh et al., 2001).  
 
The SDRs have initially been subdivided into two large families, the "classical" with 250-odd 
residues and the "extended" with 350-odd residues (Jörnvall et al., 1995). Based on patterns 
of charged residues in the cosubstrate-binding region, these families have recently been clas-
sified in seven subfamilies of “classical” SDRs and three subfamilies of “extended” SDRs. 
Three further families are novel entities, denoted "intermediate", "divergent" and "complex", 
encompassing short-chain alcohol dehydrogenases, enoyl reductases and multifunctional en-
zymes, respectively (Persson et al., 2003). 
 
One of the most important physiological functions of the SDR enzymes appears to be the 
conversion of signalling molecules to either the active or inactive state (Krozowski, 1992).  
 
II.3  Hydroxysteroid Dehydrogenases as Carbonyl Reductases 
Hydroxysteroid dehydrogenases (HSDs) are pyridine nucleotide-dependent oxidoreductases 
which mediate the interconversion of secondary alcohols and ketones. They play pivotal roles 
in the biosynthesis and inactivation of steroid hormones. Steroid hormones act by binding to 
receptor proteins in target cells, which leads to transcriptional regulation of different gene 
products and the desired physiological response. In target tissues, HSDs convert potent steroid 
hormones to their cognate inactive metabolites (and vice versa) and thus regulate the occu-
pancy of steroid hormone receptors (Penning et al., 1997; Duax et al., 2000). The reactions 
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they catalyze are position- and stereospecific and usually involve the interconversion of a car-
bonyl and a hydroxyl group on either the steroid nucleus or side chain. In normal cell physi-
ology, HSDs therefore function as important prereceptor regulators of signalling pathways by 
acting as ”molecular switches” for receptor-active and receptor-inactive hormone (Monder 
and White, 1993; Penning et al., 1996; Labrie et al., 1997). Because the enzymes have much 
greater tissue specificity than the receptors, they have emerged as attractive targets for the 
design of potent and selective drugs that combat steroid-related disorders. HSDs are found in 
every organism investigated so far. 
 
Interestingly, several HSDs exhibit other activities besides steroid oxidoreduction. In addition 
to being specific for their physiological steroid substrate, they can catalyze the carbonyl re-
duction of a great variety of non-steroidal aldehydes, ketones and quinones  (reviewed in 
(Maser, 1995). Accordingly, HSDs participate in drug metabolism and play a significant role 
in the defence of an organism against the deleterious effects of endogenous and exogenous 
toxicants. Due to the fact that several enzymes of both superfamilies exhibit pluripotency for 
steroidal and non-steroidal carbonyl substrates (Maser, 1995), AKR and SDR seem to be the 
result of a convergent evolution. 
 
Extensively characterized HSDs with carbonyl-reducing activity of the AKR superfamily are 
3-HSD (mammalian), 17β-HSD (mammalian) and 20-HSD (mammalian and protozoan) 
[reviewed in (Maser, 1995; Matsunaga et al., 2006)]. These HSDs are now classified within 
the AKR1C-subfamily. Extensively characterized HSDs with carbonyl-reducing activity of 
the SDR superfamily are 3-HSD (bacterial), 3/20β-HSD (mammalian and bacterial) and 
11β-HSD (mammalian) [reviewed in (Maser, 1995; Matsunaga et al., 2006)].  
  
The sections below include recent findings on pluripotent HSDs/carbonyl reductases of the 
SDR protein superfamily. 
General Features of the SDR Superfamily Enzymes 13
III General Features of the SDR Superfamily Enzymes 
III.1  Historical Background: Functional Characterization 
Carbonyl reductases of the SDR superfamily accept some of the same substrates as do other 
carbonyl-reducing enzymes from the AKR superfamily  (Wermuth et al., 1982). SDR car-
bonyl reductases do also metabolize aromatic ketones and quinones (Wermuth, 1982). In gen-
eral, the metabolism of a broad spectrum of xenobiotic substrates results in their detoxifica-
tion or inactivation, since the chemically more reactive carbonyl compounds (aldehyde or 
ketone) have been converted to less reactive and less lipophilic hydroxy intermediates that are 
easier to conjugate and to eliminate (Felsted and Bachur, 1980; Wermuth, 1985; Wermuth et 
al., 1986; Atalla and Maser, 1999). 
 
Human carbonyl reductase (CBR1) had been supposed to be involved in prostaglandin and 
steroid metabolism in some tissues (Lee and Levine, 1974a; Felsted and Bachur, 1980; Wer-
muth, 1981). Later, Wermuth (Wermuth et al., 1986) and Schieber (Schieber et al., 1992) 
showed that, due to high non-physiological Km values and low turnover numbers of the en-
zyme, as well as due to low tissue concentrations of the prostaglandin or steroid substrates, 
these compounds can at best be only poor endogenous substrates. In contrast, quinones from 
polycyclic aromatic hydrocarbons were much better substrates than prostaglandins or steroids 
(Wermuth et al., 1986). The best substrates for human CBR1 comprise K region ortho-
quinones of polycyclic aromatic hydrocarbons such as benzo[a]anthracene and 
benzo[a]pyrene (Wermuth et al., 1986). Menadione and 9,10-phenanthrenequinone are excel-
lent carbonyl reductase substrates, and menadione is often used as a model quinone substrate 
(Wermuth et al., 1986). 
 
Previously, it was suggested that carbonyl reductases could be divided into two groups with 
respect to their substrate specificity for endogenous prostaglandins and steroids (Ohara et al., 
1995). The first group, the carbonyl reductases of human tissues (Wermuth, 1981; Schieber et 
al., 1992), pig kidney (Wermuth, 1981; Schieber et al., 1992), and rat ovary (Iwata et al., 
1989) have been demonstrated or suggested to be identical to prostaglandin 9-ketoreductase 
or NADP+-dependent 15-hydroxyprostaglandin dehydrogenase. The second group comprised 
hepatic carbonyl reductases of rats (Penning et al., 1984), rabbits (Sawada et al., 1980; 
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Fischer et al., 1985), guinea pigs (Hara et al., 1986a) and mice (Sawada et al., 1988). This 
group did also possess 3α- or 17β-hydroxysteroid dehydrogenase and dihydrodiol 
dehydrogenase (DDH) (EC 1.3.1.20) activities and the individual enzymes have been thought 
to be identical to hydroxysteroid dehydrogenases and/or DDHs (Ohara et al., 1995). As 
pointed out above, these enzymes are today classified as members of the AKR superfamily 
where they constitute the AKR1C subfamily (Hyndman et al., 2003; Penning, 2005; Matsu-
naga et al., 2006).  
 
Lacking molecular tools, inhibitors have been used to characterize and to differentiate the 
multiplicity of carbonyl-reducing enzymes. As inhibitors for carbonyl reductases, flavonoids 
such as rutin, quercetin or quercitrin (Ahmed et al., 1979; Sawada and Hara, 1979; Sawada et 
al., 1979; Felsted and Bachur, 1980) have been used. In contrast, phenobarbital served as a 
diagnostic inhibitor of aldehyde reductase (Felsted and Bachur, 1980). Other inhibitors that 
have been identified for two carbonyl reductases from rat ovary were indomethacin, fu-
rosemide and disulfiram (Iwata et al., 1989).  
 
III.2  SDR Superfamily Classification 
The superfamily of short-chain dehydrogenases/reductases (SDR) includes members of great 
functional diversity, with sequence homologies of only 15-30%, but with very conserved spe-
cific sequence motifs as well as highly conserved folding patterns. The SDR superfamily was 
established in 1981 (Jornvall et al., 1981). At that time, only two members were known to 
belong to this family, prokaryotic ribitol dehydrogenase and an insect alcohol dehydrogenase. 
Today, the SDR superfamily consists of more than 3000 members which cover a wide sub-
strate spectrum including alcohols, sugars, steroids, prostaglandins, aromatic compounds and 
xenobiotics (Persson et al., 2003). Their general primary structure is composed of a cofactor-
binding region at the N-terminal part, a catalytic active site in the central part, a substrate-
binding region, and a C-terminal extension important for oligomerization. Despite the low 
sequence identity, their three-dimensional structures superimpose very well, except for the C-
terminal region, where the diversity between the SDR proteins is much higher (Persson et al., 
2003).  
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Initially, the SDR superfamily had been divided into 2 families, the “classical” and the “ex-
tended” SDRs. Classical SDRs consist of one-domain subunits of about 250 residues, whereas 
members of the “extended” SDR family consist of one-domain subunits of about 350 resi-
dues. Members of both families catalyze NAD(P)(H)-dependent oxidation/reduction reac-
tions. Persson and coworkers (Persson et al., 2003) further characterized the two families. The 
“extended” and “classical” families within the SDR superfamily differ, amongst others, in the 
glycine-rich pattern of the cofactor-binding region (Jornvall et al., 1995). The three glycine 
residues are characteristic for NAD(P)H-binding and are spaced differently in the two fami-
lies (Jornvall et al., 1981; Jornvall et al., 1999; Persson et al., 2003). Further differences occur 
in the motif positioned close to strand β4, which is less conserved among “extended” SDRs 
than among “classical” SDRs, as well as in the residues adjacent to the active site, a fact 
which has been described in more detail in (Persson et al., 2003). 
 
Persson and coworkers (Persson et al., 2003) used a trained hidden Markov model (Karplus et 
al., 1998; Karplus et al., 2005) which was based on a multiple sequence alignment with 
known SDRs as seed sequences to search the databases Swissprot (Apweiler et al., 2000; Bai-
roch and Apweiler, 2000) and KIND (Kallberg and Persson, 1999) for further members of the 
SDR superfamily. They found that the SDR superfamily can be clustered into five instead of 
two families, namely the “intermediate”, “divergent” and “complex” families, in addition to 
the already established “classical” and “extended” families. The overall features of these five 
families of the SDR superfamily are summarized in (Table III-1). The carbonyl reductases 
which we focus on in this article belong to the family of “classical” SDRs.  
 
Carbonyl reductases which belong to the group of “classical” SDRs reduce aldehydes and 
keto groups of prostaglandins, steroids, pterins, and quinones derived from polycyclic aro-
matic hydrocarbons. In addition, many keto drugs as well as the aliphatic keto side chain of 
the anthracycline anticancer drugs daunorubicin and doxorubicin are reduced (Bachur, 1976; 
Ahmed et al., 1978; Ahmed et al., 1981; Felsted and Bachur, 1982).   
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family 
 
feature 
Divergent Classical Intermediate Extended Complex 
Monomer size  ~ 250 residues ~ 250 residues ~ 350 residues  
Cofactors NADH NAD(P)(H)  NAD(P)(H) NADP(H) 
Catalytic reaction  Oxidation/reduction   Beta-ketoacyl reduction 
Cofactor binding GxxxxxSxA (in bacteria) TGxxxGhG G/AxxGxxG/A TGxxGhaG  
Coenzyme bind-
ing N-terminal N-terminal N-terminal N-terminal N-terminal 
Active site YxxMxxxK YxxxK   YxxxN 
Substrate binding C-terminal C-terminal C-terminal C-terminal C-terminal 
Sequence identity 
(according to 
swissprot) 
28-99% 8-99% 27-99% 10-99% 20-74% 
Examples 
Enoyl reductases 
from bacteria and 
plants 
Oxidoreductases (EC1.-.-.-), 
steroid dehydrogenases 
(including  11β-HSD1, 11β-
HSD2, 3α-HSD/CR, 3α/20β-
HSD), carbonyl reductases 
(including human CBR1 and 
CBR3)  
Drosophila 
alcohol dehydro-
genase 
Isomerases  
(EC 5.-.-.-, galac-
tose, epimerases) ; 
lyases (EC 4.-.-.- , 
glucose dehydrata-
ses) 
oxidoreductases 
Parts of multifunc-
tional enzyme 
complexes (fatty 
acid synthase) 
Table III-1: Features of the five families within the SDR superfamily according to Persson and coworkers 
(Kallberg et al., 2002b; Persson et al., 2003).  
Each of the five SDR families contain conserved sequence patterns, where “a” signalises an aromatic residue, 
“h” a hydrophobic residue, and “x” any residue. Amino acid residues are given in the one-letter code. Items with 
no data mean that no information was available in the literature. 
 
 
III.3  Structural Features of the SDR Members 
As indicated above, the criterion for SDR membership is the occurrence of typical sequence 
motifs which are arranged in a specific manner, called Rossmann fold (Rossmann et al., 
1975). These conserved residues play significant roles in the catalytically active site, the sub-
strate binding region, the cofactor binding motif, and the C-terminal extension (Fig. III-1 and 
Fig. III-2).  
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Fig. III-1: Multiple sequence alignments of some well-known members of the SDR superfamily  
Abbreviations: CBR1, CBR3 (human carbonyl reductase 1 and 3); CHCR1, CHCR2, CHCR3 (Chinese hamster 
carbonyl reductases 1-3); iCR, nCR, rtCR (inducible, non-inducible and rat-testis carbonyl reductase); Sniffer 
(carbonyl reductase Sniffer from Drosophila); 11β-HSD1-h, 11β-HSD1-m, 11β-HSD1-r, 11β-HSD1-g (11β-
HSDs from human, mouse, rat and guinea pig); PHCR (pig heart carbonyl reductase); MLCR (mouse lung car-
bonyl reductase); PLCR (pig lung carbonyl reductase); 3α/20β-HSD (S. hydrogenans); 3α-HSD/CR (C. testos-
teroni). 
The alignment indicates the existence of an extraloop-domain upstream of the conserved Tyr-x-x-x-Lys motif 
within the monomeric enzymes from human, Chinese hamster and rat. This extraloop-domain can also be found 
in the dimeric 3α-HSD/CR from C. testosteroni. Monomeric enzymes are marked in blue, dimeric enzymes in 
red and tetrameric enzymes in yellow. Colored residues represent conservation of 50% identity. Alignment was 
performed using the clustalW- and bioedit-program. 
 
 
The overall structure of the SDR superfamily members is built up of a sequence of alternating 
α-helices and β-strands. These β-strands form a four- or five-stranded parallel β-sheet with 
two or three α-helices residing on either side. This dinucleotide binding motif composed of 
βαβ units is called Rossmann fold (Rossmann et al., 1975). The Rossmann fold in the SDR 
superfamily is very stable, tolerating, despite little sequence conservations, some mutations at 
every site of the folding motif without loss of function (Duax et al., 2000). It is less readily 
understood how a protein conformation as consistent as the Rossmann fold has no structurally 
conserved residues. Once substrate specificity evolved, changes in the active site could lead to 
loss of function or change in specificity. It appears that in the SDR superfamily, function 
evolved early, while specificity evolved later (Duax et al., 2000). 
 
III.3.1 Catalytic Triade and Catalytic Mechanism 
Already in 1981, the importance of the Tyr-x-x-x-Lys segment as the most conserved se-
quence motif of the SDRs became apparent (Jornvall et al., 1981). Nearly all “classical” SDR 
enzymes use the conserved Tyr-Lys-Ser motif as catalytic residues (Jornvall et al., 1995), 
whereas the enzymes of the “divergent” use the sequence motif Tyr-x-x-Met-x-x-x-Lys  with 
the tyrosine being positioned three amino acids upstream as compared to Tyr-x-x-x-Lys. The 
subfamily of the “complex” SDRs have the unique motif Tyr-x-x-x-n (where n means any 
other amino acid) at the active site (Persson et al., 2003). The amino acids which constitute 
the catalytic triad are critically important for enzyme function. They appear to maintain a 
fixed position relative to the scaffolding of the βαβ-folding and the cofactor position.  
 
 
General Features of the SDR Superfamily Enzymes 
 
19
 
Catalytic triade Cofactor binding Extraloop
αG
αCT
βG
αCT
αG
βG
αE
αE
αF
αF
P
R P
R
P
Q
R
R
Q
P
Helices of the four helix bundle (Q-interface)
 
Fig. III-2: Folding topology of 3α-HSD/CR from C. testosteroni.  
The conserved structural elements involved in oligomerization are named only for the upper one of the two sub-
units. Note that the four helix bundle (Q-interface; blue) is blocked by the extraloop-domain (yellow). Therefore, 
oligomerization (dimerization) takes place only via helix αG and strand βG (P-interface; purple). 
 
Most likely, all SDRs share a common reaction mechanism which follows a compulsory or-
dered pathway with the cofactor binding first (Grimm et al., 2000b). After the hydroxyl or 
carbonyl substrate binds, the so-called substrate binding loop becomes well ordered and cov-
ers the substrate as well as the catalytic center from the aqueous environment. This substrate 
binding loop is highly flexible in most apo-structures of SDRs. Ghosh and coworkers (Ghosh 
et al., 1994b) proposed a model for 3α/20β-HSD in which the conserved residues Tyr, Lys 
and Ser, together with solvent molecules, could catalyze the reaction in the catalytic cavity 
(Fig. III-3). The Tyr hydroxyl has been proposed to be the proton donor in an electrophilic 
attack on the substrate carbonyl in a reduction reaction (Ghosh et al., 1994b). The positively 
charged side chain of Lys is positioned in proximity to the hydroxyl oxygen of Tyr and facili-
tates the proton transfer. The Ser also participates in catalysis by stabilizing the reaction in-
termediates or as part of a proton-relay network. After the proton is transferred from Tyr to 
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the 20-keto oxygen of the steroid, it can be replenished by the solvent surrounding the resi-
dues in the catalytic cavity (Ghosh et al., 1994b; Duax et al., 2000). The substrate is oriented 
by the catalytic Ser which stabilizes the transient reaction intermediate (Grimm et al., 2000b). 
The conserved Lys-residue plays a dual role in the catalytic triad. It orients the cofactor by 
forming hydrogen bonds to the nicotinamide-ribose moiety and lowers the pKa of the catalytic 
Tyr via electrostatic interaction (Ghosh et al., 1994b; Auerbach et al., 1997; Benach et al., 
1999). 
 
Fig. III-3: Reaction mechanism and catalytic triade exemplified by 3α/20β-HSD from S. hydrogenans  
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III.3.2 Substrate Binding and Substrate-Binding Loop 
Most of the amino acid residues which are partially conserved within the SDR superfamily 
members are located in the core of the Rossmann fold and are primarily hydrophobic (Duax et 
al., 2000). The only conserved residues in the substrate-binding cleft are those of the catalytic 
triad: Ser, Tyr and Lys. No conserved residues can be found in the substrate-binding site. This 
is indicative for the fact that, for example, the HSDs show high selectivity for their specific 
physiological steroid substrate. However, for the carbonyl reductases, specific endogenous 
substrates have not been identified until now, they rather display broad substrate specificities, 
ranging from steroids, prostaglandins, sugars and alcohols to xenobiotic aldehydes and ke-
tones (Duax et al., 2000).  
 
Usually, SDR enzymes have a substrate-binding loop of more than 20 residues which covers 
the active site and becomes well ordered after the hydroxyl or carbonyl substrate binding. 
This loop region is located between β-strand F (βF) and α-helix G (αG) and is very often dis-
ordered in apo-structures (without substrate) of SDR enzymes. After substrate binding, the 
loop shows a well-defined, mainly α-helical, geometry. In Sniffer from Drosophila no α-
helical secondary structure element is apparent in the substrate-binding loop (Sgraja et al., 
2004). Here, in the presence of NADP+, only a short loop could be detected in the electron 
density which connects strand βF and helix αG (Sgraja et al., 2004) (Fig. III-4) .  
 
When the α-carbon backbone of known SDR structures is superimposed, the conserved resi-
dues appear at the core of the structure and in the cofactor-binding domain, but not in the sub-
strate-binding pocket (Duax et al., 2000). Contrary to the variability in the substrate-binding 
pocket, the association of the Rossmann fold with the cofactor binding is very consistent and 
the NADP(H) binding domains exhibit architectural integrity, despite having sequence varia-
tions (Duax et al., 2000). The variability in the substrate-binding pocket is plausible when 
keeping in mind the variety of structures used as substrates by different members of the SDR 
superfamily (Duax et al., 2000).  
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III.3.3 Cofactor Binding 
In the N-terminal part of the SDR proteins, a glycine-rich pattern important for cofactor bind-
ing has been identified (Jornvall et al., 1995). This conserved sequence motif includes three 
glycine residues which are located at comparable points in their sequences and form a turn 
between a β-strand and an α-helix that border the cofactor-binding site (Duax et al., 2000). 
Structural analysis has shown that the glycine residues interact with the pyrophosphate moiety 
of the cofactor. The individual subfamilies of the SDR superfamily differ regarding the spac-
ing of the three glycine residues, where the Gly-x-x-x-Gly-x-Gly motif, for example, is char-
acteristic for the subfamily of the “classic” SDRs (Jornvall et al., 1981; Jornvall et al., 1999). 
The use of either reduced or oxidised NAD(P) as cofactor depends on their predominant func-
tion as a dehydrogenase or reductase of individual members of the SDR superfamily. In addi-
tion, both NAD(H) and NADP(H) bind to the classical βαβ motif of the Rossmann fold. The 
specificity for NADP(H), rather than to NAD(H), is conferred by two highly conserved basic 
residues in the N-terminal part of the peptide chain. Tanaka et al. (Tanaka et al., 1996a) iden-
tified two basic residues (Lys-17 and Arg-39) in the tetrameric mouse lung carbonyl reductase 
(MLCR) which promote NADPH binding by interaction with the 2’-phosphate group. These 
residues are believed to confer specificity for NADPH in other SDRs as well.  
  
Human monomeric carbonyl reductase (CBR1) exhibits less than 25% overall sequence iden-
tity with tetrameric MLCR (Jornvall et al., 1995). However, similar to MLCR, human CBR1 
has distal basic (Lys-15 and Arg-38) and neutral (Ala-37) residues at positions corresponding 
to Lys-17, Arg-39 and Thr-38 in tetrameric MLCR (Tanaka et al., 1996a) and is strictly 
NADPH-dependent (Wermuth et al., 1988; Sciotti and Wermuth, 2001). Sciotti and Wermuth 
(Sciotti and Wermuth, 2001) showed that a positive charge at positions 15 and 38 and the ab-
sence of a negative charge at position 37 significantly contribute to NADPH specificity. SDR 
enzymes which are NAD-dependent lack these two basic residues. Instead, an Asp which is 
adjacent to the position of the distal basic residue in NADPH-dependent enzymes appears to 
determine NAD specificity (Sciotti et al., 2000). Sequence alignments of NAD-dependent 
enzymes with the NADPH-dependent tetrameric and monomeric carbonyl reductases show 
that Ala-37 of the monomeric and Thr-38 of the tetrameric carbonyl reductase correspond to 
the Asp residue which plays a role in NAD specificity. Sciotti and Wermuth (Sciotti and 
Wermuth, 2001) substituted Asp for Ala-37 in the strictly NADPH-dependent human CBR1. 
Unexpectedly, the Asp residue had little effect on the NADH-dependent activity and NADPH 
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was still the preferred substrate of the mutant Ala37Asp. Therefore, factors other than only 
the absence of Asp at position 38 must be responsible for the low efficiency of monomeric 
human CBR1 in the presence of NADH Fig. III-1. 
 
III.3.4 C-terminal Extension and 310-Helices 
Many enzymes of the SDR superfamily contain a C-terminal extension consisting of several 
α-helices. Examples are human estrogenic 17β-HSD (Ghosh et al., 1995) and the  Drosophila 
enzymes alcohol dehydrogenase (DADH) and Sniffer. Benach and coworkers showed in 
DADH that these C-terminal helices, which are of more variable character, are main elements 
of dimer association and that these structural features have additional importance in closing of 
the active site cavity upon cofactor and substrate binding (Benach et al., 1998). 
 
310-helices are structural elements which are present as α-helical extensions in loops and as 
connectors between β-strands (Pal and Basu, 1999). In many cases they occur independently 
of any other neighbouring secondary structural elements and form novel super-secondary 
structural motifs. These motifs have possible implications for protein folding, local conforma-
tional relaxations and biological functions (Pal and Basu, 1999).  
 
The Sniffer protein has both structural features which contribute together to dimer formation. 
At the C-terminal end of the Sniffer protein there is a short loop with a sharp turn directly fol-
lowing strand βG. This loop runs perpendicular to the central β-sheet of the Rossmann fold 
and touches the 310-helix following strand βE. The C-terminal ends of the two monomers ap-
proach each other and the indole moiety of the Trp-248 interacts through its planar ring sys-
tem with the side-chain of Ile-159 which is rooted at the 310-helix of the second subunit 
(Sgraja et al., 2004).  
 
III.3.5 Oligomerization and Interfaces  
The enzymes of the SDR superfamily can be divided into different groups concerning their 
oligomerization behaviour, their subcellular localization and the existence of structural ele-
ments with significant effects on protein folding. Most enzymes of the superfamily appear as 
either homodimers, e.g. Sniffer (Sgraja et al., 2004), DADH (Benach et al., 1998) and dihy-
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dropteridine reductase (DHPR) (Varughese et al., 1992), or homotetramers like 3α/20β-HSD 
(Ghosh et al., 1994b) and mouse lung carbonyl reductase (Tanaka et al., 1996a). Only few 
members occur as monomers like for example human carbonyl reductase (CBR1) (Wermuth, 
1981) and pig testicular carbonyl reductase (PTCR) (Ghosh et al., 2001). In spite of the low 
residue identities between the SDR members, the folding pattern of the individual (sub-) units 
is highly conserved with largely superimposable peptide backbones (Krook et al., 1993b; 
Ghosh et al., 2001) (Fig. III-4).  
 
Two types of oligomerization, involving different structural elements, can be found. One type 
of monomer association is the so-called P-axis interface comprising the antiparallel associa-
tion of β-strand G and α-helix G of each subunit (Ghosh et al., 1994b). This type of oli-
gomerization is usually found in homotetrameric SDRs and has only been observed in one 
dimeric SDR, namely 3α-HSD/CR from C. testosteroni (Grimm et al., 2000a). The P-axis 
interface does not involve significant hydrophobic interactions (Ghosh et al., 1994b) and is 
less critical to the structural integrity of the active site than the second type of oligomeriza-
tion, the so-called Q-axis interface. 
 
The Q-axis interface consists of α-helix E and α-helix F of each of the two subunits to form a 
bundle of four helices. This four helix bundle represents the most important structural motif 
of the Q-axis interface, especially in dimeric SDR proteins. It is predicted to be important for 
the integrity of the active site clefts  and has been shown to be critical to function (Puranen et 
al., 1997; Ghosh et al., 2001). In addition, although more than half of the crystal structures of 
SDRs exhibit the same quaternary structure, only the four helix bundle as the main structural 
feature of the Q-axis interface that involves the largest surface area of association (Ghosh et 
al., 1994b) is conserved among the SDRs.  
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Fig. III-4: Typical Rossmann fold of SDR enzymes exemplified by 3α-HSD/CR from C. testosteroni.  
3α-HSD/CR contains an unordered substrate binding loop (SBL) and an extraloop-domain between strand βE 
and helix αF which normally are part of the four helix bundle as the main structural feature of the oligomeriza-
tion Q-interface. 
 
The dimerization interface is close to the active site and stabilizes the interior of the molecule.  
Tsigelny and Baker postulated that the neighbouring amino acids of the conserved tyrosine 
and lysine residues in the active site of SDR family members might interact with the hydro-
phobic outer surface of the αF helix and hence stabilize the dimer interface of the proteins 
(Tsigelny and Baker, 1995b). Therefore, it is suggested that monomerization of dimeric or 
tetrameric proteins in the SDR family most likely abolishes their enzyme activity. Hoffmann 
and coworkers (Hoffmann et al., 2006) redesigned the region of the interfacial four helix bun-
dle in the dimeric 3α-HSD/CR from C. testosteroni, which comprises an additional α-helical 
subdomain preventing the enzyme of dimerization along the typical Q-axis interface. Their 
data of a soluble and active protein will give further insights into the requirements of a protein 
for the architecture of the active site and the structural elements comprising the Q-axis inter-
face.  
 
In the dimeric human 17β-HSD, Puranen and coworkers (Puranen et al., 1997) substituted 
amino acids of the four helix bundle within the hydrophobic Q-axis interface resulting in inac-
tive multi-aggregates of the protein, while neither dimers nor monomers were detectable. 
Ghosh and coworkers were also able to show that the four helix bundle is critical for protein 
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function. Disruptions of the helix arrangement had negative effects on the integrity of the 
catalytic centres of the oligomerizing monomers in 3α/20β-HSD of S. hydrogenans (Ghosh et 
al., 2001).  
 
An example for a cytosolic and monomeric carbonyl reductase is human CBR1. The reason 
for the monomeric structure of this enzyme is a so-called additional extraloop-domain be-
tween the Q-interfacial strand βE and helix αF which is believed to prevent oligomerization 
along the Q-axis interface built up of the four helix bundle. Other monomeric carbonyl reduc-
tases include this α-helical subdomain as well, but with different length. Among the mono-
meric carbonyl reductases with an additional subdomain are pig testicular carbonyl reductase 
(PTCR) which has a sequence identity to human CBR1 of nearly 85%, as well as the cytosolic 
and monomeric carbonyl reductases of rat (non-inducible, nCR; inducible, iCR; testis, rtCR) 
and Chinese hamster (CHCR).  
 
The group of tetrameric carbonyl reductases is not as consistent as the group of monomeric 
carbonyl reductases. Tetrameric carbonyl reductases can be found on the subcellular level in 
the mitochondria (namely carbonyl reductases from mouse and pig lung) (Nakayama et al., 
1986; Oritani et al., 1992) and in the cytoplasm, i.e. 3α/20β-HSD from S. hydrogenans 
(Ghosh et al., 1992; Ghosh et al., 1994a; Ghosh et al., 1994b). The tetrameric carbonyl reduc-
tase from pig liver is a peroxisomal protein which contains the SRL-tripeptide (serine-
arginine-leucine) as a peroxisomal targeting signal (Usami et al., 2003) (cf. chapter IV ). 
 
The Q-interfacial dimer interface of which Sniffer provides a typical example is also present 
in tetramers (3α/20β-HSD). This interface is stabilized by interactive associations of symme-
try related α-helices αE and αF. It has been shown that while conservative variations in amino 
acids (i.e. substitution of one hydrophobic residue for another) is tolerated, non-conservative 
mutations can disrupt dimer formation and cause loss of function (Duax et al., 2000).   
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A special case represents dimeric 3α-HSD/CR from C. testosteroni. This enzyme does not 
undergo oligomerization along the Q-axis interface, because the protein contains an α-helical 
extraloop-domain within this Q-interfacial four helix bundle. As with the monomeric carbonyl 
reductases containing this α-helical extraloop-domain, oligomerization along this interface 
region is prevented because of the disruption of the Q-axis interface. Most interestingly, 3α-
HSD/CR performs dimerization along the P-axis interface (Grimm et al., 2000b). However, 
this type of oligomerization via the P-axis interface can only be found in tetrameric SDRs 
such as for example in 3α/20β-HSD from S. hydrogenans (Ghosh et al., 1994b) (see above). 
 
 
 
 
IV Pluripotent Carbonyl Reductases of the SDR Superfamily 
Carbonyl-reducing enzymes can be found ubiquitously in nature and they have been shown to 
catalyze the NADPH-dependent reduction of a wide variety of biologically and pharmaco-
logically active substrates, as well as a variety of endogenous and xenobiotic carbonyl com-
pounds including quinones (Felsted and Bachur, 1980; Wermuth, 1985; Ohara et al., 1995; 
Oppermann and Maser, 2000; Breyer-Pfaff et al., 2004; Breyer-Pfaff and Nill, 2004; Maser, 
2004; Maser et al., 2005; Hoffmann et al., 2006; Martin et al., 2006; Maser et al., 2006). As 
suggested for two-electron transferring quinone reductases (Lind et al., 1982), carbonyl re-
ductase might function as a cellular mechanism to control the toxicity of quinones, especially 
in humans (Wermuth et al., 1986). In addition, reactive aldehydes derived from lipid peroxi-
dation were found to be substrates for the enzyme (Doorn et al., 2004; Hoffmann et al., 
2006). Interestingly, activity toward endogenous prostaglandins and steroids has been demon-
strated, although the low catalytic efficiency reported raised skepticism that these compounds 
are physiological substrates of carbonyl reductases and that the corresponding pathways rep-
resent a physiological role for the enzymes (Chang and Tai, 1981; Wermuth, 1981; Jarabak et 
al., 1983; Forrest and Gonzalez, 2000).  Therefore, a general detoxification role for foreign 
and metabolically derived carbonyl compounds seems to account for the enzymes’ wide sub-
strate specificity and its ubiquitous distribution in human tissues (Wirth and Wermuth, 1992). 
An evolutionary classification of the SDR superfamily members involved in carbonyl reduc-
tion is shown in Fig. IV-1. 
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Fig. IV-1: Evolutionary tree of carbonyl-reducing enzymes from different species 
The nomenclature is according to Fig.2.   
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IV.1  Carbonyl Reductases in Non-Mammals  
Carbonyl reduction in microorganisms was mainly investigated by chemists who are inter-
ested in the production of optically active alcohols (Roberts, 1997; Faber, 1998). However, 
the studies were generally performed with crude cell extracts and the specific enzyme in-
volved was often unclear. Only a few papers reported serious work on the purification, identi-
fication and characterization of carbonyl reductases and aldehyde reductases from microor-
ganisms such as Saccharomyces cerevisiae (Ypr1p,  2-methylbutyraldehyde reductase) (Ford 
and Ellis, 2001; Ford and Ellis, 2002), Sporobolomyces salmicolor, Candida magnoliae 
(NADPH-dependent aldehyde reductase, ARII) (Kita et al., 1999), Geotrichum candidum 
(Matsuda et al., 2000), Rhodococcus erythropolis (carbonyl reductase, RECR) (Zelinski et al., 
1994), and Escherichia coli (2,5-diketo-D-gluconate reductase) (Oh et al., 1999; Yum et al., 
1999a; Yum et al., 1999b; Habrych et al., 2002; Thibault et al., 2004). In the future, reduction 
of carbonyl compounds by microorganisms might gain great importance for biotechnological 
uses (Ellis, 2002) or in the field of environmental sciences. 
 
IV.1.1 3/20β-Hydroxysteroid Dehydrogenase of Streptomyces hydrogenans 
Streptomyces hydrogenans belongs to the actinomycetes which are common in soil, plant de-
bris, dung, house dust, and many other habitats (Waksman, 1961; Backlund et al., 2005). 
3α/20β-Hydroxysteroid dehydrogenase (3α/20β-HSD) from S. hydrogenans is an NADH-
linked enzyme which is involved in the reversible oxidation of the 3α-group of androstane 
derivatives and the 20β-group of pregnane derivatives (Sweet and Samant, 1980). Interest-
ingly, although there is no known steroid hormone function in bacteria, the S. hydrogenans 
gene encodes a hydroxysteroid dehydrogenase enzyme (Duax et al., 2000).  
The structure of 3α/20β-HSD was the first structure solved and determined by X-ray diffrac-
tion of an enzyme belonging to the SDR superfamily and the third structure of an enzyme for 
which steroids are the substrate (Ghosh et al., 1991). The active form of the enzyme is a 
tetramer. The four identical monomers each consist of 253 amino acids with a calculated mo-
lecular mass of around 26 kDa and containing a single domain incorporating the active site 
and the Rossmann fold cofactor binding motif (Ghosh et al., 1994b).  
In a proposed catalytic mechanism of the 3α/20β-HSD enzyme, the Tyr-152 hydroxyl proton 
initiates the electrophilic attack on the 20-keto oxygen of the steroid (Duax et al., 2000). The 
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positively charged side chain of Lys-156 lies in close proximity to the Tyr-152 hydroxyl oxy-
gen and facilitates proton transfer. Ser-139 participates in catalysis by stabilizing the reaction 
intermediates and as part of a proton-relay network, in which a proton, once transferred from 
Tyr-152 to the 20-keto oxygen of the steroid, can be replenished by the solvent network sur-
rounding these residues in the catalytic cavity (Ghosh et al., 1994b; Duax et al., 2000). This 
mechanism of catalysis does also apply to other members of the SDR superfamily.   
 
 
IV.1.2 3-Hydroxysteroid Dehydrogenase/Carbonyl Reductase of Comamonas testos-
teroni 
Procaryotic 3-hydroxysteroid dehydrogenase/carbonyl reductase (3α-HSD/CR) has been 
first described in the gram-negative bacterium Pseudomonas testosteroni which was later re-
named Comamonas testosteroni and reclassified as belonging to the 2-group of the Proteo-
bacteria (Michel-Briand, 1969; Michel-Briand and Roux, 1969; Skalhegg, 1975; Aukrust et 
al., 1976; Shikita and Talalay, 1979; Tamaoka et al., 1987; Oppermann et al., 1993; Suzuki et 
al., 1993; Abalain et al., 1995; Floch et al., 1995). C. testosteroni has been first isolated from 
soil, mud and water, but has also been found in clinical isolates of patients suffering from 
purulent meningitis (Arda et al., 2003), endocarditis (Heredia et al., 2004) and cystic fibrosis 
(Coenye et al., 2002).  
 
These bacteria are strictly aerobic, nonfermentative and chemoorganotrophic. They rarely 
attack sugars, but grow well on organic acids and amino acids (Willems et al., 1992). In addi-
tion, C. testosteroni is able to grow on steroids as sole carbon source (Talalay et al., 1952).  
 
3α-HSD/CR is one of the first enzymes of the steroid catabolic pathway and, therefore, plays 
a central role in steroid metabolism in C. testosteroni. The enzyme mediates the oxidoreduc-
tion at position 3 of the steroid nucleus of a great variety of C19-27 steroids. This reaction is of 
importance in the initiation of the complete degradation of these relatively inert substrates and 
may significantly contribute to the bioremediation of hormonally active compounds in the 
environment. The enzyme is also involved in the degradation of fusidic acid, thereby provid-
ing resistance of C. testosteroni towards this steroid antibiotic produced by the fungus 
Fusidium coccineum (Oppermann et al., 1996). 
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In addition to steroids, 3α-HSD/CR accepts as substrates a wide spectrum of non-steroid 
xenobiotic carbonyl compounds such as the cytochrome P450 inhibitor metyrapone, a 
metyrapone-based class of environmentally safe anti-insect agents, e.g. NKI 42255 (2-(1-
imidazolyl)-1-(4-methoxyphenyl)-2-methyl-1-propanone) (Darvas et al., 1991; Belai et al., 
1995; Oppermann et al., 1996) (cf. chapter V.8 ; Detoxification of Insecticides), or the sig-
nificantly smaller p-nitrobenzaldehyde (Oppermann and Maser, 1996; Mobus and Maser, 
1998). Due to this fact, the enzyme’s name was extended from 3-hydroyxsteroid dehydro-
genase (3-HSD) to 3-hydroyxsteroid dehydrogenase/carbonyl reductase (3-HSD/CR). 
 
Interestingly, the expression of 3α-HSD/CR in C. testosteroni is inducible by steroids (Möbus 
et al., 1997). Steroid-induced bacterial cells exhibit a significantly faster degradation of ster-
oids, as well as a faster uptake and metabolism of NKI 42255 (Oppermann et al., 1996). 
Therefore, induction by steroids results not only in an increase of resistance towards the ster-
oid antibiotic fusidic acid, but also in an enhancement of insecticide detoxification  
(Oppermann et al., 1996).    
 
3α-HSD/CR uses NAD(H) as cofactor, depending on the reaction direction. Biochemical and 
structural analysis revealed that the enzyme appears as a homodimer with a mode of oli-
gomerization along the P-axis interface analogous to tetramerization of 3α/20β-HSD from S. 
hydrogenans (Ghosh et al., 1994b). Until then, this way of oligomerization had never been 
observed in a dimeric SDR enzyme, where dimerization usually takes place via the Q-axis 
interface (Grimm et al., 2000a), e.g. in Drosophila melanogaster alcohol dehydrogenase 
(Benach et al., 1998) and Sniffer (Sgraja et al., 2004) (cf. chapter III.3.5; Oligomerization and 
Interfaces). 
 
IV.1.3 Insect Carbonyl Reductase: Sniffer of Drosophila melanogaster  
The Drosophila melanogaster carbonyl reductase Sniffer is a NADPH-dependent member of 
the SDR superfamily. The enzyme shows similarity with human carbonyl reductases CBR1 
(27,4%) and CBR3 (24,9%) (Botella et al., 2004).  
 
Interestingly, Sniffer knock-out mutants had a reduced lifespan, showed  motoric dysfunctions 
and exhibited age-related and oxidative stress-induced neurodegeneration (Botella et al., 
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2004). All symptoms of the altered phenotype resembled those in patients with neurodegen-
erative dysfunction. Histological analysis of the central nervous system showed an increased 
vacuolization and apoptosis in the brain of mutant flies compared to wild-type flies. In con-
trast, overexpression of the carbonyl reductase Sniffer not only rescued the phenotype but 
even induced a prolonged survival of neurons under hyperoxia conditions in wild-type flies 
(Botella et al., 2004). These results suggested an important role of the carbonyl reductase 
Sniffer in the neuroprotection against oxidative stress. 
 
Besides being structurally related to CBR1, the Sniffer protein exhibited carbonyl reductase 
activities with the CBR1 substrates 9,10-phenanthrenequinone, p-nitrobenzaldehyde, pyri-
dine-4-carboxaldehyde and menadione (Botella et al., 2004). Since human CBR1, in turn, was 
shown to catalyze the carbonyl reduction of 4-oxononenal (Doorn et al., 2004), it is antici-
pated that the mechanism of neuroprotection by Sniffer in Drosophila is due to the detoxifica-
tion of reactive aldehydes derived from lipid peroxidation after oxidative stress (Hoffmann et 
al., 2006) (cf. chapter V.3 ; Neuroprotection by Carbonyl Reductase?).  
 
Gel-filtration experiments and the crystal structure revealed unambiguously that Sniffer ap-
pears as a dimer in solution, with a molecular mass of each monomer of 28 kDa. In the Sniffer 
protein the two long helices αE and αF from two adjacent protein molecules associate to form 
the four helix bundle (Sgraja et al., 2004) (cf. chapter III.3.5; Oligomerization and Interfaces). 
This mode of oligomerization is observed in most other dimeric SDRs whose structures have 
been solved so far (Ghosh et al., 1994b; Tanaka et al., 1996a; Benach et al., 1998). The only 
exception of this rule is 3α-HSD/CR from C. testosteroni, where dimerization occurs via an 
interface region observed only in homotetrameric SDRs (Grimm et al., 2000a) (cf. chapter 
III.3.5; Oligomerization and Interfaces).  
 
IV.2  Carbonyl Reductases in Mammals 
IV.2.1 Monomeric Cytosolic NADPH-Dependent Carbonyl Reductases 
IV.2.1.1 Human Carbonyl Reductase 1 (CBR1) 
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Human carbonyl reductase (CBR1) is a cytosolic and monomeric member of the SDR super-
family (Wermuth et al., 1988; Wirth and Wermuth, 1992; Forrest and Gonzalez, 2000). The 
enzyme is widely distributed in human tissues, such as liver, epidermis, stomach, small intes-
tine, kidney, neuronal and glial cells of the CNS, and smooth muscle fibres (Wirth and Wer-
muth, 1985; Wirth and Wermuth, 1992; Forrest and Gonzalez, 2000). Small amounts of 
CBR1 were found e.g. in cerebellum, oral cavity, oesophagus, kidney and skeletal muscle 
(Wirth and Wermuth, 1992) 
 
One of the first isolations of this enzyme was from human brain (Ris and von Wartburg, 
1973). According to its broad substrate specificity, CBR1 from human brain was previously 
also designated as secondary alcohol-NADP+ oxidoreductase (EC 1.1.1.184) (Wirth and 
Wermuth, 1992) and aldehyde reductase 1 (Ris and von Wartburg, 1973). In 1981, Wermuth 
suggested the name carbonyl reductase (CBR1) to better describe the reduction of a wide va-
riety of carbonyl substrates (Wermuth, 1981; Wermuth et al., 1986). The substrate specificity 
of human CBR1 suggested initially that the enzyme is an aldo-keto reductase. However, 
structural investigations revealed no significant homologies to the aldo-keto reductases but, in 
contrast, indicated the relationship to the short-chain dehydrogenase (SDR) superfamily 
(Bohren et al., 1989). 
 
Substrate diversity 
Wermuth and coworkers found that the enzyme reduces a number of biologically and phar-
macologically active carbonyl compounds. During catalysis the pro 4S hydrogen atom of the 
nicotinamide ring of NADPH is transferred to the substrate. Human CBR1 exhibits relatively 
poor reductive activity towards aliphatic and alicyclic ketones, with the exception of daun-
orubicin and the glutathione adduct of prostaglandin A1 (Wermuth, 1981). 
 
The best substrates are quinones, e.g. menadione, ubiquinone-1, phenanthrenequinone and 
tocopherolquinone followed by ketoaldehydes (e.g. phenylglyoxal), aromatic aldehydes con-
taining an electron-withdrawing substituent, e.g. 4-nitrobenzaldehyde or methylglyoxal, and 
the biogenic aldehydes, indol-3-acetaldehyde and 4-hydroxyphenylacetaldehyde (Wermuth, 
1981). Quinones, some of which are substrates of human CBR1, play important roles as oxi-
dation-reduction catalysts in biological processes. For example, ubiquinones (coenzyme Q) 
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are constitutive parts of the respiratory chain, and tocopherolquinone (vitamin E) is thought to 
protect lipids of biological membranes against lipid peroxidation (Wermuth, 1981). 
 
Due to its capability of daunorubicinol formation, CBR1 has also been named daunorubicin-
pH 6.0 reductase, ALR3 (Flynn and Green, 1993) and xenobiotic ketone reductase with pH 
6.0 activity (Ahmed et al., 1978). 
 
Wermuth found that CBR1 metabolized prostaglandin E1 and prostaglandin  E2, whereas 
prostaglandin A1 was not reduced at all (Wermuth, 1981). While human CBR1 was shown to 
accomplish the reduction of the 9-keto group of prostaglandin E2 to form prostaglandin F2α, 
the enzyme was later shown to be identical to prostaglandin-9-reductase (Schieber et al., 
1992; Schieber and Ghisla, 1992). However, the metabolic potency of PGE1 and PGE2 car-
bonyl reduction was only 2% of that observed with menadione. Moreover, the relative veloc-
ity for this reaction was 60-fold lower than for 9,10-phenantrenequinone reduction (Wermuth, 
1981). This casts doubt on a role of CBR1 in prostaglandin metabolism. In addition to 9-keto 
reduction, CBR1 was shown to catalyze the NADP-dependent oxidation of the hydroxy group 
at position 15 of prostaglandins. Therefore, CBR1 has also been named NADP-linked 15-
hydroxy-prostaglandin dehydrogenase. It should be noted that oxo-reduction at position 9 and 
hydroxy-dehydrogenation at position 15 are inactivation steps of prostaglandins (cf. chapter  
V.1 ; Roles in Steroid and Prostaglandin Metabolism). The fact that the glutathione adduct of 
prostaglandin A1 is a substrate of CBR1, but free PGA1 is not (Wermuth, 1981), might be 
explained by the finding that CBR1 has a glutathione binding site in close proximity to the 
catalytic centre [reviewed in (Doorn et al., 2004)]. 
 
 
Human CBR1 orthologues in other species 
Human CBR1 orthologues with sequence identities of more than 80% to CBR1 have been 
identified in several other species such as pig, rabbit, hamster, rat and mouse. The enzyme 
from pig testes (PTCR) was the first CBR1 orthologue whose three-dimensional structure has 
been solved (Ghosh et al., 1993). PTCR does also exhibit 20β-HSD activity towards C21-
steroids (Tanaka et al., 1992). Whereas in most species the enzyme is distributed in many 
tissues, it does not occur in rat liver. Rather, three CBR1 orthologues have been identified in 
rat reproductive tissues of both sexes and have been named rat testis (rtCR), gonadotropin-
Pluripotent Carbonyl Reductases of the SDR Superfamily 
 
35
inducible (iCR) and noninducible (nCR) carbonyl reductase (cf. chapter IV.2.1.5; Rat Carbo-
nyl Reductases (iCR, nCR, rtCR)). 
 
Molecular forms and autocatalytic modification of CBR1 
Purification of human brain CBR1 yields three forms which differ in their pI-value, but which 
exhibit very similar enzymatic properties (Wermuth, 1981; Inazu et al., 1992b). The three 
enzyme forms show isoelectric points of 6.95, 7.85 and 8.5, but no apparent differences in the 
amino acid composition (Wermuth, 1981; Nakayama et al., 1985; Inazu et al., 1992b). They 
differ from each other only by small structural modifications (see below). Three forms of 
CBR1 are also detected on purification from human liver cytosol by gel filtration, ion ex-
change, hydroxy apatite and affinity chromatography (Atalla et al., 2000).  
 
Finally, it was shown that the three isoforms, which show the same catalytic activity towards 
menadione (Bohren et al., 1987; Wermuth et al., 1993), result from covalent modifications of 
a lysine residue (Krook et al., 1993a; Wermuth et al., 1993; Sciotti et al., 2000). Forrest and 
coworkers first reported the occurrence of this modified lysine residue at position 239 of 
CBR1, although at that time the nature of the modification was not clarified (Forrest et al., 
1990). This modification is performed by an autocatalytic process involving the formation of 
a Schiff base between the ε-amino group of lysine and 2-oxocarboxylic acids, e.g. pyruvate 
and 2-oxoglutarate (Krook et al., 1993c; Wermuth et al., 1993). A covalent adduct is formed 
by reduction of the double bond. This autocatalytic modification has never been observed in 
other SDRs, nor in another oxidoreductase and is unique to human CBR1 (Sciotti et al., 
2000). A similar modification cannot be found in pig or rabbit carbonyl reductases (see be-
low).  
 
This process is in line with structural data from computer modeling and crystallization data, 
which located the modified lysine residue outside of the active site cleft (Krook et al., 1993b; 
Tanaka et al., 2005). Sciotti and coworkers suggested a specific structure which is required 
for this modification reaction (Sciotti et al., 2000). In human, rat and mouse carbonyl reduc-
tase the region near lysine 239 is highly conserved. For example, rabbit carbonyl reductase, 
instead of a lysine, has an asparagine at this position which cannot react with 2-
oxocarboxylates. Mouse carbonyl reductase has not been examined for autocatalytic modifi-
cation by 2-oxocarboxylates. The mouse sequence shows absolute conservation of residues 
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near lysine 239. This fact suggests that the mouse enzyme can undergo autocatalytic modifi-
cation as well (Sciotti et al., 2000).  
 
The reaction of lysine 239 in carbonyl reductase with 2-oxocarboxylates seems to be physio-
logical, because the three autocatalytically modified forms of human CBR1 are found in un-
treated brain cytosol (Wirth and Wermuth, 1992). The degree of modification of lysine de-
pends on the metabolic state of the cells, because transformed E. coli cells which are incu-
bated in media with glucose show an increased yield of pyruvate-modified CBR1 (Bohren et 
al., 1994). 
 
Inhibitors 
Enzyme activity can be inhibited by flavonoids, e.g. quercetin and rutin, indomethacin, fu-
rosemide, ethacrynic acid, flufenamic acid and dicoumarol (Wermuth, 1981; Atalla et al., 
2000; Usami et al., 2003). 4-Hydroxy-mercuribenzoate and iodoacetate inactivate the en-
zyme. Neither NADPH nor substrate protect the enzyme from the loss of activity (Wermuth, 
1981). 
 
IV.2.1.2  9-Keto-Prostaglandin Reductase and 15-Hydroxy-Prostaglandin Dehydrogenase 
Studies on the physiological role of carbonyl reductases indicated an involvement in endoge-
nous prostaglandin metabolism. This field was greatly activated when it turned out that some 
prostaglandin dehydrogenases were shown to be SDR enzymes. Two different cytosolic types 
of human prostaglandin dehydrogenase have then been characterized in more detail, a mono-
meric NADP(H)-linked enzyme and a dimeric NAD(H)-linked enzyme. Both belong to the 
SDR superfamily, have similar conformations regarding their modelled three-dimensional 
structure, but they are highly divergent regarding their primary structure, exhibiting identical 
residues at only the 20% level (Krook et al., 1993b). 
 
The NADP-dependent enzyme turned out to be identical to carbonyl reductase (EC 1.1.1.184) 
which does obviously also act as 9-keto reductase and 15-hydroxy dehydrogenase in pros-
taglandin metabolism (cf. chapter IV.2.1.1; Human Carbonyl Reductase 1 (CBR1)). The 
NAD-dependent 15-hydroxy-prostaglandin dehydrogenase is a key enzyme involved in the 
biological inactivation of many prostaglandins (Ensor and Tai, 1991). The enzyme is known 
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to be ubiquitously expressed in several organs in mammals and seems to be downregulated in 
cancer tissues (Backlund et al., 2005). Until today, there is no evidence that NAD-dependent 
15-hydroxy-prostaglandin dehydrogenase participates in xenobiotic carbonyl reduction. 
 
IV.2.1.3 Human Carbonyl Reductase 3 (CBR3) and 4 (CBR4) 
In their search for genes contributing to Down syndrome, Watanabe and coworkers 
(Watanabe et al., 1998) identified a novel carbonyl reductase gene which they named CBR3. 
The CBR3 gene is located 62 kb downstream from the original CBR1 gene on human chromo-
some 21q22.2. Comparison of the genomic structure of CBR1 and CBR3 indicated differences 
in the introns and surrounding regions but high conservation of the three exons. Coding se-
quence comparisons revealed 77.0 and 84.0% identity on the nucleotide and predicted amino 
acid level, respectively, with human CBR1 and, based thereon, CBR3 classified as a mono-
meric NADPH-dependent oxidoreductase.  
 
However, until recently there have been no reports on the catalytic properties of CBR3. 
Lakhman and coworkers (Lakhman et al., 2005) were the first to characterize the catalytic 
properties of recombinant CBR3 with the prototypical quinone substrate menadione 
(Wermuth et al., 1988). While studying the functional significance of a natural allelic variant 
of human CBR3, these authors observed a V244M polymorphism that appears common 
among different ethnic groups and encodes for CBR3 protein isoforms with distinctive cata-
lytic properties. In detail, blacks showed a higher frequency of the M244 allele than did 
whites. In addition, DNA panels from 10 ethnic groups presented a wide range of CBR3 
V244M genotype distribution. Comparative three-dimensional analyses based on the structure 
of the homologous porcine carbonyl reductase suggested that the V244M substitution is posi-
tioned in a region critical for interactions with the NADP(H) cofactor. These findings support 
the notion that CBR3 genetic polymorphisms may impact general CBR1-mediated biotrans-
formations (Lakhman et al., 2005). Further research remains to be conducted  to elucidate the 
physiological significance of CBR3, as compared to CBR1 and to genetic polymorphisms. 
Sequencing of the human genome revealed the existence of a third human isoform of carbonyl 
reductase (gene name: CBR4, Swiss Prot accession number: Q8N4T8), based on conserved 
domain profiles. The corresponding protein is named carbonic reductase 4 (CBR4). While the 
sequences of CBR1 and CBR3 are 72% identical, CBR4 shows only low similarity to CBR1 
Pluripotent Carbonyl Reductases of the SDR Superfamily 
 
38
and CBR3 (23% and 22% identity, respectively). Until now, no data characterizing the en-
zyme regarding function and tissue distribution are available (Strausberg et al., 2002; Ota et 
al., 2004).      
 
 
IV.2.1.4 Chinese Hamster Carbonyl Reductases (CHCR 1-3) 
Terada and coworkers (Terada et al., 2001) isolated three different cDNAs encoding  carbonyl 
reductase in Chinese hamster (CHCR). Comparison of the amino acid composition revealed 
that CHCR1 is highly identical to CHCR2 (>96%) and to other mammalian carbonyl reduc-
tases (>81%). CHCR3 has a high identity to human CBR3 (>86%) and a relatively lower 
identity to the other CHCRs (<76%). Structure prediction of the typical αβαβ-Rossmann fold 
motif of the CHCRs indicated the presence of a typical dinucleotide cofactor- binding motif 
which is similar to other SDR enzymes.  
 
CHCR1 and CHCR2 show potent reductase activities towards 4-benzoylpyridine, 4-
nitrobenzaldehyde and pyridine-4-carboxaldehyde. For CHCR2, metyrapone and steroids like 
5β-androstane-3,17-dione, 5α-androstane-3,17-dione and 5α-androstane-17β-ol-3-one are 
better substrates (Terada et al., 2001). CHCR3 has relatively lower activity towards 4-
nitrobenzaldehyde and pyridine-4-carboxaldehyde than CHCR1 and CHCR2.  
 
Terada and coworkers examined the function of the three CHCRs in prostaglandin metabo-
lism (Terada et al., 2003). They found that prostaglandins, e.g. PGE2, failed to act as a sub-
strate for CHCR3, whereas CHCR1 and CHCR2 showed reductase activity towards PGB2 and 
PGE2. CHCR1 and CHCR2 exhibited dehydrogenase activity towards PGA2, PGB2, PGD2, 
PGE2 and PGF2α. These findings suggest that both enzymes can catalyze the oxidoreduction 
of both the 9- and 15-hydroxy groups of these prostaglandins (Terada et al., 2003). The broad 
substrate specificity of CHCR1 suggests that this enzyme is involved in the oxidoreduction of 
the 11-hydroxy group of prostaglandins, in addition to 9- and 15-hydroxy groups (Terada et 
al., 2003). Additionally, CHCRs show reductase activity towards a variety of androstane and 
pregnane steroids, as well as towards benzoylpyridine, daunorubicin and isatin (Terada et al., 
2003).  
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IV.2.1.5  Rat Carbonyl Reductases (iCR, nCR, rtCR) 
Aoki and coworkers (Aoki et al., 1997) isolated two closely related genes encoding an induc-
ible and a noninducible carbonyl reductase in rat ovary. The inducible carbonyl reductase 
(iCR) is strongly inducible by pregnant mare serum gonadotropin (PMSG), whereas the non-
inducible carbonyl reductase (nCR) is constitutively expressed. Both carbonyl reductases are 
also expressed in rat testis and share a sequence identity of 86% with 277 (iCR) and 276 
(nCR) amino acids. The iCR and nCR show sequence homologies of 86% and 80% to human 
CBR1, respectively (Aoki et al., 1997). 
 
It is interesting to note that, while human CBR1 is ubiquitously expressed in many tissues, rat 
iCR and nCR are only expressed in gonadal and adrenal tissues. There is no carbonyl reduc-
tase expressed in rat liver (Wermuth et al., 1995).  
 
A third carbonyl-reductase-like enzyme is exclusively expressed in rat male and female re-
productive tissues and adrenal glands (rat testis carbonyl reductase, rtCR). Its expression in 
the ovary is modulated by gonadotropins and estrogens (Inazu et al., 1992a; Inazu and Satoh, 
1994). The amino acid sequence of this enzyme is highly homologous to iCR (98%) and nCR 
(86%) from rat reproductive tissues, but with the substitution of some amino acids (5 substitu-
tions to iCR, 37 to nCR) (Aoki et al., 1997).  
 
Recombinant rtCR most efficiently catalyzed the reduction of quinones, e.g. menadione, fol-
lowed by xenobiotic aromatic aldehydes and ketones. Endogenous steroids like dihydrotestos-
terone and 5α-androstane-3,17-dione were also accepted as substrates, indicating that rtCR 
could be involved in steroid hormone metabolism (Wermuth et al., 1995).  
 
rtCR shows the same length and a 86% positional identity with human CBR1 (Wermuth et 
al., 1995). Similar to human CBR1, rtCR can catalyze its own autocatalytic modification by 
pyruvate and 2-oxoglutarate (cf. chapter IV.2.1.1; Human Carbonyl Reductase 1 (CBR1)). 
Wermuth and coworkers concluded that rtCR and human CBR1 represent species-specific 
forms of the same enzyme (Wermuth et al., 1995).  
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IV.2.1.6 Pig Testicular Carbonyl Reductase (PTCR) 
Porcine testicular carbonyl reductase (PTCR) resembles human and rat carbonyl reductases in 
that it belongs to the SDR superfamily and catalyzes the NADPH-dependent metabolism of 
steroids and prostaglandins, as well as that of xenobiotic aldehydes and ketones (Tanaka et 
al., 1995; Nakajin et al., 1997). Because of its ability to reduce the 20-carbonyl group of C21-
steroids, e.g. the conversion of 17α-hydroxyprogesterone to 17α/20β-dihydroxy-4-pregnen-3-
one, the enzyme is also known as 20β-hydroxysteroid-dehydrogenase (Tanaka et al., 1992). 
The purified enzyme shows vigorous 3α- and 3β-HSD activities with 5α-androstan-17β-ol-3-
one (5α-dihydrotestosterone) as substrate. Therefore, the enzyme has sometimes been named 
PTCR/3α/β (Ohno et al., 1991). Additional names for the enzyme are prostaglandin-E2-9-
reductase and prostaglandin 9-ketoreductase, as well as 15-hydroxyprostaglandin dehydro-
genase (NADP+), because the enzyme catalyzes the NADPH-dependent reduction of pros-
taglandins (Ahmed et al., 1978; Wermuth et al., 1982; Ohara et al., 1995; Forrest and Gon-
zalez, 2000).   
 
PTCR shows a sequence identity to human CBR1 of about 85% (Tanaka et al., 1992) and is 
with a score of 80% also highly identical to rtCR (rat testis carbonyl reductase). However, 
PTCR lacks the 13 additional amino acid residues at the C-terminus of human and rat car-
bonyl reductases (Tanaka et al., 1995). In contrast to bacterial 3α/20β-HSD, human 17β-HSD 
type 1 (Ghosh et al., 1995) and 11β-HSD type 1 (Maser et al., 2002; Maser et al., 2003), as 
well as Drosophila alcohol dehydrogenase (Benach et al., 1998), which occur as oligomers 
(dimers, tetramers), the carbonyl reductases from pig (PTCR), rat (iCR, nCR, rtCR) and hu-
man (CBR1) are monomeric. This monomeric structure is the result of a 41-residue insertion 
at a strategic location in front of the conserved Tyr-x-x-x-Lys motif. This insertion describes 
an all-helix subdomain that packs against interfacial helices, thus eliminating the four helix 
bundle interface conserved in the SDR superfamily and thereby preventing oligomerization 
(Ghosh et al., 2001) (cf. chapter III.3.5; Oligomerization and Interfaces). PTCR was the first 
known monomeric structure within the SDR superfamily. 
 
Among the SDRs known so far, the carbonyl reductase Sniffer in Drosophila (cf. chapter  
3.1.3) shows the greatest similarity to PTCR with regard to crystal structure, apart from the 41 
amino acid residue insertion following strand βE (Ghosh et al., 2001; Sgraja et al., 2004). 
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IV.2.1.7 Tetrameric Peroxisomal Carbonyl Reductase 
In addition to monomeric carbonyl reductases of human (Wermuth et al., 1988), pig (Tanaka 
et al., 1992), rat (Tajima et al., 1999) and rabbit (Gonzalez et al., 1995), there do also exist 
tetrameric forms of carbonyl reductase. These are distributed as soluble forms either in mito-
chondria, as it is known for carbonyl reductases in the lungs of mouse, guinea pig and pig (cf. 
chapter IV.2.1.8; Tetrameric Mitochondrial Carbonyl Reductases), or in peroxisomes. These 
homotetrameric forms exhibit sequence identities to human CBR1 and its animal orthologues 
of only around 20%. To distinguish these tetrameric forms from monomeric CBR1 (and 
orthologues) as well as from human CBR3, they have occasionally been termed CBR2 
(Matsunaga et al., 2006).  
 
Usami and coworkers (Usami et al., 2003) identified and described a tetrameric carbonyl re-
ductase from the peroxisomes of pig heart (PHCR), but the enzyme is ubiquitously expressed 
in pig tissues, including the liver. The monomers of the homotetramer have a molecular mass 
of 27 kDa, and the protein shows the typical conserved residues of the SDR superfamily re-
garding cofactor binding and the catalytically active site (Jornvall et al., 1995). The C-
terminus bears a SRL (Ser-Arg-Leu) tripeptide sequence, which is a variant of the type 1 per-
oxisomal SKL (Ser-Lys-Leu) targeting signal (Usami et al., 2003). 
 
PHCR is not able to reduce aliphatic aldehydes and ketones, sugars, 3/20-ketosteroids, pros-
taglandins and sepiapterine (Usami et al., 2003), however, the recombinant enzyme shows 
high reductase activity towards pyridine-4-aldehyde, 3- and 4-benzoylpyridines, menadione, 
4-hexanoylpyridine, alkyl phenyl ketones, α-dicarbonyl compounds and all-trans retinal 
(Usami et al., 2003). The enzyme can be inhibited by kaempferol, quercetin, genistein and 
myristic acid (Usami et al., 2003).   
IV.2.1.8 Tetrameric Mitochondrial Carbonyl Reductases 
Tetrameric NADPH-dependent carbonyl reductases have been found in mitochondria of 
mouse (Nakayama et al., 1986; Matsuura et al., 1994), guinea pig and pig lung (Oritani et al., 
1992). The pig lung enzyme consists of four subunits with molecular masses of 24 kDa each 
(Oritani et al., 1992).  The subunits of the guinea pig enzyme have a molecular mass of 32 
kDa (Nakayama et al., 1986). 
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In vitro translation experiments from the mRNA coding for the guinea pig lung enzyme lead 
to the suggestion that the translated protein is transported into the organelle without being 
processed (Nakayama et al., 1988). According to Hartl et al. (1989) the amino terminal se-
quence of pig lung fulfils the requirements for the presequences of most mitochondrial matrix 
proteins (Pfanner et al., 1988; Tropschug et al., 1988; Hartl et al., 1989; Neupert et al., 1990; 
Pfanner et al., 1990a; Pfanner et al., 1990b). 
 
Tetrameric mitochondrial pulmonary carbonyl reductase exhibits low substrate specificity and 
affinity for aromatic and aliphatic carbonyl compounds. It catalyses the reduction of various 
aliphatic and aromatic carbonyl compounds and the oxidation of secondary alcohols and ali-
phatic aldehydes in several animal lungs (Nakayama et al., 1982; Nakayama et al., 1986; Ma-
tsuura et al., 1988; Matsuura et al., 1989; Hara et al., 1991; Oritani et al., 1992). Because of 
its substrate specificity and localization in pulmonary epithelial cells, Hara and coworkers 
(Nakanishi et al., 1995) suggested that tetrameric lung carbonyl reductase functions in the 
pulmonary metabolism of endogenous carbonyl compounds derived from lipid peroxidation, 
as well as in the metabolism of 3-ketosteroids and fatty aldehydes, in addition to the detoxifi-
cation of xenobiotics (Nakanishi et al., 1995). MLCR exhibits high cofactor preference for 
NADP(H) but does also accept NADH at much higher concentrations (Nakanishi et al., 
1995). Interestingly, MLCR is inhibited by the alcohol dehydrogenase inhibitor pyrazole 
(Nakanishi et al., 1995), which is in contrast to cytosolic monomeric carbonyl reductases. 
Nakanishi and coworkers (Nakanishi et al., 1995) also postulated that, even in lung cells, the 
expression of carbonyl reductase is regulated by environmental and hormonal factors, of 
which fatty acids are the most interesting because of their enhancement of the enzyme activity 
(Hara et al., 1992).  
 
As indicated above, tetrameric carbonyl reductase has also been found in the mitochondrial 
fraction of lung cell homogenates of mouse (MLCR) (Matsuura et al., 1990). From the vari-
ous lung cell populations, bronchiolar and alveolar epithelial cells show high levels of MLCR  
expression (Matsuura et al., 1990; Oritani et al., 1992), whereas much lower levels were 
found in other tissues, like for example in adipocytes (Nakanishi et al., 1995). According to 
immunocytochemical studies, the enzyme is located in the mitochondrial matrix of mouse 
lung epithelial cells (Matsuura et al., 1994).  
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In 1995 Tanaka and coworkers (Tanaka et al., 1995; Tanaka et al., 1996a) solved the ternary  
three-dimensional structure of MLCR with NADPH and 2-propanol, and showed that the pro-
tein comprises four identical 29 kDa protein subunits (Tanaka et al., 1996a). Each monomer 
consists of 244 amino acid residues and shows 85% identity to pig tetrameric carbonyl reduc-
tase (PHCR) but only 17% identity to human carbonyl reductase (CBR1). Like other SDR 
superfamily members, tetrameric mitochondrial carbonyl reductases contain the typical cofac-
tor and active site consensus sequences (Nakanishi et al., 1993; Nakanishi et al., 1995). 
 
IV.2.1.9 Dimeric Microsomal Carbonyl Reductase: 11-HSD Type 1 
11-Hydroxysteroid-dehydrogenase (11-HSD); EC 1.1.1.146) is a microsomal enzyme re-
sponsible for the interconversion of the active glucocorticoids cortisol (in man) and corticos-
terone (in rodents) to their hormonally inactive 11-keto metabolites, cortisone and 11-
dehydrocorticosterone, respectively (Monder and Shackleton, 1984). Thus far, two isoformic 
types of the enzyme, 11-HSD1 and 11-HSD2, have been cloned and structurally and func-
tionally characterized. Both belong to the SDR protein superfamily. Although displaying de-
hydrogenase and reductase activities in vitro, the dominant in vivo function of the type-1 en-
zyme is obviously glucocorticoid 11-oxoreduction, thus generating active cortisol from inac-
tive cortisone precursors. In glucocorticoid target tissues, notably the liver, 11-HSD1 is sug-
gested to regulate exposure of active glucocorticoids to the classical glucocorticoid (type II) 
receptor (Fig. IV-2). 
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Fig. IV-2: In vivo reaction of 11-HSD 1 and 11-HSD 2   
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11-HSD 1 distributes ubiquitously with major sites of expression in liver and adipose tissues. It acts as an oxo-
reductase and generates receptor-active cortisol from inactive cortisone. By catalyzing inactivation of cortisol to 
cortisone, 11-HSD 2 protects the mineralocorticoid receptor in aldosterone target tissues. 
 
11-HSD2 seems to work exclusively as dehydrogenase, by inactivating 11-
hydroxyglucocorticoids and thereby ensuring mineralocorticoid specificity of aldosterone to 
the mineralocorticoid (type I) receptor [reviewed in (Seckl, 1997))]. 11-HSD2 is a high- af-
finity NAD-dependent enzyme with an apparent Km for 11-hydroxyglucocorticoids in the low 
nanomolar range (Stewart et al., 1994). It is found principally in mineralocorticoid target tis-
sues such as the kidney and colon, where it protects the mineralocorticoid receptor from corti-
sol excess. Mutations in the gene encoding 11-HSD2 are responsible for a heritable form of 
hypertension, apparent mineralocorticoid excess (Stewart et al., 1996), in which cortisol acts 
as a potent mineralocorticoid. There is general consensus that the type 2 form of 11-HSD 
acts as a hormone-inactivating enzyme, since in vitro and in vivo data suggest it to function 
exclusively as an 11-dehydrogenase of physiological glucocorticoids (Seckl, 1997). How-
ever, with the synthetic glucocorticoids 11-dehydro-dexamethasone and 9-fluorocortisone 
reductase activities of 11-HSD2 could be detected (Li et al., 1997; Quinkler et al., 1997). 
 
Unfortunately, all attempts failed to purify 11-HSD type 2 in a functional state, such that it is 
not yet possible to ascribe non-steroidal carbonyl-reducing activity to this enzyme. Accord-
ingly, the discussion below focusses primarily on the hepatic isoform 11-HSD1. 
 
Whereas the biological functions of 11-HSD2 are fairly well determined, at least in aldoster-
one target tissues, the role of 11-HSD1 is less well understood. 11-HSD1 has been referred 
to as a low affinity glucocorticoid oxidoreductase, exhibiting Km values in the µM range. 
Both dehydrogenase and reductase activities could be demonstrated in homogenates or with 
purified mouse liver enzyme in the presence of NADP+ and NADPH, respectively (Maser 
and Bannenberg, 1994a; Maser and Bannenberg, 1994b), whilst under physiological condi-
tions this enzyme has been considered to function predominantly as reductase (Seckl, 1997). 
Furthermore, mice homozygous for a targeted disruption of the 11-HSD1 gene are unable to 
regenerate corticosterone from inert dehydrocorticosterone (Kotelevtsev et al., 1997). The 
preferential reaction direction of the type 1 form seems to be dependent on cellular context, 
translational modifications, subcellular environment, substrate and cosubstrate. The discrep-
ancy to in vitro observations may result from cell disruption and tissue homogenisation, and 
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indicates the importance of local 11-HSD1 environment and stabilization of the three-
dimensional enzyme architecture.  
 
A variety of diseases, including insulin resistance/type2 diabetes, dyslipidemia, and obesity, 
have been discussed in relation to 11β-HSD1. Recently, 11β-HSD1 knock-out mice were 
found to resist high-fat diet-induced obesity and showed an improved lipid and lipoprotein 
profile as well as hepatic insulin sensitivity (Masuzaki et al., 2001). In contrast, the phenotype 
of transgenic mice overexpressing 11β-HSD1 selectively in adipose tissue resulted in marked 
insulin resistance and hyperlipidemia (Masuzaki et al., 2001). Hence, the ongoing research on 
the potency and pharmaceutical properties of 11β-HSD1 inhibitors will be critical for the suc-
cessful discovery of effective human therapeutic agents to treat the metabolic syndrome 
(Alberts et al., 2002). 
 
As described above, most of the short-chain dehydrogenase/reductase (SDR) enzymes are 
active as either homodimers or –tetramers (Krook et al., 1993b; Jornvall et al., 1995; Tsigelny 
and Baker, 1995b; Tsigelny and Baker, 1995a; Penning, 1997; Grimm et al., 2000b). By gel 
permeation chromatography, it was shown that 11-HSD1 occurs as dimeric enzyme in hu-
man liver (Maser et al., 2002). The kinetic data of 11-HSD1 published so far demonstrated 
an enzyme with a micromolar affinity for glucocorticoids (GCs) (Agarwal et al., 1990; Moore 
et al., 1993; Maser and Bannenberg, 1994b; Maser and Bannenberg, 1994a; Quinkler et al., 
1997; Adams et al., 2000). This hardly seemed compatible with a role of 11-HSD1 to regu-
late access of GCs to the GR since both endogenous 'free' GC levels as well as the dissocia-
tion constants of the GR for GCs range in low nanomolar concentrations. This enigma was 
solved by functional studies and detailed kinetic analyses with purified 11-HSD1 from hu-
man liver (Maser et al., 2002). When Michaelis-Menten kinetics were considered with the 
purified enzyme, the Km values for GC oxidoreduction ranged in low micromolar concentra-
tions. However, oligomeric enzymes often display kinetics other than that described by the 
Michaelis-Menten equation. When applying sigmoidal dose-response kinetic as a significantly 
better model to fit data, cooperative kinetics of 11-HSD1 with cortisone and dehydrocorti-
costerone (glucoorticoid 11-oxo-reducing activity) were observed (Maser et al., 2002).  
 
Enzyme cooperativity is an important feature, especially of enzymes acting as regulators in 
physiological processes. 11-HSD 1 has been shown to dynamically adapt to low as well as to 
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high substrate concentrations, thereby providing the fine-tuning required as a consequence of 
great variations in circadian plasma glucocorticoid levels (Maser et al., 2002).  
 
The distribution of 11-HSD1 among tissues has been extensively studied, and its expression 
shown in glucocorticoid target tissues, such as liver, lung, gonad, cerebellum, and pituitary. 
Interestingly, evidence is emerging to suggest a fundamental role for 11-HSD1 in the reduc-
tive metabolism of non-steroidal carbonyl compounds in mammals, in addition to its implica-
tion in glucocorticoid activation (Maser and Bannenberg, 1994a; Maser and Bannenberg, 
1994b; Maser et al., 1994; Maser, 1995; Maser and Oppermann, 1995; Oppermann et al., 
1995; Maser et al., 1996; Rekka et al., 1996; Maser, 1997; Maser and Oppermann, 1997; Ma-
ser, 1998). 
 
With the enzyme purified to homogeneity it was demonstrated that 11-HSD1 is capable of 
acting as carbonyl reductase in the detoxification of aldehydes, ketones and quinones, like for 
example metyrapone, p-nitroacetophenone, p-nitrobenzaldehyde, menadione, oracin, and the 
tobacco-specific nitrosamine NNK [reviewed in (Hoffmann et al., 2006))]. Inhibition experi-
ments revealed strong sensitivity of xenobiotic carbonyl reduction to glucocorticoids and 
other endogenous steroids. The competitive nature of this inhibition suggests that both, ster-
oids (glucocorticoids) and xenobiotic carbonyl substances bind to the same catalytically ac-
tive site of 11-HSD1. It is concluded that 11-HSD1 plays an important role in phase-I bio-
transformation of pharmacologically relevant carbonyl substances as well as protecting organ-
isms against toxic aldehydes, ketones and quinones by converting them to less lipophilic and 
more soluble and conjugatable metabolites. Thus, 11-HSD1 contributes to an expanding list 
of pluripotent hydroxysteroid dehydrogenases which are involved in reductive xenobiotic 
carbonyl metabolism as well as being specific towards their physiological steroid substrate. 
 
In case of oracin, 11β-HSD1 enzyme cooperativity may become important with respect to the 
plasma concentrations that could be achieved with oracin, and to enhance the chemotherapeu-
tic efficacy of this novel anti-cancer drug (Wsol et al., 2004) (cf. chapter 4.6). Due to its co-
operativity for carbonyl reduction, 11-HSD1 is also able to metabolize even nanomolar con-
centrations of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone 
(NNK), a fact which is important in view of the relatively low levels of this carcinogen ob-
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served in smokers (Maser et al., 2003) (cf. chapter V.7 ; Protection against Tobacco Smoke-
Derived Lung Cancer). 
 
11-HSD1 is potently (in nanomolar concentrations) inhibited by glycyrrhetinic acid, the 
main constituent of licorice (Maser et al., 2003). Hence, licorice exposure may affect NNK 
detoxification by inhibition of 11-HSD1 (Maser, 2004). 
 
As a membrane-bound protein it has an extended N-terminal part relative to other SDR pro-
teins. This hydrophobic segment is likely to anchor in or span the membrane and it contains a 
possible cleavage signal-peptide sequence which is very similar in all 11β-HSD structures 
(Krozowski, 1992).  
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V Biological Functions of Carbonyl-Reducing Enzymes 
 
The physiological role of several HSDs in steroid metabolism is known so far, however, some 
exhibit pluripotency for steroid and non-steroid substrates (cf. chapter IV; Pluripotent Car-
bonyl Reductases of the SDR Superfamily) (Maser, 1995), thereby contributing to important 
detoxification reactions. The physiological role of the carbonyl reductases is still not clear. In 
some cases, their tissue distribution suggests  physiological  roles in the endogenous metabo-
lism of prostaglandins (Lee and Levine, 1974a), steroids, or tetrahydrobiopterin synthesis 
(Park et al., 1991). On the other hand, with regard to their wide substrate spectrum a general 
role in the detoxification of xenobiotic and endogenous reactive non-steroid carbonyl com-
pounds has been suggested (Wermuth et al., 1986). Moreover, it is believed that their most 
important biological role is the protection from damage by accumulation of toxic carbonyl 
compounds, such as for example quinones (Wermuth et al., 1986), aflatoxin B1 (Ellis and 
Hayes, 1995), aldophosphamide, tripeptidyl aldehydes, chordecone  [reviewed in (Maser, 
1995)], and the tobacco-specific nitrosamine NNK [reviewed in (Maser, 1997; Maser, 2004)]. 
As will be outlined in the following chapter, it is difficult to ascribe an exclusive role for en-
dogenous or exogenous substrates to carbonyl reductases, but several examples will empha-
size their contribution as general means in detoxification processes. 
 
V.1  Roles in Steroid and Prostaglandin Metabolism 
The role of 3/20-HSD of S. hydrogenans (cf. chapter IV.1.1; 3/20β-Hydroxysteroid De-
hydrogenase of Streptomyces hydrogenans), 3-HSD/CR from C. testosteroni (cf. chapter 
IV.1.2; 3-Hydroxysteroid Dehydrogenase/Carbonyl Reductase of Comamonas testosteroni) 
and 11-HSD1 (cf. chapter IV.2.1.9; Dimeric Microsomal Carbonyl Reductase: 11-HSD 
Type 1) of mammalian species in the metabolism of steroids is well established and has been 
discussed in chapter 3 of this review. Interestingly, some of the carbonyl reductases also me-
tabolize steroids. After CBR1 has been described as important enzyme in the detoxification of 
carbonyl compounds (Wermuth, 1985), Satoh and coworkers (Iwata et al., 1989; Iwata et al., 
1990b) suggested a new role for carbonyl reductases in steroid metabolism because of the 
ability to metabolize 3-ketosteroids and because of the exclusive expression in rat reproduc-
tive tissues and adrenals. Since then, the activity of carbonyl reductases has been found to be 
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regulated by estrogens and gonadotropins and was suggested to be important for the ovulation 
process (Inazu and Satoh, 1994; Inazu and Fujii, 1997; Espey et al., 2000; Fujii et al., 2005). 
In line with these findings is the fact that certain 5-reduced steroids, e.g. dihydrotestoster-
one, are among the best substrates of carbonyl reductase from rat ovary, whereas 5β-reduced 
steroids are not reduced (Wermuth, 1995). The ability of carbonyl reductases to interconvert 
prostaglandin F2α and prostaglandin E2 suggests a further regulatory role of this enzyme in 
prostaglandin function (Iwata et al., 1989; Espey et al., 2000) (cf. chapter V ; Biological 
Functions of Carbonyl-Reducing Enzymes). 
 
V.2  Tetrahydrobiopterin Synthesis 
Tetrahydrobiopterin (BH4) is required as a cofactor for aromatic amino acid hydroxylases 
which synthesize precursors of catecholamine and indoleamine neurotransmitters in the brain. 
BH4 is also a cofactor of nitric oxide synthase which generates nitric oxide as a messenger 
molecule. The biosynthesis of BH4 includes two carbonyl reduction steps: First, an intermedi-
ate, 6-pyruvoyltetrahydropterin (PPH4) is reduced to 6-(1’-oxo-2’-hydroxypropyl)-
tetrahydropterin (1’-OXPH4) or 6-(1’-hydroxy-2’oxopropyl)-tetrahydropterin (2’-OXPH4). 
Second, these intermediates are converted to BH4 (Fig. V-1). 
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Fig. V-1: Biosynthetic pathways from 6-pyruvoyltetrahydropterin (PPH4) to tetrahydrobiopterin (BH4)  
(for details see text)   
 
The enzyme sepiapterin reductase (SPR) is the main catalyst in BH4 formation in that it cata-
lyzes the carbonyl reduction of both keto groups of PPH4 to the corresponding diol form BH4 
(Park et al., 1991; Iino et al., 2003). According to its primary structure, SPR belongs to the 
SDR superfamily (Jornvall et al., 1995). Interestingly, patients with SPR deficiency show 
normal urinary excretion of pterins and no hyperphenylalaninemia, which suggests an alterna-
tive pathway of BH4 formation from PPH4.  
 
Park and coworkers (Park et al., 1991) reported that human CBR1 is able to reduce PPH4 to 
1’-OXPH4 and 2’-OXPH4, the latter being further converted to BH4 by AKR1B1 (aldose re-
ductase). They suggested an alternative pathway of PPH4 carbonyl reduction to form BH4. 
More detailed analysis revealed that, compared to its 1’-OXPH4-forming activity, human car-
bonyl reductase has a quite low activity to form 2’-OXPH4 (Iino et al., 2003). From the AKR 
superfamily, AKR1A1 (human aldehyde reductase), AKR1B1 and AKR1C1 (human 20-
HSD) form only 1’-OXPH4, whereas AKR1C2 (human 3α-HSD type 3) and AKR1C4 (hu-
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man 3α-HSD type 1) can form both, 1’-OXPH4 and 2’-OXPH4 as the major and minor prod-
ucts (Iino et al., 2003). AKR1C3 (3α-HSD type 2) only produces 2’-OXPH4 from PPH4 (Iino 
et al., 2003). In the further reaction pathway, AKR1B1 reduces specifically the 2’-keto group 
from 2’-OXPH4 to form BH4. This reaction is not catalyzed by AKR1A1, AKR1C1, 
AKR1C2, AKR1C4 and human CBR1 (Iino et al., 2003). On the other hand, AKR1B1 is not 
able to form BH4 from 1’-OXPH4. 
 
Interestingly, two carbonyl reductases (CRI and CRII) have been discovered in the fat body of 
the silkworm bombyx mori which differ from SPR and human CBR1, because CRI shows 
specificity for the reduction of the 2’-keto group of PPH4 and 2’-OXPH4, and CRII specifi-
cally reduces the 1’-keto group of PPH4 and 1’-OXPH4 (Iino et al., 2000; Iino et al., 2003). 
Enzymes similar to silkworm CRI and CRII do also exist in chicken (Iino et al., 2003). 
Accordingly, in humans, CBR1 together with some AKR enzymes show a kind of “house-
keeping” nature and play a role in case of normal pathway deficiency. 
 
V.3  Neuroprotection by Carbonyl Reductase? 
Oxidative stress in brain is the major cause of neurodegenerative disorders including Alz-
heimer`s, Parkinson`s, Huntington`s and Creutzfeld-Jakob disease (Sayre et al., 2001; Daw-
son and Dawson, 2003). Apparently, all these diseases share a common pathogenesis which is 
based on an intracellular imbalance between the formation of free radicals and antioxidative 
defence mechanisms. The central nervous system appears to be particularly vulnerable to oxi-
dative stress because of its high rate of oxygen utilization, high content of unsaturated lipids 
and because, in contrast to other organs, its anti-oxidative capacity is comparatively weak.  
 
Despite the increasing number of reports finding a causal relation between oxidative stress 
and neurodegeneration, little is known about the genetic elements that confer protection 
against the deleterious effects of oxidation in neurons. An important element that acted as a 
neuroprotective agent in the cellular defence mechanism against oxidative stress was recently 
found by Botella et al. (Botella et al., 2004). They demonstrated that oxidative stress is a di-
rect cause of neurodegeneration in the Drosophila central nervous system and they identified 
a new gene, sniffer, in Drosophila melanogaster which prevents age-dependent and oxidative 
stress-induced neurodegeneration. According to bioinformatic studies on the primary struc-
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ture, it turned out that Sniffer is a carbonyl reductase (CBR1) (Wermuth et al., 1988). How-
ever, the precise mechanism of neuroprotection by Sniffer in Drosophila remained obscure 
(Botella et al., 2004). 
 
Reactive oxygen species (ROS) seem to play a significant role in neuronal cell death in that 
they generate reactive aldehydes by membrane lipid peroxidation. Examples of such toxic 
compounds are 4-oxonon-2-enal (ONE), 4-hydroxynon-2-enal (HNE) and acrolein, which 
contain an α,β-unsaturated aldehyde capable of reacting with cysteine, histidine, and lysine in 
proteins via Michael addition to the C=C bond (Nadkarni and Sayre, 1995). Primary amines 
may alternatively react with the carbonyl group to form Schiff bases (Nadkarni and Sayre, 
1995). Importantly, a large number of neurodegenerative disease states is associated with in-
creased accumulation of protein adducts derived from reactive aldehydes produced by lipid 
peroxidation (Shapiro, 1998) (Fig. V-2).  
Fig. V-2: Scheme on the metabolic 
inactivation of the lipid peroxida-
tion product 4-oxonon-2-enal . 
Abbreviations:  
DHN = 4-dihydroxynonene;  
HNA = 4-hydroxynonan-acid;  
HNE = 4-hydroxynon-2-enal;  
HNO = 1-hydroxynon-2-en-4-one; 
ONA = 4-oxononanal;  
ONE = 4-oxonon-2-enal;   
GSH = reduced glutathione,  
AR = aldose reductase (AKR1B1); 
ALDH = aldehyde dehydrogenase; 
CBR1 = human carbonyl reductase. 
 
 
 
 
 
 
 
 
 
 
 
ROS
Reactive
aldehydes
(incl. ONE)
Membrane 
lipids
ONE
GS-ONE
Lipidperoxidation
AR     /   CBR1
+ GSH
GS-HNE
GS-DHN
HNE
+ 
GSH
AR
CBR1
HNA
ALDH
HNO
CBR1
CBR1
ONA
Brain
damage
Biological Functions of Carbonyl-Reducing Enzymes 
 
53
In general, routes of detoxification of these carbonylic lipids include spontaneous and en-
zyme-catalyzed glutathione (GSH) conjugation and either oxidation by aldehyde dehydro-
genase or carbonyl reduction catalyzed by AKR or SDR enzymes, the carbonyl reductase 
Sniffer belonging to the latter (cf. chapter IV.1.3, Insect Carbonyl Reductase: Sniffer of Dro-
sophila melanogaster). Intriguingly, human CBR1 was recently demonstrated to have activity 
toward a product of lipid peroxidation in that it catalyzed the reduction of 4-oxonon-2-enal 
(ONE) (Doorn et al., 2004). ONE was previously found to be a major product of lipid peroxi-
dation and is a particularly potent genotoxin (Dawson and Dawson, 2003), which reacts with 
DNA bases to form substituted etheno-adducts. In addition, ONE is highly reactive toward the 
protein nucleophiles cysteine, histidine, lysine, and arginine, and also toward thiols, which 
suggests that it may also play a role in lipid peroxidation-mediated cross-linking of proteins 
(Lin et al., 2005). Importantly, ONE has recently been found to be both more neurotoxic and 
more protein-reactive than 4-hydroxynon-2-enal (HNE) (Lin et al., 2005). 
 
NADPH-dependent ONE ketone reduction resulted in the production of HNE, and ONE alde-
hyde reduction yielded 1-hydroxynon-2-en-4-one (HNO) (Doorn et al., 2004). Furthermore, 
CBR1 was shown for the first time to catalyze hydride transfer to the C=C double bond of 
ONE, resulting in 4-oxononanal (ONA). Interestingly, the glutathione adduct of ONE (GS-
ONE) was also found to be a substrate for CBR1, resulting in the production of GS-HNE.  
 
The sniffer gene is expressed within the entire cortex of the fly brain, where all neuronal cell 
bodies are localized. Sniffer is, so far, the only known functional carbonyl reductase in Dro-
sophila melanogaster which emphasizes the importance of this enzyme as a neuroprotective 
agent (Botella et al., 2004). This is supported by the fact that CBR1 has been first isolated and 
cloned from human brain (Wermuth, 1981), suggesting that human brain may be an important 
site of CBR1 distribution. Hence, several lines of evidence suggest that carbonyl reductases 
represent a significant pathway for the detoxification of reactive aldehydes derived from lipid 
peroxidation and that carbonyl reductases in humans are essential for neuronal cell survival 
and to confer protection against oxidative stress-induced brain degeneration (Hoffmann et al., 
2006).  
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V.4  Quinone Detoxification 
Quinones are ubiquitous in nature and constitute an important class of naturally occurring 
compounds that are found in plants, fungi, bacteria, and mammals and that function primarily 
as components of the electron transport chains involved in cellular respiration and photosyn-
thesis (O'Brien, 1991). Human exposure to quinones can occur via drug therapy, via the diet 
or via airborne pollutants. In addition, mammals themselves synthesize quinones, primarily by 
oxidative metabolism of aromatic precursors, including endogenous compounds such as cate-
cholamines and estrogens as well as xenobiotics. Endogenous polymeric quinones are for ex-
ample the melanins that are oxidative condensates of dopa, dopamine, and cysteine, and 
which comprise the pigments of hair and skin (Monks et al., 1992). In view of the inevitable 
human exposure to quinones and their inherent reactivity, a substantial amount of research has 
focused on the chemistry and biochemical toxicology of these compounds. 
 
Quinones may be toxic to cells by a number of mechanisms including redox cycling, aryla-
tion, intercalation, induction of DNA strand breaks, interference with mitochondrial respira-
tion, and the generation of site-specific free radicals. Much research has emphasized the role 
of oxidative stress and redox cycling in this toxicity (O'Brien, 1991; Monks et al., 1992). 
Quinones may undergo enzymatic one-electron reduction by microsomal NADPH-
cytochrome P450 reductase, microsomal NADH-cytochrome b5 reductase, and mitochondrial 
NADH-ubiquinone oxidoreductase, resulting in the formation of semiquinones. Semiquinones 
may be toxic per se or react with molecular oxygen, thus forming superoxide anion radical 
and regenerating the parent quinone, which is then available for re-reduction and hence un-
dergoes a futile redox cycling. The net result of this redox cycling is an oxidative stress result-
ing from disproportionate consumption of cellular reducing equivalents and the generation of 
active oxygen species (O'Brien, 1991; Monks et al., 1992).  
 
Alternatively, two-electron reduction of quinones has generally been considered to be a de-
toxification pathway since the resulting hydroquinone may be conjugated with glucuronic 
acid or sulfate and excreted  into the bile (Wermuth et al., 1986; Lind et al., 1990; Maser, 
1993). Two-electron reduction of quinones is catalyzed by cytosolic NAD(P)H: quinone oxi-
doreductase (NQO; EC 1.6.99.2; a flavoprotein previously known as DT-diaphorase), cytoso-
lic carbonyl reductase, and microsomal 11-HSD1 (Maser, 1993). Two NQO-enzymes are 
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known, the NAD(P)H: quinone acceptor oxidoreductase (NQO1, DT-diaphorase) and dihy-
dronicotinamide riboside: quinone oxidoreductase (NQO2). NQO2 exhibits a high sequence 
identity to DT-diaphorase and is considered to be an isozyme of DT-diaphorase (Adams et al., 
2000).  
 
In some cases, such as with bioreactive alkylating agents, reduction by NQO leads to activa-
tion of the compound (Ross et al., 1993). It has also been proposed, for example, that reduc-
tion of 1,4-naphthoquinones and their glutathionyl conjugates by NQO may lead to redox 
cycling dependent on the rate of reduction to the hydroquinone followed by its autooxidation 
back to the parent quinone (Brunmark et al., 1988; Buffinton et al., 1989). The detoxification 
of quinones is conventionally understood in terms of their conjugation with glucuronate or 
sulfate. The two-electron reduction of the quinone is a chemical requirement in the course of 
its conjugation to a glucuronide, hence preventing further redox transitions.. 
 
NQOs are obligate two-electron reductases which can utilize either NADH or NADPH as an 
electron donor (Lind et al., 1990). Importantly, two carbonyl-reducing enzymes of the SDR 
superfamily have also been described to catalyze the two-electron reduction of quinones, cy-
tosolic carbonyl reductase and microsomal 11-HSD1, thereby forming conjugatable hydro-
quinone metabolites (Fig. IV-3).  
Wermuth and coworkers reported that CBR1, but not NQO, provides the enzymatic basis of 
quinone detoxification in man (Wermuth et al., 1986). 
For example, quinones such as ubiquinone-1, menadione, and phenanthrenequinone are the 
best substrates for human brain carbonyl reductase (Wermuth, 1981).  
 
Fig. V-3: Role of 11β-HSD1 and CBR1 in 
quinone detoxification.  
(NQO = NAD(P)H: Quinone-oxidoreductase; R 
= UDP-glucuronic acid or other conjugant) 
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reductase are soluble proteins, thereby acting as quinone "scavengers" in cytosol, membrane-
bound 11-HSD1 may play an exceptionally important role as protective device against en-
dogenous membrane damage. Due to its subcellular localization in the endoplasmic reticulum, 
11-HSD1, by catalyzing hydroquinone formation (Yokota et al., 1992), prevents semi-
quinone-induced oxygen radical generation and subsequent lipid peroxidation of membranes. 
 
The exact molecular mechanisms involved in quinone or hydroquinone cytotoxicity are still 
largely unknown. Their use as antitumor drugs and antibiotics, together with their widespread 
occurrence in nature, makes it imperative to understand their metabolic activation/inactivation 
and the resulting effects on cellular function. Whether a particular quinone is cytotoxic will 
depend on the biochemical makeup of the target cell. All cells have enzymes for the reductive 
metabolism of quinones, but the capacity of reductases carrying out a one-electron reduction 
versus those carrying out a two-electron reduction would be expected to cause large variations 
in the activation or de-activation of quinones. The biological significance of carbonyl reduc-
tase and 11-HSD1 in these systems requires further investigation. 
 
V.5  Carbonyl Reduction in Drug Metabolism and Pharmacology 
In general, carbonyl reduction plays a significant role in the phase-I metabolism of carbonyl-
containing drugs (Bachur, 1976; Ahmed et al., 1979; Felsted and Bachur, 1980; Imamura et 
al., 1993; Rosemond and Walsh, 2004) by converting them to less lipophilic alcohol metabo-
lites. These reduced alcohol metabolites can then be excreted as well as rapidly converted to 
glucuronyl or sulfate conjugates by phase-II metabolizing enzymes, which facilitate their 
elimination. A summary of pharmacologically relevant drugs that undergo carbonyl reduction 
is given in Table V-1. 
As is known from other phase-I reactions like oxidation by the cytochrome P450 system, car-
bonyl reduction is of significance in a variety of drug inactivation processes such as for ex-
ample for warfarin, haloperidol, or the anti-tumor drugs oracin (Wsol et al., 2003; Wsol et al., 
2004), daunorubicin (Ax et al., 2000) and doxorubicin (Maser, 1995). For the latter it is as-
sumed that the alcohol metabolite doxorubicinol is responsible for the cardiotoxicity observed 
upon doxorubicin chemotherapy (Olson et al., 2003). On the other hand, the respective carbi-
nols formed may retain their therapeutic potency (e.g. metyrapol from metyrapone), thus pro-
longing the pharmacodynamic effect of the parent drug or, in some instances, a compound 
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gains activity through carbonyl reduction, as is the case for pentoxifylline, chloral hydrate, 
and the prodrug precursors of the -adrenergic blockers propranolol and alprenolol. An im-
portant example of drug activation by carbonyl reduction is dolasetron. This drug is adminis-
tered in its keto form and undergoes carbonyl reduction by CBR1 and several AKR enzymes 
(Breyer-Pfaff and Nill, 2004). The resulting alcohol reduced dolasetron has a 40-fold higher 
serotonin antagonist activity compared to the parent compound (Boeijinga et al., 1992). Feno-
fibrate undergoes hydrolytic cleavage to fenofibric acid followed by ketone reduction, and 
reduced fenofibric acid contributes to the lipid-lowering activity of this drug (Caldwell, 
1989). 
 
Drugs: 
 
acetohexamide, actinomycin D, adriamycin, befunolol, chloral hydrate, 
daunorubicin, dolasetron, ethacrynic acid, fenofibrate, haloperidol, hydro-
morphone, isatin, ketoconazole, ketoprofen, levobunolol, lisofylline, loxo-
profen, metyrapone, mitomycin C, moperone, naftazone, naloxone, 
naltrexone, oxisuran, pentoxifylline, tienilic acid, timiperone, trifluperidol, 
warfarin, wortmannin 
Toxicants/ 
Carcinogens: 
 
acetophenone, [acetaldehyde] (after ethanol oxidation), [aflatoxin B1], 
alachlor, aldehydes (various, e.g. from fruits), [aldophosphamide], benzal-
dehyde, benzoylpyridine, chlordecone, 3-deoxyglucosone, methylglyoxal, 
quinones (ubiquinone, naphthoquinone, phenanthrenequinone, benzanthra-
cenequinone etc.), NNK (tobacco-specific nitrosamine), zearalenone. 
 
Endogenous: 
 
biogenic aldehydes, endogenous quinones (e.g. metabolites from cate-
cholamines), prostaglandines, products of lipid peroxidation (acrolein, 4-
hydroxynonenal, malondialdehyde etc.), steroids.  
 
Table V-1: Multiplicity of carbonyl substrates 
 
The opioid antagonists naloxone and naltrexone are stereoselectively metabolized by carbonyl 
reduction at the C-6 oxogroup to 6-naloxol (Yamano et al., 1999) and 6β-naltrexol (Dayton 
and Inturrisi, 1976), respectively. Of the carbonyl-reducing enzymes isolated from human 
liver cytosol, AKR1C4 proved to be the most efficient in naltrexone reduction followed by 
AKR1C2, whereas CBR1 was devoid of activity (Breyer-Pfaff and Nill, 2004). A high-
affinity stereoselective carbonyl reduction of ketotifen and of 10-oxonortriptyline has recently 
been reported (Breyer-Pfaff and Nill, 1999; Breyer-Pfaff and Nill, 2000). 
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V.6  Role in Chemotherapy Resistance 
In anti-tumor chemotherapy, the occurrence of drug resistance is a major obstacle and origi-
nates principally from pharmacodynamic or pharmacokinetic mechanisms. Anthracyclines 
like daunorubicin (DRC) and doxorubicin (DOXO) are the most valuable cytostatic agents in 
chemotherapy, but their usefulness is limited by intrinsic or acquired resistance towards these 
drugs. Anthracycline resistance is not merely the result of alterations in drug uptake and re-
tention (McGrath and Center, 1987; Gessner et al., 1990; Ramachandran et al., 1993; Toffoli 
et al., 1994), but also mediated by enzymatic anthracycline detoxification that is upregulated 
upon exposure to these drugs (Soldan et al., 1996a; Soldan et al., 1996b). Interestingly, 13-
hydroxy metabolites of anthracyclines, such as doxorubicinol and daunorubicinol, are signifi-
cantly less potent than the parent drug in terms of inhibiting tumor cell growth in vitro (Beran 
et al., 1979; Ozols et al., 1980; Yesair et al., 1980; Dessypris et al., 1986; Schott and Robert, 
1989; Ohara et al., 1995; Olson et al., 2003), suggesting that carbonyl reduction is an impor-
tant biochemical mechanism in the detoxification of carbonyl group-bearing anthracyclines. 
Therefore, elevated levels of anthracycline carbonyl-reducing enzymes constitute a mecha-
nism in the development of resistance towards DRC and DOXO (Soldan et al., 1996a; Soldan 
et al., 1996b).  
 
Three enzymes capable of catalyzing DRC carbonyl reduction have been identified in human 
liver: AKR1A1 (aldehyde reductase) and AKR1C2 (dihydrodiol dehydrogenase 2) from the 
AKR superfamily and carbonyl reductase (CBR1) from the SDR superfamily (Ohara et al., 
1995) (Fig. V-4). 
 
In a study by Ax and coworkers (Ax et al., 2000), a resistant descendant of the human stom-
ach carcinoma cell line EPG85-257 was selected in the presence of increasing concentrations 
of DRC. The resulting cells were used to evaluate an induced carbonyl reduction as a new 
determinant in DRC resistance. IC50 values of DRC increased almost 8-fold in the resistant 
descendants compared to the parental cell line. Resistant cells possessed 6-fold higher levels 
of carbonyl-reducing activity, leading to the less toxic 13-hydroxy metabolite daunorubicinol. 
The 6-fold higher daunorubicinol formation roughly parallels the 8-fold increase of DRC IC50 
values during cell selection, and therefore was suspected to account for DRC resistance in 
these cells. The determination of specific carbonyl-reducing enzymes known to be involved in 
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DRC detoxification, revealed that mainly the mRNA expression of CBR1 increased in the 
resistant descendant, in addition to some minor increase in AKR1B1 and AKR1C2 levels. 
Hence, DRC resistance in human stomach carcinoma cells may mainly result from an induc-
tion of CBR1. 
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Fig. V-4: Scheme of daunorubicin carbonyl reduction  
(for details see text) 
 
Oracin, is a new anti-cancer drug which is presently in phase II clinical trials. The main ad-
vantages of this novel chemotherapeutic are the possibility of peroral administration, the ab-
sence of cardiotoxicity (Gersl et al., 1996) (which e.g. is the main dose-restricting factor in 
clinical chemotherapy of DOXO), the negative results in the Ames test on mutagenicity, very 
low hepatotoxicity, and its favorable pharmacokinetics. From its chemical structure, a DNA 
intercalation mode of action can be inferred, similar to that of anti-tumor antibiotics from the 
anthracycline group. In addition, several other mechanisms affecting tumor cell growth have 
been proven. They involve the inhibition of topoisomerase II (Miko et al., 2002), the stimula-
tion of aerobic consumption of glucose and, to a lesser extent, the formation of lactate in tu-
mor cells, as well as induction of apoptosis (Melka, 1993). 
 
Metabolic studies have revealed carbonyl reduction of oracin to dihydrooracin (DHO) as the 
main metabolic pathway in common laboratory animals (Szotakova et al., 1996; Wsol et al., 
1996; Wsol et al., 1998) as well as in human liver (Wsol et al., 2000). Reduction of the pro-
chiral carbonyl group at the 11-position of oracin leads to the formation of chiral DHO, which  
was found both in microsomal and cytosolic fractions of all species studied (Wsol et al., 
1999). 
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The enzyme responsible for oracin carbonyl reduction in human liver microsomes was identi-
fied as 11-HSD1  (cf. chapter IV.2.1.9, Dimeric Microsomal Carbonyl Reductase: 11-HSD 
Type 1) (Szotakova et al., 1996; Wsol et al., 1996; Wsol et al., 1998; Wsol et al., 2003; Wsol 
et al., 2004). In human liver cytosol, CBR1 and three members of the aldo-keto reductase 
(AKR) superfamily were found to mediate oracin carbonyl reduction, namely AKR1C1, 1C2 
and 1C4. Interestingly, AKR1C2 and AKR1C4 are absolutely stereospecific and produce (+)-
DHO exclusively, whereas AKR1C1 produces also minor amounts of ()-DHO. On the other 
hand, the efficiency of AKR1C1 in oracin reduction is higher by at least one order of magni-
tude than those of the other two enzymes. 
 
The clinical consequences of these findings remain to be established. It is noteworthy that 
several flavonoids serve as potent inhibitors of carbonyl-reducing enzymes (Wermuth, 1985; 
Inazu et al., 1992b). Co-administration of flavonoids during anthracycline chemotherapy may, 
therefore, represent an attractive means to bypass classical drug resistance via inhibition of 
DRC and DOXO detoxification by carbonyl reduction. 
 
As stated above, prevention of carbonyl reduction may represent a potential approach to en-
hancing the safety and efficiency of cytostatics in clinical chemotherapy (Propper and Maser, 
1997). This could be achieved either by inhibiting the enzymes responsible for drug inactiva-
tion or by chemically modifying the chemotherapeutic molecule, such that it looses its affinity 
for the inactivating enzymes. This latter approach was used in case of the novel chemothera-
peutic benfluron (B), where a dimethoxy substitution of the parent compound resulted in the 
development of 3,9-dimethoxybenfluron (D) (Miko et al., 1991). Benfluron (B) is a potential 
benzo[c]fluorene antineoplastic agent with high activity against a broad spectrum of experi-
mental tumors in vitro and in vivo (Miko et al., 1991). The introduction of the two methoxy 
groups lead to a protection of the carbonyl group, such that 3,9-dimethoxybenfluron gained a 
9-fold resistance against carbonyl reduction compared to benfluron (Skalova et al., 2002). 
Carbonyl reduction of D in comparison to that of B was 4 times less extensive in human liver 
microsomes and and 6 – 10 times less extensive in cytosol. Moreover, about 10 – 20 times 
higher amounts of dihydro-B than dihydro-D were produced in primary cultures of human 
hepatocytes. Two human enzymes of the SDR superfamily, 11HSD1 and CBR1, were 
shown to reduce B and D. With 11HSD1, about 10 times higher rates of carbonyl reduction 
were observed for B than for D 
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The results clearly demonstrate that dimethoxy substitution protects the carbonyl group of the 
benzo[c]fluorene moiety against the deactivation by microsomal and cytosolic reductases. 
Therefore, chemical modification seems to be a promising way of preventing the metabolic 
inactivation of anti-cancer drugs and may be advantageous in the development of potent 
chemotherapeutics, as are information on the participating enzymes and their specific inhibi-
tors. 
 
V.7  Protection against Tobacco Smoke-Derived Lung Cancer 
Among the more than 40 different carcinogens present in tobacco and tobacco smoke, 4-
methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK = nicotine-derived nitrosamine ketone) is 
the most potent and abundant (Hecht, 1998). NNK is generated by nitrosation of nicotine dur-
ing tobacco curing and smoking (Hecht, 1998). It induces lung tumors in all laboratory animal 
species tested (Hoffmann et al., 1985; Hecht, 1994) and has also been shown to induce nasal 
cavity, pancreatic, and liver tumors in rats (Hoffmann et al., 1985; Hecht, 1994). From studies 
on the occurrence, carcinogenicity and metabolic activation of tobacco-specific nitrosamines, 
NNK is believed to play a role in human tobacco-related cancers (Hoffmann et al., 1985; 
Hecht, 1994). NNK requires metabolic activation in order to exert its carcinogenic effect and 
there are competing pathways for NNK activation and detoxification (Fig. V-5. The major 
pathways of NNK metabolic activation proceed by -hydroxylation at the carbons adjacent to 
the N-nitroso group. This leads to a series of unstable intermediates that alkylate DNA and 
hemoglobin. The DNA alkylation products are critical in carcinogenesis by NNK (Hecht, 
1996). 
 
However, the competing pathway for NNK activation is NNK detoxification, which proceeds 
via carbonyl reduction of NNK to NNAL, followed by glucuronidation of NNAL (Fig. V-5). 
Although N-oxidation has been considered as a NNK inactivation reaction, this pathway plays 
only a minor role in man in vitro and in vivo (Hecht, 1994; Carmella et al., 1997). It has there-
fore been postulated that the susceptibility of a tissue to tumor formation may vary depending 
on the extent of the competing pathways -hydroxylation versus carbonyl reduction (Maser et 
al., 1996; Maser, 1997; Maser, 1998; Atalla et al., 2000; Maser, 2004). 
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Carbonyl reduction to NNAL is a very efficient pathway of NNK in animal and human tissues  
(Maser, 1997; Maser, 1998). In laboratory animals, the main metabolites in blood and urine 
after i.v. administration of NNK resulted from carbonyl reduction (followed by glucuronida-
tion or N-oxidation), indicating that carbonyl reduction to NNAL greatly exceeds metabolism 
by NNK -hydroxylation (Adams et al., 1985a; Adams et al., 1985b; Hecht et al., 1993). The 
predominance of carbonyl reduction has been confirmed by a characterization and quantifica-
tion of NNK metabolites in the urine of smokers and smokeless tobacco users. The results 
clearly demonstrate that detoxification of NNK in vivo occurs mainly by carbonyl reduction 
and glucuronidation (Fig. V-5) (Maser, 1997; Maser, 1998). 
 
In vitro studies revealed that NNAL was the major metabolite in hepatocytes and liver micro-
somal preparations indicating that the liver plays the predominant role in metabolism of NNK. 
In rodent lung tissue, carbonyl reduction was in the same range as -hydroxylation and N-
oxidation, whereas in rat nasal mucosa no NNAL was detectable (Maser, 1997; Maser, 1998). 
The absence of NNAL formation in the nasal mucosa might explain why nasal mucosa is par-
ticularly susceptible to NNK-induced carcinogenesis.  
 
In numerous studies, cytochrome P450 isozymes mediating NNK activation via -
hydroxylation have been investigated. However, although constituting the major pathway of 
NNK metabolism in several tissues, the enzymes that catalyze the carbonyl reduction of NNK 
to NNAL have awaited their characterization since 1980 (Hecht, 1996). 
 
We could finally isolate and characterize five different enzymes catalyzing NNK carbonyl 
reduction in man (Fig. V-5). These are microsomal 11-hydroxysteroid dehydrogenase type 1 
(11-HSD1) (EC 1.1.1.146) (Maser et al., 1996; Maser, 1998) and cytosolic carbonyl reduc-
tase (CBR1)  (EC 1.1.1.184) (Atalla et al., 2000), both enzymes belonging to the SDR super-
family. In addition, three members of the AKR superfamily have been shown to mediate 
NNK carbonyl reduction, namely AKR1C1, AKR1C2 and AKR1C4 (EC 1.3.1.20) (Atalla et 
al., 2000), previously designated as dihydrodiol dehydrogenases DDH1, DDH2 and DDH4, 
respectively. 
 
Because NNK is metabolized to both the (S)- and (R)-enantiomers of NNAL, two di-
astereomeric glucuronides of NNAL are formed (Hecht, 1998). This is important, since 
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stereochemical aspects of NNAL and NNAL-glucuronide formation could play an important 
role in the metabolic detoxification of NNAL as well as its carcinogenic activity (Hecht, 
1998; Upadhyaya et al., 1999). Enantiomer analysis of NNAL produced from NNK in human 
liver and lung cytosol gave results in accordance with a predominant role of CBR1 and the 
AKR1C enzymes in these compartments (Breyer-Pfaff et al., 2004) . 
Fig. V-5: The metabolic acti-
vation and inactivation of  4-
(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK).  
Abbreviations:  
TSNA, tobacco-specific nitro-
samines;  
P450, cytochrome P450; 
NNAL, 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol;  
UGT, UDP-glucuronosyl-
transferase;  
11β-HSD 1, 11β-hydroxy-
steroid dehydrogenase type 1; 
CBR1, human carbonyl reduc-
tase;  
AKR, aldo-keto reductase.  
 
Any impact on NNK carbonyl reduction could have consequences with regard to NNK-
induced cancerogenesis. For example, differences in tissue expression of NNK reductases 
may be causally related to the organospecificity of NNK-induced cancerogenesis. Moreover, 
genetic polymorphisms, age-dependent differential expression (Maser et al., 1994) and/or 
modulation by several xenobiotics of NNK reductase activity may impair the activation-
detoxification balance in favour of activation, rendering the lung vulnerable to the carcino-
genic effect. It is, therefore, important to study the tissue distribution of NNK-activating and  
-inactivating enzymes in order to understand the biochemical mechanisms of NNK carcino-
genesis.  
 
Several studies on the profile of NNK metabolites in smokers' urine have revealed high inter-
individual variations with respect to NNAL, NNAL-glucuronide and NNAL-N-oxide quanti-
ties (Carmella et al., 1995; Meger et al., 1996). It is these variations that are of greatest inter-
est, since they may not only be linked to lung cancer susceptibility but also to a genetic poly-
morphism in terms of NNK reductase expression. Only 16 % of habitual smokers develop 
lung cancer, suggesting that individual susceptibility and environmental factors (e.g. air pollu-
tion) contribute to the risk of developing this disease. Interestingly, a number of studies have 
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demonstrated a familial component to lung cancer risk. Evidence supporting familiality sug-
gests that the etiology of lung cancer includes shared genes, shared environments, or both. 
Association studies performed on polymorphic genes coding for phase-I and phase-II en-
zymes that play a role in the activation of carcinogens in tobacco smoke, i.e. CYP1A1, 
CYP2D6, CYP2E1, and GSTM1, have often yielded conflicting results (Schwartz et al., 
1996). Therefore, it would be of greatest interest to perform studies on family history of lung 
cancer and putative aberrations or polymorphisms in NNK-metabolizing enzymes in these 
individuals. For example, experiments on the expression of 11-HSD1 in human lung demon-
strated that the level of this NNK carbonyl-reducing enzyme varied by a factor of 20 in only 
ten patients investigated (Soldan et al., 1999). 
 
 
A variety of factors may influence the detoxification capacity of the NNK reductases, thereby 
contributing to the interindividual variabilities observed in the response to smoking. As an 
example, the fact that chronic alcohol consumption greatly enhances the carcinogenic re-
sponse to smoking and tobacco-derived nitrosamines (Ahrendt et al., 2000) may be causally 
related to an inhibitory action of ethanol treatment of rats on 11-HSD1 activity (Valentino et 
al., 1995); in addition, ethanol exerted weak inhibitory effects on human AKR1C1, 1C2 and 
1C4 in vitro (Atalla et al., 2000).  
  
11-HSD1 and the three AKR enzymes are potently (in nanomolar to low micromolar con-
centrations) inhibited by glycyrrhetinic acid (GA), the main constituent of licorice (Monder et 
al., 1989; Reidenberg, 2000; Maser et al., 2003; Ota et al., 2004). Consequently, by shifting 
the NNK/NNAL equilibrium towards NNK activation, GA as a tobacco additive or as a con-
fectionery may potentiate the carcinogenic response towards cigarette smoking. Moreover, 
GA is known to act as an inducer of cytochromes P450 (Paolini et al., 1999). The resulting 
increase in NNK activation would be synergistic to NNK reductase inhibition, thereby further 
aggravating the toxicological consequences of smoking. 
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V.8  Detoxification of Insecticides 
Agricultural and domestic use of neuroactive zoocides is still widespread, and new types of 
anti-insect agents are continually sought in order to avoid the possible side effects in verte-
brates. In this respect, much effort has been spent to exploit the invertebrate or insect-specific 
hormonal system (Belai et al., 1995). The poly-hydroxylated ecdysteroids serve as moulting 
hormones in arthropods and are unique to nonvertebrates. The cytochrome P450-dependent 
monooxygenase system is important for the biosynthesis of insect ecdysteroids in which ec-
dysone 20-monooxygenase plays a central role in ecdysone activation to 20-
hydroxyecdysone. The development of anti-ecdysteroid agents that inhibit or inactivate cyto-
chrome P450 and thus prevent the formation of active moulting hormones offers promising 
opportunities to selectively disrupt insect reproduction and development. Based on the find-
ings that metyrapone is a potent cytochrome P450 inhibitor, several metyrapone analogues 
have been synthesized and found to be toxic to insects by impairing ecdysteroid activation in 
vivo (Belai et al., 1995).  
 
Since metyrapone itself is mainly reduced at its ketone moiety to the hydroxy metabolite 
metyrapol, the same metabolic fate was anticipated in case of the insecticidic metyrapone 
analogues (Rekka et al., 1996). Indeed, these azole analogues of metyrapone are extensively 
metabolized via carbonyl reduction by 11-HSD1 in microsomes and CBR1 in the cytosol of 
human liver (Rekka et al., 1996). Interestingly, cytotoxicity assays reveal that the resulting 
hydroxy metabolites are far less toxic to mammalian cells than the parent compounds, indicat-
ing that carbonyl reduction represents an important detoxification step of the biologically ac-
tive insecticides in mammals (Rekka et al., 1996). By mediating their detoxification in non-
target organisms, such as humans and other mammals, 11-HSD1 and CBR1 provide the ba-
sis for a selectivity between insects and humans and a safer application of these biologically 
active insecticides. 
The reduced alcohol metabolite formation of the metyrapone azole analogues by 11-HSD1 
and CBR1 can be strongly influenced by substituents of the phenyl ring (Rekka et al., 1996). 
Therefore, by using as substrates a diverse spectrum of these molecules, with different sub-
stituents, it should be possible to derive from the kinetic data a hypothetical optimal substrate 
configuration. 
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VI Physiological Implications 
Pluripotent hydroxysteroid dehydrogenases (HSDs) are of special interest because of their 
selectivity for oxidoreduction at specific carbon atoms at the steroid nucleus, combined with 
their rather unspecific metabolic affinity for non-steroidal carbonyl compounds [reviewed in 
(Maser, 1995)]. This substrate pluripotency is important for many aspects of both cell physi-
ology and toxicology. Substrate interactions may lead to either malfunctions of steroid hor-
mones or to an impaired detoxification of harmful aldehydes, quinones and ketones.  
 
The existence of enzymes that have arisen independently to have a common activity has been 
repeatedly observed before in different enzyme groups. In many cases, such analogous en-
zymes seem to evolve by recruitment of enzymes acting on different but related substrates, 
i.e. by minor structural change of a protein that leads to a novel specificity or even a new class 
of reactions. It remains to be elucidated whether the selective pressure to resist the deleterious 
effects of toxic aldehydes, ketones and quinones, coupled with independent adaptation to en-
docrine requirements makes the recruitment of these pluripotent HSDs particularly advanta-
geous.  
 
With their pluripotent substrate specificities, the HSDs of this study add to an expanding list 
of those enzymes that, on the one hand, are capable of catalyzing the carbonyl reduction of 
non-steroidal endo- and xenobiotics, and that on the other hand exhibit great specificity for 
their physiological substrates [reviewed in (Maser, 1995)]. As the HSD/carbonyl reductase 
project continues to progress, it is anticipated that new members of these groups of enzymes, 
which play important roles in not only the metabolism of xenobiotics but also the biotrans-
formation of a variety of endogenous steroids, are bound to emerge.  
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VII Perspectives 
Apparently, the role of HSDs and other carbonyl-reducing enzymes in biotransformation has 
been underestimated. There is increasing evidence for the crucial involvement of these en-
zymes in the detoxification of carcinogens and the development of tumor resistance towards 
cytostatics. The further determination of structure-function relationships and expression 
analyses of the particular enzymes are therefore prerequisites for the understanding of interac-
tions and implications with the endogenous hormone metabolism and the development and 
risk assessment of drugs and biocides. 
 
Knowledge on the pluripotent activity of these enzymes for a specific toxic and/or cancero-
genic substrate would improve risk estimates from exposures in the home and workplace. 
Thus, as the pieces to the puzzle of carbonyl-reducing enzymes are put together, further pos-
sibilities are revealed that may have application in basic sciences and medicine. Future stud-
ies, including heterologous expression in appropriate systems, will be aimed to definitively 
establish their role in detoxification processes.  
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VIII Zusammenfassung 
Die Carbonylreduktion von Aldehyden, Ketonen sowie Quinonen zu ihren entsprechenden 
Hydroxylderivaten spielt eine wichtige Rolle im Phase-I- Metabolismus vieler endogener (bi-
ogene Aldehyde, Steroide, Prostaglandine, Produkte der oxidativen Degradation von Lipiden) 
sowie xenobiotischer Verbindungen (pharmakologische Verbindungen, Karzinogene, Toxi-
ne). 
Carbonylreduktasen lassen sich in zwei große Protein-Superfamilien untergliedern, die Aldo-
Keto-Reduktasen (AKR) und die kurzkettigen Dehydrogenasen/Reduktasen (SDR). Während 
Aldehydreduktasen und Aldosereduktasen zu den AKR gehören, zählen verschiedene Formen 
der Carbonylreduktasen zu den SDRs. Zusätzlich existiert eine Gruppe von pluripotenten 
Hydroxysteroid-Dehydrogenasen (HSDs) beider Superfamilien, die spezifisch die Oxidore-
duktion an verschiedenen Positionen des Steroid-Nukleus katalysieren. Weiterhin katalysiert 
die Gruppe der HSDs  unspezifisch den reduktiven Metabolismus einer großen Zahl an nicht 
steroidalen Carbonylverbindungen.  Der vorliegende Übersichtsartikel fasst die letzten Er-
kenntnisse über Carbonylreduktasen und pluripotente HSDs der SDR Protein-Superfamilie 
zusammen. 
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I Introduction 
I.1  3α-HSD/CR of C. testosteroni as a Model System 
One of the most important model systems of bacterial steroid degradation is the Gram-
negative bacterium Comamonas testosteroni, which belongs to the beta-group of the proteo-
bacteria, and which is known to be able to grow on testosterone as sole carbon source. These 
strictly aerobic, nonfermentative, chemoorganotrophic bacteria rarely attack sugars, but grow 
well on organic acids and amino acids (Willems et al., 1992). As a member of this family C. 
testosteroni is able to use steroids as sole carbon source and may be an attractive means for 
the removal of these stable compounds from the environment.  
Since the pioneering work of Talalay and co-workers it is well known that 3-hydroxysteroid 
dehydrogenase/carbonyl reductase (3-HSD/CR) from C. testosteroni is one of the first en-
zymes of the steroid catabolic pathway and, therefore, plays a central role in steroid metabo-
lism (Marcus and Talalay, 1956). In a comparison of the protein patterns separated by two-
dimensional gel electrophoresis of testosterone-induced C. testosteroni cells versus control 
extracts, a strong increase of 3-HSD/CR expression was found (Möbus et al., 1997). As one 
physiological function 3-HSD/CR catalyzes the interconversion of hydroxy and oxo groups 
at position 3 of the steroid ring structure. Moreover, this enzyme is capable of catalyzing the 
carbonyl reduction of nonsteroidal xenobiotic carbonyl compounds (Oppermann et al., 1996). 
It has been demonstrated that this substrate pluripotency not only enhances the metabolic ca-
pacity of insecticide degradation, but also increases the resistance of C. testosteroni to the 
steroid antibiotic fusidic acid (Oppermann et al., 1998). 
3-HSD/CR from C. testosteroni is a member of the short-chain dehydrogenase/reductase 
(SDR) superfamily. The primary structure of 3-HSD/CR shows two sequence motifs which 
are typical for the enzymes of the SDR family. First, the amino-terminal cofactor binding mo-
tif Gly8-x-x-x-Gly12-x-Gly14 and second, the Tyr155-x-x-x-Lys159 motif which is structurally 
located in the active site and forms together with the conserved Ser114 a catalytic triad. Proba-
bly all enzymes of the SDR family share a common reaction mechanism which follows a 
compulsory ordered pathway with the cofactor binding first. After binding of the hydroxyl or 
carbonyl substrate a so-called substrate binding loop, which is highly flexible in most apo-
SDR enzymes, becomes well ordered and shields the substrate as well as the catalytic center 
from aqueous environment. Together with a hydride ion a proton is transferred via the Tyr-
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residue of the catalytic triad. In parallel the catalytic Ser orients the substrate and stabilizes 
the transient reaction intermediate.  
Alternatively to this pathway it has been proposed that the deprotonated Ser may act as a cata-
lytic base with the Tyr playing a subsidiary role during catalysis (Winberg et al., 1999). The 
Lys in the catalytic triad plays a dual role both in the proper orientation of the cofactor by 
forming hydrogen bonds to the nicotinamide-ribose moiety and to lower the pKa  of the cata-
lytic Tyr via electrostatic interaction (Ghosh et al., 1994b; Auerbach et al., 1997; Benach et 
al., 1999).  
 
Most of the SDR enzymes are either homodimers or homotetramers (Jörnvall et al., 1995). 
The members of this family share an amino acid identity only in the 15% to 30% range. De-
spite this fact they reveal a striking similarity in their tertiary structure. Their overall structure 
is based upon a typical dinucleotide binding motif composed of  units called Rossmann 
fold. This motif builds up a parallel -sheet sandwiched between two arrays of parallel -
helices (Rossmann et al., 1975) (Fig. I-1). In 3-HSD/CR there is an insertion of 28 amino 
acids within the Rossmann fold motif between strand E and helix F forming a predomi-
nantly -helical subdomain (Grimm et al., 2000b).  
SBL
extraloop
βC
αB
βB βA βD βE βF βG
αD αE
αF
αG
αCT
N
C
αEF1
αEF2 αEF3
 
Fig. I-1: Typical Rossmann fold of SDR enzymes exemplified by 3α-HSD/CR from C. testosteroni.  
3α-HSD/CR contains an unordered substrate binding loop (SBL) and an extraloop-domain between strand βE 
and helix αF which normally are part of the four helix bundle as the main structural feature of the oligomeriza-
tion Q-interface. 
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All structures of homotetrameric SDRs determined so far show two main subunit interfaces 
arranged about two non-crystallographic 2-fold axes which are perpendicular to each other 
and referred to as P and Q  (Ghosh et al., 1994b; Tanaka et al., 1996a; Grimm et al., 2000b). 
The Q-axis interface is formed of a four helix bundle composed of helices E and F of two 
interacting subunits, e.g. in 3/20-HSD of S. hydrogenans. In all homodimeric SDRs, which 
structures have been determined so far, dimerization occurs along an interface corresponding 
to the Q-axis interface of tetrameric SDRs, e.g. alcohol dehydrogenase (ADH) of Drosophila 
lebadonensis (Benach et al., 1998). The dimer interface of alcohol dehydrogenase corre-
sponds to the Q-axis interface of 3/20-HSD. Because of the 28 amino acids insertion (“ex-
traloop”) into the classical Rossmann fold motif between strand E and F this mode of 
dimerization is sterically impossible in 3-HSD/CR (Grimm et al., 2000b) Fig. V-5; p 63) 
As a consequence, in 3-HSD/CR dimerization takes place via a P-axis interface which corre-
sponds to the P-axis interface of 3/20-HSD. The dimerization about a P-axis interface has 
been discussed as a possible mode of oligomerization in SDRs (Krook et al., 1993b), but has 
never been observed in a crystal structure so far.  
 
To investigate the role of the extraloop in the oligomerization behaviour of 3-HSD/CR a 
mutation-approach was performed to replace the extraloop by the much shorter corresponding 
3/20-HSD loop. This was pursued both in silico (by homology modeling) and in vitro (by 
applying PCR-techniques). The resulting truncated 3-HSD/CR (3-HSD/CR-tr) was theo-
retically analysed by molecular dynamics simulations and experimentally characterized by 
enzymatic methods.  
 
I.2  Correct Protein Folding as the Key for an Active and Functional 
Protein 
Based on the crystal structure it was the aim of this study to investigate the structure-function 
relationship of 3α-HSD/CR from C. testosteroni. In both, the computer-based and the molecu-
lar biological approach a question of great importance was whether the mutant including 8 
new aa instead of 36 original ones can adopt a correct native folding and how the architecture 
of the un-mutated regions is influenced by the redesign. Therefore a short introduction into 
protein structure and protein folding is given.  
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The structure of a protein is described on four different levels. First by the primary structure 
(amino acid sequence) and the secondary structure, wherein the polypeptide backbone assem-
bles into local regions of alpha-helices and beta-sheets as the most common motifs (Wilmot 
and Thornton, 1988) and into coils and turn. The tertiary structure refers to the entire 3-
dimensional structure of the protein. The quaternary structure describes interactions between 
separate polypeptide chains. These separate polypeptide chains are called domains and exist 
in some large protein complexes. 
The biological function of a protein is dependent on the protein folding into the correct, or 
"native", state. Proteins are linear polymers of amino acids that fold into complex conforma-
tions dictated by the physical and chemical properties of the amino acid chain. Therefore the 
amino-acid composition (primary structure) of a protein can be seen as a predisposition to 
fold into its correct native conformation (Anfinsen, 1973). Most of the proteins do so sponta-
neously during or immediately after their synthesis. Other proteins require the assistance of 
enzymes, which, for example, catalyze the formation and exchange of disulfide bonds. En-
zymes like chaperones bind to the partly folded polypeptide chain and prevent it from making 
illicit associations with other folded or partly folded proteins. In addition, a chaperone can 
promote the folding of a polypeptide chain it holds.   
The folding process is mainly guided by Van der Waals forces. Water-soluble proteins bear 
polar and charged amino-acids on their surface whereas the hydrophobic parts of the protein 
are oriented inwards. This type of residue packing is assumed to be of entropic origin and to 
be almost perfect (Klapper, 1971; Szweda et al., 1993).  
 
There are various different parameters in the solution where protein folding occurs that influ-
ence the folding behaviour of the protein. Among these factors are the nature of the primary 
solvent such as water or lipids, salt concentration, temperature and the presence of chaperons. 
A given amino-acid sequence forms roughly the same intermediates to the correct final fold-
ing. First, secondary structural elements such as alpha helices and beta strands are built up 
until tertiary and quaternary structures are assembled. Tertiary structures involve covalent 
bonding in the form of disulfide bridges between two cysteine residues.  
 
Protein folding is usually a spontaneous process, and often when a protein unfolds because of 
heat or chemical denaturation, it will be capable of refolding into the correct conformation, as 
soon as it is removed from the environment of the denaturant. That means that folding and 
unfolding under these circumstances are reversible.   
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A protein which is fully denatured lacks secondary and tertiary structure. This folding status 
can be described as “random coiled” and can be caused under some non-native conditions a 
protein will not fold at all. Among these are temperatures above or under the normal living 
conditions of the cell, high concentrations of solutions and extreme pH values. 
 
Molten globules as intermediates in the folding pathway 
As the first event during the folding pathway the unfolded and unordered polypeptide chain 
collapses and acquires most of its correct secondary structure elements like α-helices and β-
strands. This state, called “molten globular state” has a looser tertiary structure than the native 
state. The proper packing interactions in the interior of the protein have not been formed. In 
this state the interior side chains may be highly mobile. They resemble more a liquid than the 
solid-like interior of the folded native state. The molten globular state can not be seen as a 
structural entity but as an ensemble of related structural elements which are rapidly intercon-
verting. The interconversion of these states requires only a few milliseconds. After the poly-
peptide has reached this state the compaction to go from the molten globular state to the final 
native fold occurs spontaneously. 
After the molten globule persistent native-like structural elements, possibly in the form of 
subdomains, begin to develop in a second step which can last up to 1 second. Compared to the 
molten globule the ensemble of conformations is much reduced but can not be referred to be a 
single native form. This form is reached in a final stage of folding. In this stage the formation 
of native interactions, hydrophobic packaging in the interior and the fixation of surface loops 
occur.   
 Protein folding is a time-dependent process which can span from minutes or hours for the 
slowest proteins to time scales of milliseconds for proteins with several hundred amino acids. 
The fastest proteins need only a few microseconds for correct folding. Fig. I-2 shows a sche-
matic overview of the folding process. 
 
The kinetics of protein folding and protein stability 
According to the thermodynamic hypothesis, a native protein structure corresponds to the 
global minimum of free energy in the protein-solvent system. In 1968 Levinthal showed that 
protein folding cannot be simulated or screened via a systematical search of all possible con-
formation. This would take “longer than the lifetime of a universe” (Levinthal, 1968). As is 
generally known proteins fold much faster. Hence, Levinthal proposed that a random confor-
mational search does not occur in folding, and that the protein therefore must fold following a 
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pre-determined pathway. The protein folding process has been investigated in detail by Monte 
Carlo (MC) simulations (Sali, 1995a; Sali, 1995b; Dinner et al., 1996). A three-stage process 
was postulated for protein folding: after a rapid collapse from a random-coil state to a random 
semi-compact globule a slow and rate-determining search through the semi-compact states 
takes place to find one of about several thousand similar transition states. From this state the 
protein-chain rapidly folds to the native state.  
 
Although three dimensional protein structures solved on the basis of crystallographic data 
give the impression, a protein in its native state is not static. The structural elements, α-helices 
and β-strands, as well as entire domains continually undergo small movements in space. 
These movements can be either small fluctuations of individual atoms or collective motions 
of groups of atoms. The conformational changes are essential for functional activities of many 
proteins, e.g. for ligand binding.  
 
The energy difference between the native state of a biologically active protein to the dena-
tured inactive state is about 5-15 kcal/mol. This is not much more than the energy contribu-
tion of a single hydrogen bond (2-5 kcal/mol).  
Two major factors contribute to the energy difference between folded and denatured state: 
enthalpy and entropy. Enthalpy derives from the energy of all noncovalent interactions within 
the polypeptide chain. Among these are “van der Waals” interactions, hydrogen bonds and 
ionic bonds. In the native and the denatured state the covalent bonds within and between the 
amino acid residues of the polypeptide are the same with the exception of disulfide bonds 
between cysteine residues. The noncovalent interactions differ very much between the two 
folding states. In the native folded state the interactions are maximized to produce a compact 
globular molecule with a tightly packed hydrophobic core. In the denatured unfolded state the 
side chains are more loosely packed. Therefore their energy contribution, the enthalpy, is 
much larger. The difference in enthalpy between the native and the denatured state can reach 
several hundred kcal/mol.  
Introduction 80 
The second factor which contributes to the energy difference between the two states is en-
tropy. This factor describes that energy is required to create order. Native folded proteins are 
highly ordered in one main conformation whereas unfolded denatured proteins are highly dis-
ordered with many different conformations. Like in the case of enthalpy, the difference in 
entropy between native and denatured state is several hundred kcal/mol, but in the opposite 
direction to enthalpy. Therefore the energy difference of 5-15 kcal/mol is the difference be-
tween the major factors enthalpy and entropy and is called the free energy of the system.  
 Fig. I-2 
The polypeptide chain is flexible in the unfolded and denatured state. The molten globular state is the intermedi-
ate state with a reduced number of conformations. In comparison to the folded native state the molten globular 
state is less compact and the proper packing interactions in the interior of the protein have not been formed, but it 
has most of the secondary structure of the native state. (Rossmann et al., 1975)  
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I.3  Homology Modeling and Molecular Dynamics Simulations as 
Computational Tools  
Homology Modeling 
Today homology modeling is the most reliable technique for prediction of protein structures 
and requires one or more protein structures as template proteins with preferably high se-
quence identity. At the beginning of a modeling procedure one or more template proteins with 
high sequence homology to the protein which structure has to be modelled have to be identi-
fied. Then the template and the target sequences have to be aligned and the three-dimensional 
structure of the target sequence has to be generated on the basis of the coordinates of the 
aligned residues of the template proteins. For loop regions and unaligned sequence segments 
models are generated. Several refinement steps are performed to resolve structural implausi-
bilities.   
 
Several methods for molecular modeling exist which differ in the way the coordinates for the 
target sequence are calculated from the template structures. The method used for the modeling 
of the structure of the 3α-HSD/CR-Mutant in this thesis is the method of modeling by satis-
faction of spatial restrains, implemented in the program modeller 6. This approach uses either 
distance geometry (Havel and Snow, 1991; Srinivasan et al., 1993) or optimisation techniques 
(Sali and Blundell, 1993) to satisfy spatial restrains which occur at the alignment of the target 
sequence to the homologous template protein.  The original modeling method is based on 
rigid-body assembly. In this approach the model is constructed from several core regions, 
loops and side chains, which are taken from related structures (Browne et al., 1969; Sali and 
Blundell, 1993; Thibault et al., 2004) and involves the fitting of rigid bodies onto a frame-
work defined as the average of the Cα atoms in the conserved folding regions. Another group 
of methods can be classified as modeling by segment matching. In this approach the coordi-
nates of the not-conserved atoms are calculated on the basis of approximate positions of con-
served atoms from the template protein structures (Jones and Thirup, 1986; Claessens et al., 
1989; Levitt, 1992; Duplomb et al., 2004).  
 
The accuracy of a comparative model corresponds to the percentage sequence identity of the 
two proteins and therefore correlates with the relationship between their structural and se-
quence similarity (Sanchez and Sali, 1998; Koehl and Levitt, 1999; Marti-Renom et al., 
2000). Baker and Sali showed in 2001 that models which have a sequence identity of at least 
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50% with their templates tend to not exceed 1 Å rms (root mean square) deviation with re-
spect to main chain atoms. Comparative models with a sequence identity of 30 to 50% show 
about 90% of the main-chain modelled with 1,5 Å rms error. Bates and coworkers showed 
that the regions predicted best are often regions with biological significance, because their 
structure is conserved by evolution (Bates et al., 2001).  
 
Molecular Dynamics (MD) Simulations 
Molecular Dynamics simulations provide a computational tool to simulate the motions of a 
molecular system. During MD-simulations the configuration space, the entirety of configura-
tions accessible to the system, is sampled and a trajectory is generated. A prerequisite for 
MD-simulations is an interaction potential from which interatomic forces can be calculated. 
The method is based on the physical principle that at ambient temperatures biological macro-
molecules are never at rest and that their hierarchy of motions ranges from small fluctuations 
of hundredths of an Ångstrom to domain movements in the magnitude of tens of Ångstroms 
(Karplus and Petsko, 1990). Flexibility of a protein domain is of essential importance for pro-
tein function as it enables binding of ligands, enzyme catalysis and conformational changes in 
general.  
 
Newton’s equation of motion is the basis for classical MD simulations 
F = mi ai 
In this equation the acceleration a of a particle or atom i of mass m is directly proportional to 
the acting force F. The acceleration a is the first derivative of the velocity with respect to time 
and the second derivative of the atomic positions with respect to time. Therefore expressions 
for the coordinates and the velocities of the particles as a function of time can be derived.   
 
If the interatomic forces as well as a set of starting coordinates ri(t0) and velocities vi(t0) are 
known the positions ri(t1) and the velocities vi(t1) of the atoms for a following time t1 = t0 + Δt 
can be evaluated.  The values for positions and velocities at t1 serve then to calculate positions 
and velocities at subsequent times t2 and so forth.  
 
The value needed is the forces between the particles. First, a suitable interaction potential has 
to be assigned which describes the energy of the system as a function of the atomic coordi-
nates. In the first derivative of the potential with respect to the atom position the forces can be 
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derived. The potential consists of a set of empirically parameterized terms for bond lengths, 
bond angles and torsion angles, as well as terms for the non-bonded van der Waals interac-
tions and Coulomb interactions. This set of parameters is defined in a molecular mechanics 
force field. In addition to these chemical parameters some further aspects important for prac-
tical MD simulations of biomolecules have to be defined. Among these are the definition of 
appropriate boundary conditions for the system minimizing the edge effects in simulations of 
liquids, solution or solids, the handling of the solvent, regulation of temperature and pressure 
and the treatment of long-range electrostatic forces (Gunsteren and Berendsen, 1990). A MD 
simulation results primarily in a trajectory of the simulated system which consists of a series 
of conformations as a function of time. The accuracy of a MD simulation heavily depends on 
the potential energy function and a sufficient sampling time for which the configurations of 
the system are generated. 
 
In this study MD simulations are performed together with homology modeling to prove the 
plausibility of the approach to redesign a complete loop region in 3α-HSD/CR by substitution 
of the extraloop domain by a shortened homologous loop of 3α/20β-HSD on the basis of two 
crystallographically determined structures.  
 
 
I.4  Motivation -  A Combined in silico and Molecular Biology Strategy 
The main subject of this study was the question, which role the additional extraloop domain 
plays in 3α-HSD/CR from C. testosteroni and if this structural feature has a fundamental role 
for protein stability and/or functionality. To investigate this question a mutated 3α-HSD/CR-
protein (3α-HSD/CR-tr) had to be established which lacks the extraloop domain. As described 
in chapter I.2  the primary structure of a protein bears the information for secondary structure 
and correct protein folding. Solely to delete the amino acids of the alpha-helical subdomain 
which constitutes the extraloop-domain would lead to incorrect protein folding with conse-
quences not only for the relative positions of the neighbouring amino acids.  
As mentioned above (chapter I.1 ) the Q-axis interface as the typical interface region for 
dimeric SDR-proteins is built up of the four helix bundle consisting of helices αE and αF. In 
3α-HSD/CR the extraloop-domain is located within this interface region which is thought to 
be the reason for dimerization along the P-axis interface of normally tetrameric SDR-proteins. 
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Mutational changes by deletion of the extraloop-domain within the Q-axis-interface would 
unavoidably have consequences for the oligomerization behaviour (Fig. III-2, p19.)    
Another substantional criterion not only to delete the extraloop-domain is the fact, that in the 
SDR superfamily the amino acids of the catalytic triad are adjacent to the structural elements 
of the four helix bundle. Fundamental changes in the structural integrity of this region would 
have effects also on the catalytic efficiency of the protein.  
Based on these concerns, an approach was performed in which at the end 36 amino acids of 
the alpha-helical extraloop-domain were substituted by an 8-residue loop of the homologous 
region of 3α/20β-HSD of S. hydrogenans. This selection showed the best quantitative scores 
to retain protein stability, correct folding and thereby an untouched architecture of the cata-
lytic triad. This approach ensured that the effects which arised after mutation could be attrib-
uted to the lack of the extraloop-domain and not to the destruction of the entire protein archi-
tecture.  
The complexity of the desired mutation was much higher than for single point mutations, es-
pecially because of expected changes in the solubility of the overexpressed protein. Hence, 
this mutation was first modelled and simulated to estimate the structural consequences for the 
whole protein and to minimize endevours due to intricacies in protein production.. 
 
 
I.5  Aim of this Study 
The aim of this study was to investigate whether the lack of this predominantly -helical sub-
domain leads to the formation of a homotetramer or even a novel oligomerization mode. In 
this study re-design of this interface was performed on the basis of site-directed mutagenesis 
and according to other SDR structures by an approach combining “in silico” and “wet chemis-
try”. Simulations of sterical and structural effects after different mutations, by applying a 
combination of homology modeling and molecular dynamic simulations, provided an effec-
tive tool for extensive mutagenesis studies. First activity tests after successful protein expres-
sion could constitute an evidence for an active and correctly folded protein.  
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II Materials 
II.1  Chemicals 
1,1,1-Trichlorethan Merck, Darmstadt 
Acrylamid Serva/Heidelberg 
Agarose Gibco-BRL/Eggenstein 
Ampicillin Appligene/Heidelberg 
APS Merck/Darmstadt 
ABTS   2.2'-Azino diethyl-benzothiazoline sulfonic acid  Boehringer Mannheim 
ATP Boehringer/Mannheim 
Bacto-Agar Difco, Detroit (USA) 
Bacto-Trypton Difco, Detroit (USA) 
Borsäure Fluka, Neu-Ulm 
Bromphenolblau Merck/Darmstadt 
BSA Sigma, Deisenhofen 
Calciumchlorid Merck, Darmstadt 
DAB (3,3‘-Diaminobenzidintetrahydrochlorid) Sigma/Deisenhofen 
Dichlordimethylsilan Sigma, Deisenhofen 
Diethylether Roth, Karlsruhe 
Di-Natriumhydrogensulfat Merck, Darmstadt 
dNTPs Boehringer/Mannheim 
DTT (1,4-Dithio-L-threitol) Fluka, Neu-Ulm 
EDTA (Ethylendiaminotetraessigsäure) Roth, Karlsruhe 
Essigsäure Fluka, Neu-Ulm 
Ethanol Roth, Karlsruhe 
Ethidiumbromid Sigma/Deisenhofen 
Formaldehyd Merck, Darmstadt 
Glutaraldehyd Sigma/Deisenhofen 
Glycerin Roth, Karlsruhe 
Glycin Roth, Karlsruhe 
Harnstoff Roth, Karlsruhe 
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Hefeextrakt Difco, Detroit (USA) 
Heparin Sigma/Deisenhofen 
Isopropanol Roth, Karlsruhe 
Kaliumacetat Merck, Darmstadt 
Kaliumchlorid Roth, Karlsruhe 
Magnesiumchlorid Merck, Darmstadt 
Magnesiumsulfat Roth, Karlsruhe 
Mercapthoethanol Merck, Darmstadt 
MOPS (Morpholinopropansulfonsäure) Roth, Karlsruhe 
N, N`-Methylenbisacrylamid Serva/Heidelberg 
Natriumacetat Roth, Karlsruhe 
Natriumchlorid Roth, Karlsruhe 
Natriumdihydrogensulfat Merck, Darmstadt 
Natriumdodecylsulfat (SDS) Roth, Karlsruhe 
Natriumhydrogenphosphat Merck, Darmstadt 
Natriumhydroxid Fluka, Neu-Ulm 
Octylphenolethylenglykolether (Triton X-100) Serva/Heidelberg 
Protein A Sepharose CL-4B Pharmacia Biotech, Freiburg 
PEG 4000 Fluka, Neu-Ulm 
Proteinmarker BioRad/München 
Salzsäure Roth/Karlsruhe 
TEMED Sigma/Deisenhofen 
Tris-(hydroxymethyl)- aminoethan Roth/Karlsruhe 
Tween 20 (Polyoxyethylensorbitanmonolaurat) Sigma/Deisenhofen 
X-Gal Roth/Karlsruhe 
X-Phosphat (5-Bromo-4-chloro-3-indoylphosphat) Boehringer/Mannheim 
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II.2  Technical Equipment 
HPLC-System Merck Hitachi L-6220 Intelligent Pump,  
Merck Hitachi AS-2000 A Autosampler 
Merck Hitachi L-4000 A UV Detector 
Äkta-Explorer Amersham Biosciences 
Autoradiograpgiekassette Goos, Heidelberg 
Durchflußphotometer 2210 LKB-Bramm 
Elektrophoresekammern Agarose Universität Marburg 
Elektrophoresekammern SDS-PAGE, Protean 3 BioRad  Münschen 
Entwicklermaschine Agfa-Gevaert; Gevamatic 110 
Superloop Amersham Biosciences 
Powerpack BioRad, München 
Glaswolle Merck, Darmstadt 
Kryobad  KH-3, Biometra 
Kühlzentrifuge  Megafuge R 1.0, Heraeus 
Biofuge frigo, Heraeus 
Magnetrührer  Variomag Mono, H+P Labortechnik 
Nylonmembran Hybond-C Amersham, Braunschweig 
PCR-Cycler Personal Cycler, Biometra  
Photometer  Ultrospec 3000, Pharmacia 
GenQuant, Amersham, Sweden 
Probenschüttler IKA MTS 4, Janke und Kunkel 
Reaktionsgefäßschüttler  Reax 2000, Heidolph 
Röntgenfilme X-OMAT Kodak 
Ultrasonic Sonifier Brandeln 
Schüttler  WT-12, Biometra 
Speed-Vac Speed Vac; Uniequipe,  
Thermoblock Biometra, Göttingen 
Thermoblock  Driblock DB.2A, Techne 
Tischzentrifuge  Biofuge 13 pico, Heraeus 
UV-Transilluminator TI 1, Biometra 
Vakuumzentrifuge Uniequipe,  
Vortex-Gerät Vortex Genie 2, MAGV, Rabenau, Londorf
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Wasserschüttelbad  GFL 10013 
Whatman-G50 Whatman, New Jersey (USA) 
 
 
II.3  Enzymes and Kits 
Alkalische Phosphatase, Shrimp Roche,  
BioRad-Reagenz BioRAD, Richmond (USA)  
PfuTurboR-Polymerase  Stratagene, Heidelberg 
Pfu-Polymerase  Stratagene, Heidelberg 
DpnI Stratagene 
Deoxynucleotide Mix Stratagene 
Quick Change Site-Directed Mutagenesis Kit Stratagene 
Rapid DNA Ligation & Transformation Kit MBI-Fermentas 
Quick Ligation Kit New England Biolabs 
Restriktionsendonukleasen New England Biolabs, Schwalbach 
DNAseI Stratagene 
RNAse A  Boehringer, Mannheim 
T4-DNA-Ligase  Boehringer, Mannheim 
Topo TA Cloning Kit Invitrogen 
Taq DNA Polymerase  Promega 
Taq-Polymerase Promega, Heidelberg;  
Boehringer Mannheim 
Vent-Polymerase New England Biolabs 
 
II.4  Chromatography Columns 
HisTrapTM HP Columns 5ml, pre-charged Amersham Biosciences 
HisTrapTM HP Columns 1ml, pre-charged Amersham Biosciences 
HiTrapTM Chelating Column 5ml Amersham Biosciences 
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II.5  Bacterial Strains and Cultivation 
II.5.1 E.coli Strains 
K-12 DH 5  (Life Technologies, Eggenstein) 
dlacU 169, F-, end A1, hsd R17, sup E44, thi-1, rec A1, gyr A96, rel A1, f 80 dlac Z, dM15, 
Lamda -   
 
XL10-Gold Ultracompetent Cells (Stratagene) 
TetRΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
The [F’ proAB laclqZ ΔM Tn10 (TetR)Amy CamR] 
 
E.coli XL1 MRF’ (Stratagene) 
∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F´ 
proAB lacIqZ∆M15 Tn10 (Tetr)] 
 
BL21 (Stratagene) 
E. coli B F– dcm ompT hsdS(rB– mB–) gal 
 
BL21(DE3) (Stratagene) 
E. coli B F– dcm ompT hsdS(rB– mB–) gal λ(DE3) 
 
BL21(DE3)pLysS (Stratagene) 
E. coli B F– dcm ompT hsdS(rB– mB–) gal λ(DE3) [pLysS Camr] 
 
BL21-Gold strain (Stratagene) 
E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal endA The 
 
BL21-Gold(DE3)pLysS strain (Stratagene) 
E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte [pLysS Camr] 
 
Origami TM B(DE3) (Novagen) 
E. coli F- ompT hsdSB (rB-mB-) gal dcm lacY1gor522::TN10(TcR) trxB::kan (DE3) 
 
 
II.5.2 E.coli -Cultivation 
For bacteria cultivation LB- media (Luria-Bertani-medium) was used: bactotrypton, 5g yeast 
extract, 5g NaCl per litre media. 
For Agar-plates 1,5% Bacto-Agar was added. 
For screening for ampicillin resistance ampicillin was added to a final concentration of 
100µg/ml in the media. 
Bacteria cultivation was performed in a horizontal shaker with temperature incubation.  
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II.6  Antibodies 
For Western-blot analysis the following antibodies were used 
 
antibody supplier 
Anti-CBR1 AG Prof. Maser, Kiel 
Anti-3α-HSD/CR rabbit-made AG Prof. Maser, Kiel 
Anti HIS-IgG, mouse -made Amersham Biosciences, Freiburg 
Anti rabbit IgG, goat-made, per-
oxidase conjugate 
Sigma, Deisenhofen 
Anti rabbit IgG, pig-made, peroxi-
dase conjugate 
DAKO GmbH,  
Anti mouse IgG, peroxidase conju-
gate, sheep-made 
Amersham Biosciences, Freiburg 
 
 
 
II.7  Protein and DNA-Standards 
Precision Plus Protein Standard Dual 
Color 
Bio-Rad 
MagicMarkTM Western Protein Standard Invitrogen 
GeneRuler 50bp DNA Ladder MBI Fermentas 
GeneRuler 100bp DNA Ladder MBI Fermentas 
GeneRuler 1 kb DNA Ladder MBI Fermentas 
GeneRuler DNA Ladder Mix MBI Fermentas 
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II.8  Synthetic Oligonucleotides and Plasmids 
II.8.1 Oligonucleotides 
oligonucleotide sequence                         5’  ….   3’ 
3HSD-Gen1-for ATG TCC ATC ATC GTG ATA AGC GGC TGC GCC ACC 
3hsd-Gen1-rev GGA AGC CAC GGA CGA GAT GAC GAC GGC TGC GGG 
C 
3HSD-Gen2-for GCC TAT GCG GGC AGC AAG AAT GCT TTG ACG GTG 
GC 
3HSD-Gen2-rev TCA GGA CTG TGT CGG GCG CAT CAC CGC  
3HSD-Gen1-for-Nde GGG AAT TCC ATA TGT CCA TCA TCG TGA TAA GCG 
GCT GCG CCA CC 
3HSD-Gen2-rev-Bam GGA TCC GAG GTG AGA ACT GTG TCG GGC GCA TCA 
CCG C 
3HSDH-U1 GCA GCG GCC TGG TGC CGG GCG GCA GC 
3HSDH-U2 CAG CTT CCT TTC GGG CTT TGT TAG CAG CC 
3HSDH-M1 CAG TGC CAA TCC CAT TAA GGA AGC CAC GGA CGA 
GAT GAC 
3HSDH-M2 ATG GGA TTG GCA CTG ACA AGT GCC TAT GCG GGC 
AGC AAG AAT GC 
3HSD1 CGT CAT CTC GTC CGT GGC TTC CTT AAT GGG ATT 
GGC ACT GAC AAG TGC CTA TGC GGG CAG CAA GAA 
TGC  
3HSD2 GCA TTC TTG CTG CCC GCA TAG GCA CTT GTC AGT 
GCC AAT CCC ATT AAG GAA GCC ACG GAC GAG ATG 
ACG   
CCGCATAGG CCG CAT AGG CAC TTG TCA GTG CCA ATC CCA TTA 
AGG AAG CCA CG 
T7-promoter TAA TAC GAC TCA CTA TAG GG 
T7-terminator GCT AGT TAT TGC TCA GCG G 
Mu22 CAT TCT TGC TGC CCG CAT AGG C 
3hsd-Gen-rev-
BamHI 
CGC GGA TCC GAG GTC AGA ACT GTG TCG GGC GCA 
TCA CCG C 
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II.8.2 Plasmids 
pUC18  (Norrander et al., 1983) MBI Fermentas 
 
 
 
 
 
 
 
 
pET15b Novagen 
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II.9  Buffer, Media and Solutions 
II.9.1 Media for E.coli Cultivation 
LB-media 1% Bactotrypton 
0.5% Hefeextrakt 
85.5 mM NaCl  
100 g/ml Ampicillin (for E.coli-cultivation) 
 
LB-Agar 1% Bactotrypton 
0.5% Hefeextrakt 
85.5 mM NaCl  
1.5% Bacto-Agar 
 
LB-Amp-X-Gal-plates; 1% Bactotrypton 
0.5% Hefeextrakt 
85.5 mM NaCl  
100 g/ml Ampicillin 
40 mg/l X-Gal in 2 ml Dimethylformamid 
1,5 % Agar-Agar (w/v) 
 
II.9.2 Buffer and Solutions for Gel Electrophoresis 
Loading buffer:  
 
0.5% Xylencyanol FF 
0.5% Bromphenolblau 
40% Glycerin in TAE oder TBE 
 
TAE-buffer (20 x) 0,8 M Tris-Acetat (pH 8,3) 
10 mM EDTA (pH (8,0) 
Loading buffer for DNA- gel elektrophoresis
  
  
  
  
1 mg/ml Bromphenolblau (0.5%) 
2 mg/ml Xylencyanol-FF 
2 mg/ml Orange-G 
40 % Glycerin (w/v) 
1 mM EDTA (pH 8,0) 
Ethidiumbromid-stock solution  10 mg/ml Ethidiumbromid in 1 x TE 
 
II.9.3 Solutions for DNA-Preparation from Agarose Gels 
 Amersham pharmacia biotech 
acetat- und chaotrophaltig,  
10 mM Tris-HCL pH 8.0 
1 mM EDTA 
80% EtOH 
 
TE-buffer (10x) 10 mM Tris/HCL (pH 8.0) 
1 mM EDTA 
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II.9.4 Solutions for Preparation of Competent Cells 
SOB 
  
2 % Bacto-Trypton (w/v) 
0,5 % yeast extract (w/v) 
10 mM NaCl 
2,5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
 
RF1 0,302g RbCl 
2,023g MnCl 
0,559g KCl 
0,367g CaCl 
35ml  85% Glycerine  = 1.23 g/ml 
ad  250 ml with sterile H2O 
10 mM RbCl 
50 mM MnCl 
30 mM KCl 
10 mM CaCl 
15% Glycerin 
All components were solved in 50 ml A.dest. pH was adjusted to 5.8 with NaOH and the solu-
tion was sterile filtered. After addition of sterile glycerine the solution was filled up with sterile 
water to a final volume of 250 ml. 
RF 2 10 mM MOPS (pH 6,8) 
10 mM RbCl 
75 mM CaCl2 
15 % Glycerin (w/v) 
Components of solution RF2 were solved in 50 ml of sterile H2O and sterile filtered.After addi-
tion of 14 ml of  85% sterile glycerine (density  = 1,23 g/ml) the solution was filled up with 36 
ml of sterile H2O to a final volume of 100 ml. 
 
II.9.5 Solutions for PCR 
dNTP-Mix  
  
  
  
2 mM dATP 
2 mM dTTP 
2 mM dCTP 
2 mM dGTP 
PCR-buffer (10 x)  
  
  
  
500 mM KCl 
500 mM Tris 
25 mM MgCl2 
0,1 % Gelatine (w/v) 
PBS  130 mM NaCl 
7 mM Na2HPO4 
3mM NaH2PO4 
PBT 0.1% Tween 20 in PBS 
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II.9.6 Solutions for Preparation of Plasmid DNA 
Analytical scale 
P1 (Resuspensation buffer) 50 mM Tris/HCL (pH8.0) 
10 mM EDTA 
400g RNAse A 
 
P2 (Lysis buffer) 200 mM NaOH 
 
P3 (Neutralization buffer) 2.55 M potassium acetate (pH 4.8) 
 
 
Preparative scale 
P1-buffer (Resuspensation buffer) 
  
  
50 mM Tris 
10 mM EDTA (pH 8,0) 
RNAse A (100 g/ml) 
P2-buffer (Lysis buffer) 
  
200 mM NaOH 
1 % SDS (w/v) 
P3-buffer (Neutralization buffer) 3,2 M potassium acetate (pH 5,5) 
Buffer QBT    (Equilibration buffer) 750 mM NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
0,15 % TritonX-100 (v/v) (pH 5,0) 
 
Buffer QC (Wash buffer) 
  
1.0 M NaCl 
50 mM MOPS, pH 7.0 
15% isopropanol (v/v) 
 
Buffer QF (Elution buffer) 1,25 M NaCl 
50 mM Tris-HCl (Ph 8,5) 
15% isopropanol (v/v) 
 
 
II.9.7 Solutions for SDS-PAGE 
 Auftrennungsbereich 20 – 70 kDa eingesetzt: 
Stacking gel  5% 30 % Acrylamid 
2 % Methylenbisacrylamid 
1 M Tris/HCL, pH 6.8 
10 % SDS 
A.dest. 
10 % APS 
TEMED 
1.7 ml 
0.6 ml 
1.25 ml 
100 l 
5.7 ml 
50 l 
5 l 
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Resolving gel: 30 % Acrylamid 
2 % Methylenbisacrylamid 
1 M Tris/HCL pH 8.7 
10 % SDS 
A.dest. 
10 % APS 
TEMED 
6.25 ml 
1.55 ml 
5.6 ml 
150 l 
1 ml 
50 l 
10 l 
TBE-Puffer siehe 1.1.8  
SDS running buffer  0.25 M Tris 
1.9M Glycin, pH 6.8 
1 % SDS 
 
1 x SDS-gel-loading buffer 
 
50 mM Tris/HCL, pH 6.8 
100 mM DTT 
2 % SDS 
0.1% Bromphenolblau 
10 % Glycerin 
 
Coomassie-Blue-staining solution 40 % Methanol 
10 % Essigsäure 
1 % Coomassie Brillant Blue 
 
Solution for de-staining 
 
40 % Methanol 
10 % Essigsäure 
 
 
 
II.9.8 Solutions For Renaturation of Inclusion Bodies 
Lysis buffer 100 mM Tris-HCl, pH 7.0 
5 mM EDTA 
5 mM DTT (770 mg/l) 
5 mM Benzamidine (780 mg/l) 
Wash buffer 100 mM Tris-HCl, pH 7.0 
5 mM EDTA 
5 mM DTT (770 mg/l) 
2 M Urea 
2% Triton X-100 (20g/l) 
Solubilization buffer 6 M GdmCl 
100 mM DTT 
0,1 M Tris-HCl, pH 8,0 
See “Methods” for details  
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II.9.9 Solutions for Western Blot Analysis 
2 x SDS-Loading buffer 100 mM Tris/HCL pH 7.9 
200 mM DTT 
4% SDS (w/v) 
0.2 % Bromphenolblau (w/v) 
20% Glycerin (w/v) 
Western-transfer buffer 
(Towbin et al., 1979) 
25 mM Tris/HCL ,pH 8.3 
192 mM Glycin 
20 % (v/v) Methanol 
Regenaration buffer 2% SDS 
62.5 mM Tris/HCL pH 6.7 
0.7% Mercaptoethanol 
 
II.9.10 Solutions for Affinity Chromatography 
Resuspensation buffer 
 
Tris-HCl 20mM 
10% Glycerin  
pH 7.4 
Buffer A 20 mM Kaliumdihydrogenphosphat  
10 mM Imidazol 
100 mM NaCl 
pH 7.4 
Buffer B 20 mM Kaliumdihydrogenphosphat  
500 mM Imidazol  
100 mM NaCl  
pH 7.4  
 
Stripping buffer buffer A  
0,05 M  EDTA  
ad 100ml  
 
Loading buffer 0,1M Nickel-II-Sulfat-Hexahydrat 
 ad 100ml 
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III Methods 
III.1  Generation of 3α-HSD/CR-Mutants by Overlap-Extension PCR-
Technique 
The amplification of specific DNA fragments is facilitated by polymerase chain reaction. The 
synthetically manufactured oligonucleotides serve as specific primers to amplify the DNA of 
interest. The thermo stable polymerase plays a major role in the synthesis of complementary 
DNA from the template. By the cyclic denaturation and renaturation the DNA region of inter-
est amplifies exponentially.  
 
3-HSD/CR was cloned into the pK15 vector which served as template. The TGA stop codon 
sequence was modified to yield the reverse primer containing a BamHI site. 
To introduce the mutation, a primer pMU10 was designed containing the sequence to be in-
serted with flanking regions. In a second PCR the purified product was used as a primer to-
gether with a reverse primer containing the BamHI restriction site. As a template for the sec-
ond PCR the pK15 vector was used. A 25cycles PCR reaction was run against plasmid DNA 
of pK15 containing the 3-HSD/CR gene under the conditions listed below. The resulting 
PCR product was digested with NdeI and BamHI restriction enzymes to give a 690bp frag-
ment. After PCR the fragments were purified by gel-electrophoresis and phenol-chloroform 
extraction. The resulting fragment was inserted into the TOPO-vector according to the sup-
plier’s manual. After restriction analysis the subclone was cloned into the pET15b vector. The 
insert was sequenced (Eurogentec) to confirm the correct in-frame DNA sequence and the 
absence of any mutations. 
 
The reaction was done in a total volume of 20 µl by adding the following reaction compo-
nents. After all components were added the reaction tubes were vortexed, centrifuged and 
placed in the PCR cycler. 
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Template-DNA 10 ng 
Primer A (25 pmol/l) 5 l 
Primer B (25 pmol/l) 5 l 
dNTP (je 2.5 mM) 5 l 
MgCl2 (only with Taq-Polymerase) 3 l 
10 x PCR-buffer 5 l 
Proof-Reading-Polymerase 1 l (= 2,5 U) 
Taq-Polymerase 0,2 l (= 1U) 
A.dest. ad 50 l 
 
The following PCR-program was used: 
Step  Cycles Temperature Time 
1: denaturation  1 950C  2 min 
2: denaturation 950C 
3: annealing 45 0C 
4: polymerization 
 
25x 720C 
30 sec 
30 sec 
1 min je kb, 1:40 min je kb 
bei proof-reading-
Polymerase 
5: polymerization  1 720C 2:30 min 
6: storage  1 40C  
 
 
III.2  Cloning of DNA in Plasmid DNA 
III.2.1 Production of Chemically Competent Bacteria (Escherichia coli) 
250 ml of SOB medium was inoculated with 2.5 ml of fresh E. coli-culture (1:100) and incu-
bated at 37°C with continuous shaking till it reached up to a OD600 of 0.5-0.6. After 15 min-
utes of incubation on ice the cells were centrifuged at (4000 rpm, 4° C, 10 min), and the pellet 
was resuspended in 80 ml cold RF1-buffer and placed again on ice for 15 minutes. The cells 
were centrifuged to pellet (4000 rpm, 4° C, 10 min) and resuspended in 20 ml RF2- buffer 
and incubated on ice for 15 minutes. The cell suspension was finally aliquoted into 200 µl 
each and quick frozen in liquid nitrogen. The cells were used immediately for transformation 
if needed and the remaining aliquots were frozen at -80°C for future use.  
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III.2.2 Production of Chemically Competent Bacteria (Escherichia coli) with CaCl2 
250 ml LB-Media were seeded with a o.N. culture in a 1:100 ratio. After amplification the 
number of cells was around 1 x 108 cells/ml ( 0.5 – 0.6 OD). After 15 min of incubation on 
ice the cells were harvested at 2000 x g for 10 min at 40C  (2000 xg = 3400 rpm with  Mega-
fuge R1). The precipitated cells were gently resuspended in 20 ml CaCL2 and incubated on 
ice for 30 min. After centrifugation for 10 min at 40C the precipitated bacteria were resus-
pended in 2 ml CaCL2 and incubated on ice for additional 30 min. For transformation 100µl 
of chemical competent cells were used.  
 
III.2.3 Digestion of DNA with the Help of Restriction Endonucleases 
The following formula is generally used to determine the units of restriction enzyme required 
to cleave the DNA with a particular concentration. 
 
required units  =          pmol DNA  x  number of restriction sites of the enzyme in the DNA 
                                             0.03 x number of restriction sites of the enzyme in -DNA 
 
 
Restriction endonuclease digestion was performed using the enzymes and buffer from New 
England Biolabs according to the given instruction in the manual. Reactions were generally 
performed in the total volume of 20 µl. For some enzymes (EcoRI) which show the star activ-
ity BSA was added in a final concentration of 10% to prevent star activity. Double digestions 
were done with suitable buffers which are compatible with both the chosen enzymes. All di-
gestions were done at 37°C for 2 hours.  
 
III.2.4 Dephosphorylation of the 5` Ends to Prevent Religation of the Vector 
To prevent the linearized vector from religation in the future ligation reactions, the 5`end of 
the DNA was dephosphorylated. Thus, the ester-reaction between the 5’-phosphate-ends and 
the free 3’-hydroxyl group is not longer possible. The DNA to be dephosphorylated was sub-
jected to alkaline phosphates treatment subsequent to restriction reaction, where 0.5 Units of 
alkaline phosphatase was used in 1/10 V of the reaction buffer in a 40µl reaction volume and 
incubated at 37°C for 15 min. Inactivation of the enzyme was performed by incubation at 
650C for 10 minutes.   
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III.2.5 Ligation of DNA Fragments 
(Revie et al., 1988) 
The main principle of the ligation reaction with T4-DNA-ligase is the covalent linkage of 3’-
OH-ends and 5’-phosphate ends under hydrolysis of ATP. To calculate the required concen-
trationsof vector-DNA and insert-DNA the following formula was used. 
pmolgkbDNAsize /
3
2)(   
 
The ligation of DNA fragments requires the presence of compatible ends. 100-150 ng of vec-
tor DNA were used together with a three to fivefold molar excess of insert depending upon 
the insert size with 1/10 V of ligation buffer and 1 unit of T4-DNA ligase in a final reaction 
volume of 15-20 µl. The ligation mixture was incubated at 16°C overnight and completely 
applied to the ligation reaction. 
 
III.2.6 Transformation of Chemically Competent Bacteria  
(Sambrook et al., 1989) 
To amplify the DNA kloned into vector-DNA the plasmids were transformed into competent 
cells.  
200 µl competent cells were thawed on ice for 10-15 minutes, 1-10 µl plasmid DNA 
solution or ligation mixture was added and incubated on ice for 30 minutes. During Inkuba-
tion plasmid-DAN attaches to the outer membrane of the cells. The cells were heat shocked in 
42°C waterbath for 60-90 seconds and immediately placed on ice for 5 min. During heat-
shock the plasmid-DNA is picked up into the the bacteria. In the mean time LB medium was 
warmed to room temperature. 450 µl of LB medium was added to the ice cold competent cell 
mixture and incubated at 37°C for 1 hour and light shaking to gain antibiotic resistance. Plate 
the cell mixture on LB selection plate (ampicillin 100 mg/ml, Kanamycin 50 mg/ml, IPTG, 
X-Gal) depending on the type of antibiotic resistant gene used.  Dry the plates and incubate in 
37°C overnight. 
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III.3  Amplification of Plasmid- DNA 
III.3.1 Mini Preparation of Plasmid DNA from E. coli (Alkaline Lysis Method)  
(Birnboim and Doly, 1979) 
Mini-preparation serves as a quick method for plasmid-preparation subsequent to cloning but 
results in only small amounts of DNA. 
3 ml of LB medium containing 2,4µl of ampicillin (100mg/ml) was inoculated with a single 
colony of bacteria and incubated at 37°C with continuous shaking for 10-12h at 210rpm 
hours. To pellet down the cells the culture was centrifuged at 13000 rpm for 1 minute and the 
supernatant was discarded. 100µl of buffer P1 was added to resuspend the cells. After addi-
tion of 100µl of buffer P2 and gentle shaking for several times the mixture was incubated at 
RT for 5 minutes. In this step the cell membranes of the bacteria were lysed. To neutralize the 
mixture and to precipitate chromosomal DNA and proteins 100µl of buffer P3 were added and 
the mixture was mixed gently giving curd like appearance. After centrifugation at room tem-
perature for 10-15 minutes at 13000 rpm the curd separates from the supernatant. The super-
natant containing plasmid-DNA was transferred to another eppendorf tube. 0.5V of isopropa-
nol was added to the supernatant and the mixture was vortexed and centrifuged at 13000 rpm 
for 30 minutes at 4°C. The supernatant was vortexed together with 500µl of 70% ethanol and 
centrifuged for 15 minutes at 13000rpm to dissolve salts. The pellet was dried and dissolved 
the DNA in 10-30 µl of ddH2O or TE-buffer depending on the concentration required. 
 
 
III.3.2 Midi Preparation of Plasmid DNA  
(Qiagen, according to the manufacturers’ instruction given in the manual) 
Midi-preparation provides the production of exceptionally pure DNA in larger quantities by 
using anion-exchange chromatography columns. This method uses the different behaviour of 
chromosomal- and plasmid-DNA at the change of basic pH to acid pH. The separated single-
strands of the plasmid-DNA are able to fit together faster than the complete separated strands 
of the bacterial DNA.  
To prepare the large amount of plasmid DNA which is pure and free of all the materials such 
as SDS and salts Midi preparation was done. 50ml LB media were inoculated with 50µl am-
picillin and 20µl of a mini-overnight-culture and incubated overnight on a shaker at 180rpm. 
The incubated 50 ml bacterial culture was transferred into 50 ml Falcon tubes and centrifuged 
at 4000 rpm for 10 minutes. The pellet was resuspended in 4 ml of P1-buffer and the cells are 
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finally lysed by addition of 4ml P2-buffer with a gentel mix. This mixture was incubated for 
15 minutes and 4ml of P3- Buffer is added for neutralization. The mixture was centrifuged at 
6000 rpm at room temperature for 20 minutes. The curd separates from the supernatant con-
taining plasmid DNA. Slowly the supernatant was transferred to the pre- equilibrated anion 
exchange column with QBT-Buffer. The solution was let to pass through the column by grav-
ity flow. The column-matrix binds the plasmid-DNA. When all the solution was passed, the 
column was washed twice with QC-buffer, 10 ml each. the solution was let to pass through 
the column completely. Finally the plasmid DNA was eluted by adding 5 ml QF-buffer. The 
eluted DNA was mixed with 0.7 V isopropanol. Centrifuge at 4°C , 6000 rpm for 15 minutes. 
The supernatant was decanted, washed with 70% ethanol and centrifuged again as stated 
above. The supernatant was decanted and the DNA pellet is vacuum dried. The DNA was 
dissolved in required amount of ddH2O for the future use. 
 
 
III.4  Detection of DNA 
III.4.1 Agarose Gel Electrophoresis  
(Sambrook et al., 1989) 
Agarose gel electrophoresis is used to separate DNA-fragments of more than 50 bp size be-
cause of their different behaviour during electrophoresis regarding their fragment size. Longer 
fragments move more slowly in the gel than smaller fragments.  
For proper separation based on the size of the DNA to be analyzed the agarose concentration 
of 0.8 – 2% (w/v) in 1x TAE buffer was used to which ethidiumbromide was added. Agarose 
was boiled in 1x TAE-buffer and Ethidiumbomide was added to a final concentration of 
10µg/ml. Ethidiumbormide incorporates into the DNA and enables detection of the loaded 
DNA.  The horizontal gels of the size 6 cm x 9 cm or 8 cm x 12 cm were used. The DNA 
samples to be loaded onto the gel were mixed with 1/10 V of loading buffer. As running 
buffer 1xTAE-buffer was used. Loading buffer contains xylencyanol FF and bromphenolblue 
which moves in the electric field towards the anode and flags the front of the samples. The gel 
was run at 50- 100 V. Subsequently the gel was documented with UV light in a UV-
transilluminator and the picture was printed out. To estimate the size of the DNA fragments 
-DANN digested with EcoRI/HindIII restriction endonucleases was used.  
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III.4.2 Isolation of DNA from Agarose Gels  
The desired fragment was cut with a sharp scalpel under the mild UV light from the agarose 
gel and transferred to a dialysis tube (12mm). 600 µl TAE-buffer were added to the tube 
which was placed into the electrophoresis chamber. During electrophoresis for 10 min the 
DNA-fragment was extracted from the gel. To avoid binding of DNA to the dialysis mem-
brane polarity was chnaged according to the following scheme: 
 
 
time 10 min 30 sec 30 sec 10 sec 10 sec 5 sec 5 sec 
Polarity 
+ 
- 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
After Gel-extraction DNA solved in TAE-buffer was purified according to 5.1. 
 
III.4.3 Estimation of DNA-Concentrations 
III.4.3.1 Estimation of DNA Concentrations using Spectrophotometer 
Nucleic acids can be quantified due to their maximum absorption at the wavelength of λ = 
260 nm using spectrophotometer. From the absorption (optical density = OD) the nucleic acid 
concentration can be computed in µg/ml using a quartz cuvette with the thickness of 1 cm 
considering the following parameters.  
 
Double stranded DNA in g/ml OD260 x 50 x dilution factor 
RNA in g/ml  OD260 x 37 x dilution factor 
Single stranded DNA in g/ml OD260 x 33 x dilution factor 
 
For spectrophotometric estimation of DNA-concentrations DNA-dilutions from 1:10 to 
1:1000 were performed in quartz cuvettes with a thickness of 1cm and a volume from 10µl to 
100µl. For blank value determination water or buffer was used in dependency of the DNA-
dilution.  
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III.4.3.2 Estimation of DNA Concentration using Agarose Gels 
If the expected DNA-concentration was very low 1µl and 0,1µl of the DNA-solution were 
loaded on a 1% agarose gel together with 10µl of DNA-standard. The concentration of the 
preparated DNA could be estimated by comparison of the fluorescent DNA-bands with the 
bands of the DNA-standard.  
 
III.5  Purification of DNA 
III.5.1 Phenol-Chlorophorm-Extraction of DNA 
Phenol-chlorophorm extraction is the method of choice to eliminate proteins from DNA-
solutions.Phenol can build up hydrogen bonds very easily and forms hydrophobic interactions 
with amino acid side-chains. Therefore phenol can dissoziate protein-DNA-conplexes into 
their free components. Proteins are denatured during the procedure and accumulate in the or-
ganic phenol-phase.  
To purify DNA, e.g. after gel-extraction, the solution was filled up with H2O to a final volume 
of 200 µl. To the aqueous phase 200 µl phenol are added, vortexed and incubated at RT for 5 
minutes. After centrifugation for 30 sec at 13.000 rpm the aqueous phase was discared and 
200 µl of chlorophorm were added. Vortexing and centrifugation was repeated and the or-
ganic phase was discared. After a second chlorophorm-step 650 µl of 100% EtOH were 
added, vortexed and centrifugated at 13.000 rpm for 10 min. The supernatand was discared 
and the sedimented nuclein acids were washed with 600 µl of 70% EtOH. The pellet was re-
suspended in 10 µl H2O. 
 
III.5.2 Precipitation of DNA from Aqueous Solutions with Alcohols 
Alcohol precipitation is the method of choice to concentrate, desalt and recover nucleic acids. 
Precipitation is achieved by the use of high concentrations of salt and the addition of either 
isopropanol ort ethanol. Isopropanol precipitation of DNA is typically carried out using 0.6 – 
0.7 volumes of alcohol, while ethanol precipitation requires 2-3 volumes of alchol. Therefore 
isopropanol is preferrd for precipitating DNA from large volumes since less alcohol is re-
quired.  
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III.5.2.1 Ethanol Precipitation 
(Crouse and Amorese, 1987; Ausubel et al., 1993) 
Ethamol precipitation provides an effective tool to concentrate DNA and to remove proteins, 
salts and free nucleotides from the solution. By increasing of monovalent kations the Dielek-
trizitätskonstante is increased as well. Thus, the rejection of the negatively charged phospho-
diesther-backbone is reduced which enables the DNA-precipitation by removal of solvent by 
ethanol addition.  
To precipitate the DNA solved in bufer 1/20 VT 5M natriumchloride and 2.5 VT 100% etha-
nol were added and vortexed. Thereby, nucleid acids sample out as sodium salts and were 
harvested by centrifugation at 13.000 rpm at 40C for 30 minutes. After washing with 70% and 
centrifugation at 13.000 rpm at 40C for 10 minutes with EtOH the DNA was dried and re-
solved in 10 µl A.dest or TE-buffer.  
 
III.5.2.2 Isopropanol Precipitation 
Isopropanol precipitation requires 0.6 – 0.7 VT of alcohol and can be performed at RT. This 
minimizes co-precipitation of salt and minimized the risk that co-precipitated salt will inter-
fere with downstream applications.  
Ideally salt concentration should be at 2.0 – 2.5 M final concentration. 0.7 VT room-
temperature isopropanol was added to the DNA solution and vortexed. The sample was cen-
trifuged immediately at 13.000 rpm at 40C for 30 minutes. The supernatant was decanted 
carefully. The DNA pellet was washed by adding a suitable volume of 70% EtOH which re-
moves co-precipitated salt and replaces isopropanol with the more volatile EtOH making the 
DNA easier to resolve. The sample was centrifuged again at 13.000 rpm at 40C for 15 min-
utes, the supernatant was decanted and the pellet was air dried. DNA was resolved in a suit-
able volume of H2O or TE-buffer  
 
III.6  Sequencing 
DNA sequencing was performed by MWG Biotech, (Ebersberg, Germany). For sequencing 
the universal T7 primers, already available by MWG, have been used. 
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III.7  Overexpression of 3-HSD/CR 
The 3-HSD/CR gene (Möbus and Maser, 1998) as well as the mutated gene was cloned into 
the NdeI/BamHI restriction sites of the pET15b vector (Novagen) which additionally codes 
for an N-terminal His-tag sequence with an integrated thrombin-cleavage site. The corre-
sponding primers for PCR were constructed as follows: The ATG start codon sequence was 
modified to yield the forward primer containing a NdeI site (Fig. IV-15, p143).  
Transformation of E. coli BL21 was performed by heat shock according to the supplier’s in-
struction. Overnight cultures harbouring the recombinant pET15b vector were diluted 1:50 
into fresh LB medium containing the appropriate antibiotics (final concentration 50µg/ml 
ampicillin). Cells were grown to an optical density of 0.6 at 600 nm as 2l-cultures at room 
temperature, and then recombinant 3-HSD/CR overexpression was induced by addition of 
IPTG to a final concentration of 0.1 mM. After 8 h of induction at room temperature, cells 
were harvested and lysed by freezing, lysozyme digestion and ultrasonication (3 x 10 s), and 
the debris removed by spinning at 16.000 x g for 1 h. This procedure was repeated at least for 
three times to ensure all cells are broken.  
 
III.8  Detection of Overexpressed Proteins 
III.8.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
(Laemmli, 1970; Sambrook et al., 1989) 
In order to control the purity of the enzyme preparations or to perform Western blot analysis, 
polyacrylamide gel electrophoresis under denaturing conditions was performed to separate 
proteins according to their molecular weights. According to their different amino acid (aa) 
composition proteins carry different electric charges. SDS incorporates in constant rates into 
the proteins masking their individual charge from their aa-composition. After SDS-treatment 
the proteins differ only in their molecular mass and move in the constant electric field towards 
the anode. 
 
Preparation of the gel: 
The electrophoresis was employed using the BioRad electrophoresis apparatus Mini Protean 
II cell (BioRad, München, Germany). The gels (80 mm × 65 mm × 0,75 mm) composition is 
indicated in “materials”. Cleaning of the glass plates was performed using 70% ethanol. As-
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sembling of the electrophoreses apparatus was carried out according to the manufacturers 
instructions. For the vertical gel electrophoresis first the resolving gel was prepared. Polym-
erization of the solution is started by APS and TEMED which therefore should be added im-
mediate before the solution is filled between the glass plates. After polymerization the stack-
ing gel was prepared and filled in. In a final step the comb is placed in the glass plates. 
To obtain a resolving of proteins between 20 and 70 kDa a 10% acrylamide/bisacrylamide gel 
was prepared (see materials).  
 
Electrophoresis 
 Before electrophoresis the protein samples were diluted 1:2 with protein loading buffer and 
denatured for 5 min at 95oC. Subsequently, 3-20 µl of the samples were loaded to the gel. The 
electrophoresis chamber was completely filled with Tris/glycine-electrophoresis buffer. The 
electrophoresis was started with a voltage of 80 V until the bromphenol blue marker reached 
the top of the separating gel then performed at 150 V until the tracking dye reached the bot-
tom of the separating gel. As molecular weights standards in SDS-PAGE different Molecular 
Weight Astandards have been used (see materials). 
 
After electrophoresis, the proteins were visualized by staining the gel at room temperature for 
several hours in a solution of Coomassie Brillant blue R 250. Destaining was carried out at 
room temperature in a mixture of water/isopropanol/acetic acid (81:12:7).  
 
III.8.2 Determination of Protein Concentrations 
Protein concentrations were determined with the BioRad Protein Microassay (BioRad Labora-
tories, München, Germany) (Bradford, 1976), a dye-binding assay based on the differential 
colour change of a dye in response to various concentrations of protein (Bradford, 1976). The 
principle of this method is based on the observation that the absorbance maximum for an 
acidic solution of Coomassie Brillant Blue G-250 shifts from 465 nm to 595 nm when binding 
to protein occurs. Each time the assay was performed, a standard curve was prepared using 
bovine serum albumin as protein standard (0-10 mg ml-1); A595 was corrected for the blank. 
0.8 ml of appropriately diluted samples or bovine serum albumin were mixed with 0.2 ml dye 
protein reagent and the absorbance of the solution at 595 nm was measured at room tempera-
ture with a spectrophotometer (Kontron) after 10 minutes. 
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III.8.3 Protein Immunodetection by Western blot Analysis 
(Towbin et al., 1979; Ogata et al., 1983; Kyhse-Andersen, 1984) 
After electrophoresis, the protein samples were transferred from an unstained SDS-
polyacrylamide gel to polyvinylidene fluoride membrane (ProBlott PVDF-Membran, Applied 
Biosystems, Weiterstadt, Germany) using a Semy-dry transfer system (Trans-Blot SD, Bio-
Rad Laboratories, München, Germany). The transfer was performed using 3 tiers of 
whatman-paper saturated with cathode-buffer, the protein gel, a Hybond-C membrane satu-
rated with anode-buffer and additional 6 tiers of whatman paper saturated with anode-buffer. 
Protein transfer could be monitored using a prestaned protein standard. The Tris/glycine 
buffer system was used as transfer buffer, as indicated in “Materials”. 
 
The electroblotting was performed applying a constant current of 0.8 mA/cm2 for 2 h. Follow-
ing the electrotransfer of proteins, the membrane was blocked for at least 30 min with 5% 
(w/v) dried milk in PBST with gentle shaking at room temperature. After washing the mem-
brane for 3 times with PBST the membrane was then incubated at 40C over night with 
1:10.000 dilutions of a rabbit anti-3α-HSD/CR antibody in 2.5 % (w/v) dried milk in PBST. 
After washing 3 × 10 min with PBST, in order to remove the unbound primary antibody, the 
membrane was incubated for 2 h in 2.5 % (w/v) dried milk in PBST with 1:20000 dilutions of 
alkaline phosphatase-conjugated anti- (rabbit IgG) antibody, (Amersham Biosciences, 
Freiburg, Germany). Excess of conjugates was removed by washing the membrane 3 × 10 
min with PBST. Immunodetection was performed with the protocol for the ECF detection kit 
provided by Amersham Biosciences using the Kodak X-OMAT films  to detect the light emit-
ted during the reaction of the substrate ECF with the alkaline phosphatase-linked to the sec-
ondary antibody. 
 
To detect the His-tag conjugated to the 3α-HSD/CR-protein anti-His-antibody, mouse made, 
(Amersham Biosciences) was used in 1:5000 dilution. The second antibody, anti mouse IgG, 
peroxidase conjugate, sheep-made was used in 1:50.000 dilution. 
 
Detection of chemiluminescence with x-ray radiographs 
After incubation with ECL-reagent the membrane was put into a transparency film and in-
serted together with the x-ray-film into the autoradiography cassette. Different exposure times 
were tested to yield the best contrast and less background.  
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III.8.4 Enzyme Linked ImmunoSorbent Assay (ELISA) 
The Enzyme-Linked Immunosorbent Assay (ELISA) is a useful and powerful method to de-
tect proteins as antigens in the range of ng/ml to pg/ml in solutions by an antibody. Based on 
the principle of antibody-antibody interaction, this test allows for easy visualization of results 
and can be completed without the additional concern of radioactive materials use. The test is 
performed in a 8 cm x 12 cm plastic plate which contains an 8 x 12 matrix of 96 wells, each 
of which are about 1 cm high and 0.7 cm in diameter.  
As the main principle a first antibody is specific for the protein to be detected and the second 
antibody which is specific for the first antibody bears a linked enzyme. The linked enzyme 
causes a chromogenic or fluorogenic substrate to produce a signal. 
 
As a standard 200, 100, 50, 25, 12.5, 6.25 ng of purified 3α-HSD/CR protein was applied in 
coating buffer into the wells. 200µl of 12 different samples were tested according to the 
scheme in Fig. III-1. Each sample was diluted 1:100 in wash-buffer. The coating buffer fixes 
the antigen to the surface of the wells. After 30 min incubation at 370C all wells are washed 
with 250 µl of wash buffer. 200µl of anti-3α-HSD/CR-antibody, diluted 1:1000 in wash 
buffer, are added to the samples. After washing for 3 times with wash buffer excess of un-
bound antibodies are removed and only the antibody-antigen complexes remains attached to 
the well. A second antibody (DAKO, anti rabbit, pig made) was added in 1:1000 dilution (in 
wash buffer) which will bind to any antigen-antibody complexes. The second antibody is 
coupled to the substrate-modifying enzyme HRP. After 30 min incubation at 370C and wash-
ing for 4 times with 250µl of wash buffer the substrate (100µl ABTS, Böhringer) was added 
to the wells which are converted by the enzyme to elicit a chromogenic signal. After final 
incubation for 30 min at 370C the chromogen was measured at 404 nm. The reference was 
measured at 490 nm. The enzyme (HRP) linked to the second antibody acts as an amplifier: 
even if only few enzyme-linked antibodies remain bound, the enzyme molecules will produce 
many signal molecules.  
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Fig. III-1: ELISA for detection of 3α-HSD/CR during overexpression. 
 
III.9  Affinity Chromatography 
Affinity chromatography allows to separate proteins on the basis of a reversible interaction 
between the protein and a ligand coupled to a chromatography matrix which is specific for the 
protein to be purified. The technique combines high resolution and selectivity, easy handling 
and high capacity for the protein of interest. 
The protein which should be purified has a N-terminal (His)6 tag which allows purification 
according to the IMAC principle (Immobilized Metal Affinity Chromatography). Doubly 
charged cations such as Ni2+ are immobilized by a chelating ligand to the chromatography 
matrix. These cations dispose interactions with the His-side chains.  
For Affinity chromatography an Äkta-Explorer (Amersham Biosciences) was used. His-
TrapTM HP columns are used to purify the recombinant His-tagged protein.  
Recombinant protein was applied in resuspensation buffer after cell-lysis into a superloop (50 
ml) which was mounted to the Äkta-Explorer.  
The following program including application of the protein to the column, several wash steps 
and elution was run.  Pure protein was eluted by a linear gradient of imidazole (0 to 0.5 M) in 
20 mM phosphate buffer, pH 7.5 and 0.1 M NaCl. Fractions containing purified 3-HSD/CR 
were stored at –80oC or immediately further tested. 
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III.9.1 Scouting 
To find ideal purification conditions scouting was performed. Scouting is reasonable in the 
first experimental phase to select purification conditions for each stage of the purification and 
to test them. 
In scouting unit operation candidates are selected and tests are performed that screen for their 
performance at small scale. From these studies a purification scheme can be proposed. To 
reduce work load scouting was only performed for purification conditions which are known to 
work in general for the given purification system.  
 
III.10  Pulse-Renaturation of Inclusion Bodies 
III.10.1 Resuspensation and Breaking of the Cells 
After protein expression the pellet of 1l of bacteria culture was resuspended in 4ml lysis-
buffer/g of cell-pellet. Lysozyme was added to a final concentration of 200µg/ml and the so-
lution was incubated for 20 minutes at room temperature. After Incubation sonification for 
several cycles (5 sec on, 5 sec off) was performed to break the cells. During centrifugation at 
22.000 g for 1h cells which are not broken and inclusion bodies were harvested.  
To wash the cell-pellet the material was resuspended in 10ml/g material in wash buffer and 
centrifuged at 22.000 g for 30 minutes. This procedure was repeated till the supernatant 
showed no clouding. To reduce viscosity of the supernatant the solution was treated with 
DNAseI for 1h at 370C at a final concentration of 20mg/l DNAseI-enzyme. At this stage all 
cells are broken and soluble protein can be found in the supernatant after centrifugation. The 
pellet contains only inclusion bodies and material of the broken cells.  
 
III.10.2 Inclusion Body Solubilisation 
The pellet containing the inclusion bodies were incubated for 2h at 200C in solubilisation 
buffer. DTT was added to reduce disulfide bridges. During incubation the protein concentra-
tion should be at 5mg/ml. To remove the reductant the solution was dialyzed against 6 M 
GdmCl, pH 4.5 without DTT.  
The following conditions were tested to refold the 3α-HSD/CR protein to the native state 
from the denatured state (Table III-1).  
Methods                                                                                                                113 
 additives 
 EDTA DTT Tris-HCl, pH 7.5 
L-Arginin-
Chloride GdmCl Sorbitol 
Ammoni-
umsulfate NAD 
Pyrro-
phosphate Tris 
1 5 mM 
EDTA 
2mM 
DTT 
1 M Tris-
HCl, pH 
7.5 
L-
Arginin-
Chlo-
ride, 0.5 
M 
GdmCl 
0.5 M 
20% 
Sorbitol     
2 5 mM 
EDTA 
2mM 
DTT 
1 M Tris-
HCl, pH 
7.5 
L-
Arginin-
Chlo-
ride, 1 M 
GdmCl 
0.5 M 
20% 
Sorbitol     
3 5 mM 
EDTA 
2mM 
DTT 
1 M Tris-
HCl, pH 
7.5 
L-
Arginin-
Chlo-
ride, 1 M 
GdmCl 
0.5 M 
20% 
Sorbitol 
Ammo-
niumsul-
fate 0.5 
M 
   
4 5 mM 
EDTA 
2mM 
DTT 
1 M Tris-
HCl, pH 
7.5 
L-
Arginin-
Chlo-
ride, 1 M 
GdmCl 
0.5 M 
20% 
Sorbitol 
Pyrro-
phos-
phate 
150 mM 
NAD 5 
mM   
5 5 mM 
EDTA 
2mM 
DTT  
L-
Arginin-
Chlo-
ride, 0.5 
M 
      
6 5 mM 
EDTA 
2mM 
DTT  
L-
Arginin-
Chlo-
ride, 1 M 
      
7 5 mM 
EDTA 
2mM 
DTT   
GdmCl 
0.5 M      
8 5 mM 
EDTA 
2mM 
DTT    
20% 
Sorbitol     
9 5 mM 
EDTA 
2mM 
DTT     
Ammo-
niumsul-
fate 0.5 
M 
   
10 5 mM 
EDTA 
2mM 
DTT      
NAD 5 
mM   
11 5 mM 
EDTA 
2mM 
DTT       
Pyrro-
phos-
phate 
150 mM 
 
12 5 mM 
EDTA 
2mM 
DTT        1M Tris 
13 5 mM 
EDTA          
14 5 mM 
EDTA  
1M Tris-
HCl, pH 
7,5 
       
15 5 mM 
EDTA    
GdmCl 
0.5 M      
16 5 mM 
EDTA     
0.06 
mg/ml 
Lauryl-
Malto-
side 
    
17 5 mM 
EDTA      
20% 
Glycerol    
 
Table III-1: Refolding screen of denatured protein. 
All approaches were performed with a protein concentration of 1mg/ml, at 40C and over 
night. Refolding of the protein was performed by a dialysis-approach in which 5 ml of the 
denatured protein (in 6 M GdmCl, pH 4.5) was dialysed against 200 ml of the refolding solu-
tion at 40C over night. After the dialysis the final concentration of guanidine hydrochloride is 
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reduced approximately 40-fold. After refolding the renaturation-solutions were dialyzed 
against 50mM M Tris-HCl, pH 8,0 and centrifuged at 25.000 rpm, 40C for 30 minutes. Re-
moval of arginine will precipitate improperly folded protein. 
III.10.3 PEG-Concentration Strategy 
To concentrate the protein-solutions in the most gentle way PEG 4000 was used. The protein 
solutions in the dialysis-tubes (~25ml) were embedded each in ca 400 ml volume of PEG 
4000 which dehumidifies the dialysis tubes. After 12 h at 40C the dialysis tubes were opened 
and the protein solutions stored at 40C for further testing.  
 
Fig. III-2: PEG-concentration of renatu-
ration solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEG
Renaturation solution
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III.11  Assay of pNBA Carbonyl Reduction 
To test biological activity of 3α-HSD/CR mutant a Metyrapone- and pNBA-assay was per-
formed. The following components were incubated for 1h at 370C and the reaction was 
stopped by placing the reaction mixture on ice.  
p-nitrobenazaldehyde metyrapone 
10µl Phosphate-buffer, 50 mM 20µl Phosphate-buffer, 50 mM 
20µl 
NADPH-regenerating system 
2 mg NADP 
6 mg Glucose-6-Phosphate 
100µl Phosphate-buffer, 50 mM  
100µl MgCl2, 100 mM 
5µl Glucose-6-Phosphate-Dehydrogenase 
20µl 
NADPH-regenerating system 
2 mg NADP 
6 mg Glucose-6-Phosphate 
100µl Phosphate-buffer, 50 mM  
100µl MgCl2, 100 mM 
5µl Glucose-6-Phosphate-Dehydrogenase 
10 µl  p-nitrobenzaldehyde, 5 mM, in 50% EtOH 10 µl  metyrapone, 5 mM 
60 µl protein 50 µl protein 
 
After incubation a small amount of NaCl, 20µl ammonia (diluted 1:1) and 200 µl of acetic 
acid ethyl ester were added, vortexed for 10 seconds and centrifuged for 1 minute to sediment 
organic material. The phase at the top was collected. The phase at the bottom of the eppendorf 
tube was vortexed and centrifuged with 100µl acetic acid ethyl ester for 2 times. All phases at 
the top of the tube were collected and evaporated for 20 minutes. The material was resus-
pended in 100 µl of 0.1% ammonium acetate pH 7.2 and 30% acetonitrile.  
 
III.11.1 Detection by HPLC 
Detection and determination of carbonyl reduction was performed using a reverse-phase 
HPLC system consisting of a C18-column (Merck) and an isocratic mobile phase of 0.1% 
ammonium acetate pH 7.2, 30% acetonitrile. The HPLC system consists of a Merck Hitachi 
L-6220 Intelligent Pump, Merck Hitachi AS-2000 A Autosampler, Merck Hitachi L-4000 A 
UV Detector and a 4.6 mm £ 25 cm LiChrosphere 100 RP18 column (Merck, Germany). De-
tection of substrates was at 254 nm (metyrapone, p-nitrobenzaldehyde). Elution was per-
formed with an eluent of 30% acetonitrile in 0.1% ammonium acetate buffer, pH 7.4. The 
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identity of metyrapol and p-nitrobenzalcohol was determined by injecting authentic standards 
of both substances onto the HPLC system.  
III.12  Homology Modeling and MD-Simulations 
A three-dimensional model of the 3α-HSD/CR-tr monomer was generated with MODELLER 
6 (Sali and Blundell, 1993), version 6a, using standard settings. A two-step procedure was 
followed in order to generate the 3α-HSD/CR-tr model: in a first instance, the substrate bind-
ing loop, which is not resolved in the crystal structure of 3α-HSD/CR (PDB 1fjh), was mod-
elled into the structure of the 3α-HSD/CR wildtype; the structure of ADH (PDB 1a4u) was 
used as template for this purpose. Ten protein models were generated from which the model 
with the lowest MODELLER target function value was selected. In a second step, the 
tetramerization-preventing "extraloop" (residues 118-153) was removed from the 3α-HSD/CR 
structure and replaced by an 8-residue loop of 3α/20β-HSD; PDB structure 2hsd was used as 
template for modeling the 3α-HSD/CR-tr structure with this inserted 3α/20β-HSD loop.  To 
analyze the stability and plausibility of this model, molecular dynamics (MD) simulations 
were performed. For comparative purposes, the structure of the 3α-HSD/CR wildtype with the 
modelled substrate binding loop was also subjected to MD simulations. The simulations were 
carried out  with AMBER 6 (Case et al., 1999), using the Cornell et al. force field (Cornell et 
al., 1995) (parm99). The protein was simulated in aqueous solution using a box of TIP3P wa-
ter molecules (Jorgensen et al., 1983) and periodic boundary conditions. Long-range electro-
statics were considered through the Particle Mesh Ewald (PME) method (Darden et al., 1993). 
After minimization, heat-up to 300 K and initial equilibration, a trajectory of 1 ns length was 
sampled under NPT conditions and saved at regular intervals of 0.5 ps. The temperature was 
kept constant by coupling to a heat bath through the Berendsen algorithm (Berendsen et al., 
1984), pressure was adjusted by isotropic position scaling using a Berendsen-like algorithm. 
Covalent bonds to hydrogen atoms were constrained by the SHAKE algorithm (Ryckaert et 
al., 1977), allowing a time step of 2 fs to be used. 
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III.13  Abbreviations 
Fig. Figure 
ABTS    2.2'-Azino diethyl-benzothiazoline sulfonic acid 
ADH Aldehyde Dehydrogenase 
PEG Poly ethylene glycol 
APS Ammoniumpersulfat 
ATP Adenosintriphosphat 
bp Base pair 
cDNA „complementary DNA“ 
Ci Curie 
DAB 3,3‘-Diaminobenzidintetrahydrochlorid 
dATP Desocyadenintriphosphat 
dCTP Desoxycytosintriphosphat 
dGTP Desoxyguanintriphosphat 
DMSO Dimethylsulfoxit 
dNTP Desoxynukleotidtriphosphat 
DTT 1,4-Dithio-L-threitol 
dTTP Desoxythymidintriphosphat 
FITC Fluorescein-5-isothiocyanat 
IgG Immunbglobulin G 
IPTG Isopropyl--galaktosid 
kDA Kilodalton 
MOPS Morpholinopropansulfonsäure 
Mr Relative mass 
mRNA messenger-RNA 
NBT 4-Nitroblautetrazolimchlorid 
nt Ribonukleotide 
OD Optical density 
ORF offener Leserahmen (open reading frame) 
PCR Polymerase-Chain-Reaction 
RNAse Ribonuklease 
rpm „radiation per minute“ 
RT Room temperature 
SDS Natriumluarylsulfat 
TAE Tris-Acetat-EDTA 
TBE Tris-Borat-EDTA 
TCE „translational control element“ 
TE Tris-EDTA 
TEMED N,N,N‘, N‘-Tetramethylethylendiamin 
Tris Tris-(hydroxymethyl)-aminomethan 
TritonX-100 Octylphenolpolyethylenglycolether 
Tween 20 Polyoxyethylensorbitanmonolaurat 
U Unit 
IMAC Immobilized Metal Affinity Chromatography 
UV Ultraviolett light 
v/v volume per volume  
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MD Molecular Dynamic 
PDB Protein Data Bank 
VT Volume part 
w/v weight per volume 
PME Particle Mesh Ewald 
X-Gal 5-Brom-4-Chlor-3-indoyl--D-galaktosid 
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IV Results and Discussion 
IV.1  Structural Characterization Identifies the Extraloop-Domain as a 
Putative Sterical Inhibitor of Common Dimerization  
IV.1.1 The Dimerization Pattern of 3α-HSD/CR Represents a Novelty within the 
SDR-Superfamily 
The majority of the SDR enzymes appear as either homodimers or homotetramers (Jornvall et 
al., 1995). Despite the fact that they share an amino acid identity of only in the 15 to 30% 
range they reveal a striking similarity in their tertiary structure. This tertiary structure is based 
upon the typical dinucleotide binding motif composed of βαβ units for members of the SDR 
superfamily which is called Rossmann fold. This motif builds up a parallel -sheet sand-
wiched between two arrays of parallel -helices (Rossmann et al., 1975) (Fig. I-1; Introduc-
tion) Typical examples for different types of oligomerization follow consolidated ways of 
arrangement of the monomer-subunits.  Fig. IV-1 shows typical examples for the arrangement 
of identical monomers within the SDR enzymes. 
Tetrameric SDR enzymes show an arrangement of the four identical monomers via two dis-
tinct oligomerization interfaces, Q and P. An example for this way of oligomerization is the 
bacterial 3α/20β-HSD from Streptomyces hydrogenans. Enzymes which exist of two identical 
monomers in general feature a dimerization via the Q-axis interface. This is the predominant 
way of oligomerization within dimeric SDR enzymes. An example for this it is alcohol dehy-
drogenase of Drosophila lebadonensis.  
However, 3α-HSD/CR of C.testosteroni as dimeric enzyme, features an unusual type of oli-
gomerization, via the P-axis interface, which otherwise can only be found in tetrameric SDR 
enzymes.  
Detailed structural analysis of different members of the SDR-superfamily elucidates the 
mechanism and requirements of the different types of oligomerization within the SDR en-
zymes.  
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Q
P
3/20-HSD
Q
ADH
SBL
P
SBL
3-HSD/CR
extraloop
 
Fig. IV-1: Overview of oligomerization behaviour of SDR enzymes  
All SDR enzymes follow the typical Rossmann fold motif consisting of a central -sheet between two arrays of 
-helices. 3-HSD/CR shows a novel type of dimerization along the P-axis-interface and contains an -helical 
subdomain („extraloop“) which is marked by arrows. 
 
 
IV.1.2 Three Dimensional Comparison of Different Oligomerization Behaviours Re-
veals Distinct Structural Elements 
IV.1.2.1 Structural Alignment of Three SDR Proteins 
Within the SDR superfamily distinct oligomerization behaviours can be found. These types of 
oligomerization are based on typical structural equipment which enables the proteins exhibit-
ing these structural elements to accumulate in distinct ways. Alignment analyses based on 
structural information derived from the PDB-Protein Data Bank  (http://www.rcsb.org) were 
performed to compare the structural configuration of typical representatives of the different 
oligomerization classes (Fig. IV-2). Structural features like helices and sheets are graphically 
added on the structural basis for human carbonyl reductase 1 (CBR1), as well as the nomen-
clature of these.   
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ADH-Droso
3α-HSD-CT
3α/20β-HSD-SH
1  
1   
1   
βA αB βB βC αD βB
-MDLTNKNVIFVAALGGIGLDTSRELVKRNLK--NFVILDRVE--NPTALAELKAINPKVNITFHTYDVTVPVAESKKLLKKIFDQLK---TVDILINGAGILDD------- 97  
----MSIIVISGCATGIGAATRKVLEAAGH---QIVGIDIRD--------------------AEVIADLSTAEGRKQAIADVLAKCSK--GMDGLVLCAGLGPQT------ 76  
NDLSGKTVIITGGARGLGAEAARQAVAAGA---RVVLADVLDEEGAATARELG------DAARYQHLDVTIEEDWQRVVAYAREEFG---SVDGLVNNAGISTGMFLE-TE 98  
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSG--DVVLTARDVTRGQAAVQQLQAEGLS---PRFHQLDIDDLQSIRALRDFLRKEYG---GLDVLVNNAGIAFKVADP-TP 102 1  CBR1-human
ADH-Droso
3α-HSD-CT
3α/20β-HSD-SH
βF
173 GVTAYSINPGITRTPLVHTFNSWLDVEPRVAELLL--------~----SHPTQTSEQCGQNFVKAIEANK-NG---AIWKLDLGTLEAI--EWTKH---WDSHI----------------  254 
173 RIRVNSVHPGMTYTPMTAET----------GI--RQGEGNYPN~--TPMGRVGEPGEIAGAVVKLLSDTS-SYVTGAELAVDGGWTTGPTVKYVMGQ-----------------------  253 
177 GVRLNTIAPGATETP~LLQA----------GLQD-PRYGESIAKFVPPMGRRAEPSEMASVIAFLMSPAA-SYVHGAQIVIDGGIDAVMRPTQF--------------------------  257 
220 KILLNACCPGWVRTDMAGP------------------------~-----KATKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW--------------------------------  277 CBR1-human
ADH-Droso
3α-HSD-CT
3α/20β-HSD-SH
αE αE βE αEF1 αEF3αEF2 αF
97  --HQIERTIAINFTGLVNTTTAILDFWDKRKGG-
99  SVERFRKVVEINLTGVFIGMKTVIPAMKDA-----
76  --KVLGNVVSVNYFGATELMDAFLPALKK----G-
PGGIIANICSVTGFN---------------------------------------------AIHQVPVYSASKAAVVSFTNSLAKLAP--IT-
GGGSIVNISSAAGLM---------------------------------------------GLALTSSYGASKWGVRGLSKLAAVELG--TD
HQPAAVVISSVASAHLAFDKNPLA-------------LALEAGEEAKARAIVEHAGEQGG-N---LAYAGSKNALTVAVRKRAAAWG--EA
CBR1-human 103 FHIQAEVTMKTNFFGTRDVCTELLPLI-K------PQGRVVNVSSIMSVRALKSCSPEL-QQKFRSETITEEELVGLMNKFVEDTKKGVHQKEGWPS---SAYGVTKIGVTVLSRIHARKLSEQRK
- 172 
--- 172 
-- 176 
GD 219 
 
Fig. IV-2: Structural alignment of 4 members of the SDR superfamily  
Structural information are based on Protein Data Bank. Alignment was done with the program  CE-MC (Guda et 
al., 2001; Guda et al., 2004; Guda et al., 2006) 
 
Human carbonyl reductase 1 (CBR1) whose structure has been solved only a few years ago 
(Tanaka et al., 2005) exhibits a monomeric structure. Structural comparison to other members 
of this family reveals the existence of an additional alpha-helical subdomain between the Q-
interfacial strand βE and helix αF comparable to that of 3α-HSD/CR from C.testosteroni. This 
structural feature is believed in homology to 3α-HSD/CR to prevent oligomerization along the 
Q-axis interface built up of the four helix bundle. This α-helical subdomain can be found in 
other monomeric carbonyl reductases as well, but with different length. Among the mono-
meric carbonyl reductases with an additional subdomain are pig testicular carbonyl reductase 
(PTCR) which has a sequence identity to human CBR1 of nearly 85%, as well as the cytosolic 
and monomeric carbonyl reductases of rat (non-inducible, nCR; inducible, iCR; testis, rtCR) 
and Chinese hamster (CHCR).  
 
Alcohol dehydrogenase (ADH) from Drosophila lebadonensis can be seen as a typical protein 
for dimerization of two identical monomers across the Q-axis and features  α-helix E and α-
helix F as the main structural features of each of the two subunits to form a bundle of four 
helices. This four helix bundle represents the most important structural motif of the Q-axis 
interface, especially in dimeric SDR proteins and is therefore the most widespread type of 
dimerization within dimeric proteins of the SDR superfamily.  
 
As a typical example for a tetrameric SDR-protein with four identical monomers oligomeriz-
ing along the P- and Q-axis 3α20β-HSD from Streptomyces hydrogenans was included in the 
alignment. Fig. IV-2 demonstrates that 3α20β-HSD lacks the alpha-helical extraloop subdo-
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main and exhibits only a 6-amino acid sequence as link between strand βE and helix αF (see 
also Fig. IV-3). Based on the fact that 3α20β-HSD from Streptomyces hydrogenans appears as 
homotetramer which apparently bears structural features for both oligomerization interfaces P 
and Q this protein was included in the modeling and simulation approaches to elucidate the 
peculiar oligomerization behaviour of 3α-HSD/CR from C.testosteroni. 
 
3α-HSD/CR from C.testosteroni consists of two identical monomers showing the typical SDR 
architecture of the Rossmann fold (Grimm et al., 2000b). Nevertheless the topology of this 
dimeric protein differs in some details from that of other proteins within the SDR protein su-
perfamily which are believed to have significant consequences on the overall folding topol-
ogy.  
The canonical structural motif is as expected a βαβ-dinucleotide binding motif (Rossmann 
fold) which consists of  a central six-stranded parallel β-sheet sandwiched between two arrays 
of α-helices (Rossmann et al., 1975; Grimm et al., 2000b). Likewise the folding pattern is, 
according to other SDR proteins, extended at its COOH terminus by at least one additional α-
helic (αG) and a seventh partallel β-strand (βG) (Fig. IV-3; Fig. IV-4). Contrary to the typical 
folding pattern in 3α-HSD/CR the Rossmann fold motif is truncated. It lacks helix αC and 
shows an only rudimentary left strand βC. These structural modifications can also be found in 
dihydropterin reductase (Varughese et al., 1992) and GDP-fucose synthetase (Somers et al., 
1998), also members of SDR superfamily. Additionally 3α-HSD/CR contains an insertion of 
28 amino acids within the Rossmann fold motif between strand βE and helix αF (Fig. IV-2; 
Fig. IV-3) which forms a predominantly α-helical subdomain.  
This 28 amino acids insertion (“extraloop”) is believed to prevent the typical dimerization via 
the Q-axis interface involving helices αE and αF by making it sterically impossible (Grimm et 
al., 2000b) (Fig. IV-4; Fig. IV-5). As well as in the monomeric carbonyl reductases contain-
ing this α-helical extraloop-domain, oligomerization along this interface region is prevented 
because of the disruption of the Q-axis interface. Consequently in 3-HSD/CR dimerization 
takes place via a P-axis interface which corresponds to the P-axis interface of 3/20-HSD. 
The dimerization about a P-axis interface has been discussed as a possible mode of oligomeri-
zation in SDRs (Krook et al., 1993b) but has never been observed in a crystal structure so far. 
However, this type of oligomerization via the P-axis interface can only be found in tetrameric 
SDRs such as for example in 3α/20β-HSD from S. hydrogenans (Ghosh et al., 1994b). 
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Fig. IV-3: Structural alignment of the 
SDR enzymes 3-HSD/CR, 3/20-
HSD and ADH.  
All SDRs known so far lack the addi-
tional „extraloop“-domain (red). The 
homologous region of 3/20-HSD is 
given in green. 
 
 
 
 
 
 
 
 
 
IV.1.2.2 Distinct Sructural Elements of SDR Enzymes have varying Influence of the 
Folding Topology 
Catalytic Triade and Catalytic Mechanism 
Jörnvall and coworkers described already in 1981, the importance of the Tyr-x-x-x-Lys seg-
ment as the most conserved sequence motif of the SDRs (Jornvall et al., 1981) which is nearly 
used by all “classical” SDR enzymes as an conserved catalytic residues Tyr-Lys-Ser  
(Jornvall et al., 1995) Slightly different composition of the catalytic residues can be found 
within the “divergent” and the “complex” class within the SDR superfamily (see Part I). The 
amino acids which constitute the catalytic triad are critically important for enzyme function 
(for catalytic mechanism refer to Part I). They appear to maintain a fixed position relative to 
the scaffolding of the βαβ-folding and the cofactor position.  
 
Substrate Binding and Substrate-Binding Loop 
In the core of the Rossmann fold most of the primarily hydrophobic amino acid residues 
which are partially conserved within the SDR superfamily members are located (Duax et al., 
2000). Within the substrate-binding cleft the only conserved residues are those of the catalytic 
triad: Ser, Tyr and Lys. No conserved residues can be found in the substrate-binding site. This 
is indicative for the fact that, for example, the HSDs show high selectivity for their specific 
physiological steroid substrate.  
FF
Substrate Binding Loop
cHSDH 1 -----MSIIVISGCATGIGAATRKVLEAAGH-QIVGIDIR------------------DA
sHSDH 1 NDLS-GKTVIITGGARGLGAEAARQAVAAGA-RVVLADVLDEEGAATAREL----GDAAR
dADH 1 -MDLTNKNVIFVAALGGIGLDTSRELVKRNLKNFVILDRVE-NPTALAELKAINPKVNIT
A BB
DC D E
cHSDH 37 EVIADLSTAEGRKQAIADVLAKC--SKGMDGLVLCAGLGP-------QTKVLGNVVSVNY
sHSDH 55 YQHLDV--TI-EEDWQRVVAYAREEFGSVDGLVNNAGISTGMFLETESVERFRKVVEINL
dADH 59 FHTYDV--TVPVAESKKLLKKIFDQLKTVDILINGAGIL--------DDHQIERTIAINF
cHSDH 145 HAGEQGGNLAYAGSKNALTVAVRKRAAAWGEAGVRLNTIAPGA
sHSDH 144 ---GLALTSSYGASKWGVRGLSKLAAVELGTDRIRVNSVHPGMTYT--PMTAETGIRQGE
dADH 144 ---AIHQVPVYSASKAAVVSFTNSLAKLAPITGVTAYSINPGITRTPLVHTFNSWLDVEP
cHSDH 209    FVPPMGRRAEPSEMASVIAFLMSPAASYVHGAQIVIDGGIDAVMRPTQF-----
sHSDH 199 GNYPNTPMGRVGEPGEIAGAVVKLLSDTSSYVTGAELAVDGGWTTGPTVKYVMGQ--
dADH 201 RVAELLLSHPTQTSEQCGQNFV---KAIEANKNGAIWKLDLGTLEAIEWTKHWDSHI
E EF2EF1E EF3
G CTG
cHSDH 88 FGATELMDAFLPA---LKKGHQPAAVVISSVASAHLAFDKNPLALALEAGEEAKARAIVE
sHSDH 112 TGVFIGMKTVIPAM---KDAGGGSIVNISSAAGLM-------------------------
dADH 109 TGLVNTTTAILDFWDKRKGGPGGIIANICSVTGFN-------------------------
3-HSDH
320-
ADH
3-HSDH
320-HSDH
ADH
3-HSDH
320-
ADH
3-HSDH
320-
ADH
3-HSDH
320-
ADH
TETPLLQAGLQDPRYGES
IAK
Results and Discussion  124
Usually, SDR enzymes have a substrate-binding loop of more than 20 residues which covers 
the active site and becomes well ordered after the hydroxyl or carbonyl substrate binding. 
This loop region is located between β-strand F (βF) and α-helix G (αG) and is very often dis-
ordered in apo-structures (without substrate) of SDR enzymes. After substrate binding, the 
loop shows a well-defined, mainly α-helical, geometry. However, in Sniffer from Drosophila 
no α-helical secondary structure element is apparent in the substrate-binding loop (Sgraja et 
al., 2004). Here, in the presence of NADP+, only a short loop could be detected in the electron 
density which connects strand βF and helix αG (Sgraja et al., 2004).  
 
When the α-carbon backbone of known SDR structures is superimposed, the conserved resi-
dues appear at the core of the structure and in the cofactor-binding domain, but not in the sub-
strate-binding pocket (Duax et al., 2000). Contrary to the variability in the substrate-binding 
pocket, the association of the Rossmann fold with the cofactor binding is very consistent and 
the NADP(H) binding domains shows architectural integrity, despite having sequence varia-
tions (Duax et al., 2000). The variability in the substrate-binding pocket is plausible when 
keeping in mind the variety of structures used as substrates by different members of the SDR 
superfamily (Duax et al., 2000).  
 
Cofactor Binding 
In the N-terminal part of the SDR proteins, a glycine-rich pattern important for cofactor bind-
ing has been identified (Jornvall et al., 1995). This conserved sequence motif includes three 
glycine residues which are located at comparable points in their sequences and form a turn 
between a β-strand and an α-helix that border the cofactor-binding site (Duax et al., 2000). 
Structural analysis has shown that the glycine residues interact with the pyrophosphate moiety 
of the cofactor. The individual subfamilies of the SDR superfamily differ regarding the spac-
ing of the three glycine residues, where the Gly-x-x-x-Gly-x-Gly motif, for example, is char-
acteristic for the subfamily of the “classic” SDRs (Jornvall et al., 1981; Jornvall et al., 1999). 
The use of either reduced or oxidised NAD(P) as cofactor depends on their predominant func-
tion as a dehydrogenase or reductase of individual members of the SDR superfamily. In addi-
tion, both NAD(H) and NADP(H) bind to the classical βαβ motif of the Rossmann fold. The 
specificity for NADP(H), rather than to NAD(H), is conferred by two highly conserved basic 
residues in the N-terminal part of the peptide chain. Tanaka et al. (Tanaka et al., 1996a) iden-
tified two basic residues (Lys-17 and Arg-39) in the tetrameric mouse lung carbonyl reductase 
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(MLCR) which promote NADPH binding by interaction with the 2’-phosphate group. These 
residues are believed to confer specificity for NADPH in other SDRs as well.  
  
Human monomeric carbonyl reductase (CBR1) shows less than 25% overall sequence identity 
with tetrameric MLCR (Jornvall et al., 1995). However, similar to MLCR, human CBR1 has 
distal basic (Lys-15 and Arg-38) and neutral (Ala-37) residues at positions corresponding to 
Lys-17, Arg-39 and Thr-38 in tetrameric MLCR (Tanaka et al., 1996a) and is strictly 
NADPH-dependent (Wermuth et al., 1988; Sciotti and Wermuth, 2001). Sciotti and Wermuth 
(Sciotti and Wermuth, 2001) showed that a positive charge at positions 15 and 38 and the ab-
sence of a negative charge at position 37 significantly contribute to NADPH specificity. SDR 
enzymes which are NAD-dependent lack these two basic residues. Instead, an Asp which is 
adjacent to the position of the distal basic residue in NADPH-dependent enzymes appears to 
determine NAD specificity (Sciotti et al., 2000). Sequence alignments of NAD-dependent 
enzymes with the NADPH-dependent tetrameric and monomeric carbonyl reductases show 
that Ala-37 of the monomeric and Thr-38 of the tetrameric carbonyl reductase corresponds to 
the Asp residue which plays a role in NAD specificity. Sciotti and Wermuth (Sciotti and 
Wermuth, 2001) substituted Asp for Ala-37 in the strictly NADPH-dependent human CBR1. 
Unexpectedly, the Asp residue had little effect on the NADH-dependent activity and NADPH 
was still the preferred substrate of the mutant Ala37Asp. Therefore, factors other than only 
the absence of Asp at position 38 must be responsible for the low efficiency of monomeric 
human CBR1 in the presence of NADH (cf Part I, Fig. III-2 chapter III.3.3, Cofactor Binding, 
p19). 
3α-HSD/CR shows the typical amino-terminal cofactor binding motif Gly8-x-x-x-Gly12-x-
Gly14. As cofactor 3α-HSD/CR and depends on NAD(H) and hardly accepts NADP(H) which 
supports the catabolic nature of 3a-HSDH (Grimm et al., 2000b).  
This is supported by structural analyses. In the binary complex NAD+ is bound at the car-
boxyl-terminal ends of the β-strands and is well superimposable with the cofactors present in 
other binary or ternary complexes of SDRs. Therefore both ribose rings are present as 29 
endo-conformers, the nicotinamide ring is bound in a syn and the adenine base in an anti-
torsion  angle to the respective ribose moiety (Grimm et al., 2000b).  
 
In 3α-HSD/CR Asp-32 is like in other SDRs, highly conserved among enzymes preferring 
NAD(H) . The side chain carboxylate of Asp-32 forms hydrogen bonds to both the 2´ and the 
3’ OH group of the adenosine ribose.  
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For correct cofactor binding Lys-159, a residue of the catalytic triade, plays also a crucial role 
and provides proper orientation of the cofactor by forming hydrogen bonds to the nicotina-
mide moiety. Additionaly Lys-159 lowers the pKa of the catalytic Tyr via electrostatic inter-
action (Ghosh et al., 1994b; Auerbach et al., 1997; Benach et al., 1999).  
This implicates that not only the correct structural localization of residues involved in cofac-
tor but also the correct structural arrangement of other residues which partly assist e.g. the 
amino acids responsible for cofactor binding, is essential for cofactor binding as an important 
criterion for correct enzyme function.  
 
 
C-terminal Extension and 310-Helices 
Many enzymes of the SDR superfamily contain a C-terminal extension consisting of several 
α-helices. Examples are human estrogenic 17β-HSD (Ghosh et al., 1995) and the  Drosophila 
enzymes alcohol dehydrogenase (DADH) and Sniffer. Benach and coworkers showed in 
DADH that these C-terminal helices, which are of more variable character, are main elements 
of dimer association and that these structural features have additional importance in closing of 
the active site cavity upon cofactor and substrate binding (Benach et al., 1998). 
 
310-helices are structural elements which are present as α-helical extensions in loops and as 
connectors between β-strands (Pal and Basu, 1999). In many cases they occur independently 
of any other neighbouring secondary structural elements and form novel super-secondary 
structural motifs. These motifs have possible implications for protein folding, local conforma-
tional relaxations and biological functions (Pal and Basu, 1999).  
 
The Sniffer protein has both structural features which contribute together to dimer formation. 
At the C-terminal end of the Sniffer protein there is a short loop with a sharp turn directly fol-
lowing strand βG. This loop runs perpendicular to the central β-sheet of the Rossmann fold 
and touches the 310-helix following strand βE. The C-terminal ends of the two monomers ap-
proach each other and the indole moiety of the Trp-248 interacts through its planar ring sys-
tem with the side-chain of Ile-159 which is rooted at the 310-helix of the second subunit 
(Sgraja et al., 2004).  
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Fig. IV-4: Structural elements involved in folding topology as in 3α-HSD/CR from C. testosteroni 
 
 
Oligomerization and Interfaces  
The enzymes of the SDR superfamily can be divided into different groups concerning their 
oligomerization behaviour, their subcellular localization and the existence of structural ele-
ments with significant effects on protein folding. Most enzymes of the superfamily appear as 
either homodimers, e.g. Sniffer (Sgraja et al., 2004), DADH (Benach et al., 1998) and dihy-
dropteridine reductase (DHPR) (Varughese et al., 1992), or homotetramers like 3α/20β-HSD 
(Ghosh et al., 1994b) and mouse lung carbonyl reductase (Tanaka et al., 1996a). Only few 
members occur as monomers like for example human carbonyl reductase (CBR1) (Wermuth, 
1981) and pig testicular carbonyl reductase (PTCR) (Ghosh et al., 2001). In spite of the low 
residue identities between the SDR members, the folding pattern of the individual (sub-) units 
is highly conserved with largely superimposable peptide backbones (Krook et al., 1993b; 
Ghosh et al., 2001) (Part I, Fig. III-1 p.18, Fig. IV-1 p.28).  
 
Results and Discussion  128
Two types of oligomerization, involving different structural elements, can be found. They use 
two main subunit interfaces arranged about two non-crystallographic 2-fold axes which are 
perpendicular to each other and referred to as P and Q  (Ghosh et al., 1994b; Tanaka et al., 
1996a; Grimm et al., 2000b) (Fig. IV-1; Fig. IV-4).  
One type of monomer association is the so-called P-axis interface comprising the antiparallel 
association of β-strand G and α-helix G of each subunit (Ghosh et al., 1994b). This type of 
oligomerization is usually found in homotetrameric SDRs and has only been observed in one 
dimeric SDR, namely 3α-HSD/CR from C. testosteroni (Grimm et al., 2000a). The P-axis 
interface does not involve significant hydrophobic interactions (Ghosh et al., 1994b) and is 
less critical to the structural integrity of the active site than the second type of oligomeriza-
tion, the so-called Q-axis interface. 
 
All structures of homotetrameric SDRs determined so far show the wo main subunit inter-
faces referred to as P and Q  (Ghosh et al., 1994b; Tanaka et al., 1996a; Grimm et al., 2000b).  
The Q-axis interface consists of α-helix E and α-helix F of each of the two subunits to form a 
bundle of four helices. This four helix bundle represents the most important structural motif 
of the Q-axis interface, especially in dimeric SDR proteins. It is predicted to be important for 
the integrity of the active site clefts  and has been shown to be critical to function (Puranen et 
al., 1997; Ghosh et al., 2001). In addition, although more than half of the crystal structures of 
SDRs exhibit the same quaternary structure, only the four helix bundle as the main structural 
feature of the Q-axis interface that involves the largest surface area of association (Ghosh et 
al., 1994b) is conserved among the SDRs.  
The dimerization interface is close to the active site and stabilizes the interior of the molecule.  
Tsigelny and Baker postulated that the neighbouring amino acids of the conserved tyrosine 
and lysine residues in the active site of SDR family members might interact with the hydro-
phobic outer surface of the αF helix and hence stabilize the dimer interface of the proteins 
(Tsigelny and Baker, 1995b). Therefore, it is suggested that monomerization of dimeric or 
tetrameric proteins in the SDR family most likely abolishes their enzyme activity. Hoffmann 
and coworkers (Hoffmann et al., 2006) redesigned the region of the interfacial four helix bun-
dle in the dimeric 3α-HSD/CR from C. testosteroni, which comprises an additional α-helical 
subdomain preventing the enzyme of dimerization along the typical Q-axis interface. Their 
data of a soluble and active protein will give further insights into the requirements of a protein 
for the architecture of the active site and the structural elements comprising the Q-axis inter-
face.  
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In the dimeric human 17β-HSD, Puranen and coworkers (Puranen et al., 1997) substituted 
amino acids of the four helix bundle within the hydrophobic Q-axis interface resulting in inac-
tive multi-aggregates of the protein, while neither dimers nor monomers were detectable. 
Ghosh and coworkers were also able to show that the four helix bundle is critical for protein 
function. Disruptions of the helix arrangement had negative effects on the integrity of the 
catalytic centres of the oligomerizing monomers in 3α/20β-HSD of S. hydrogenans (Ghosh et 
al., 2001).  
 
An example for a cytosolic and monomeric carbonyl reductase is human CBR1. The reason 
for the monomeric structure of this enzyme is a so-called additional extraloop-domain be-
tween the Q-interfacial strand βE and helix αF which is believed to prevent oligomerization 
along the Q-axis interface built up of the four helix bundle. Other monomeric carbonyl reduc-
tases include this α-helical subdomain as well, but with different length. Among the mono-
meric carbonyl reductases with an additional subdomain are pig testicular carbonyl reductase 
(PTCR) which has a sequence identity to human CBR1 of nearly 85%, as well as the cytosolic 
and monomeric carbonyl reductases of rat (non-inducible, nCR; inducible, iCR; testis, rtCR) 
and Chinese hamster (CHCR).  
 
The group of tetrameric carbonyl reductases is not as consistent as the group of monomeric 
carbonyl reductases. Tetrameric carbonyl reductases can be found on the subcellular level in 
the mitochondria (namely carbonyl reductases from mouse and pig lung) (Nakayama et al., 
1986; Oritani et al., 1992) and in the cytoplasm, i.e. 3α/20β-HSD from S. hydrogenans 
(Ghosh et al., 1992; Ghosh et al., 1994a; Ghosh et al., 1994b). The tetrameric carbonyl reduc-
tase from pig liver is a peroxisomal protein which contains the SRL-tripeptide (serine-
arginine-leucine) as a peroxisomal targeting signal (Usami et al., 2003) (cf. chapter IV.2.1.7; 
Tetrameric Peroxisomal Carbonyl Reductases, Part I, p41). 
 
The Q-interfacial dimer interface of which Sniffer provides a typical example is also present 
in tetramers (3α/20β-HSD). This interface is stabilized by interactive associations of symme-
try related α-helices αE and αF. It has been shown that while conservative variations in amino 
acids (i.e. substitution of one hydrophobic residue for another) is tolerated, non-conservative 
mutations can disrupt dimer formation and cause loss of function (Duax et al., 2000).   
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A special case represents dimeric 3α-HSD/CR from C. testosteroni. This enzyme does not 
undergo oligomerization along the Q-axis interface, because the protein contains an α-helical 
extraloop-domain within this Q-interfacial four helix bundle. As with the monomeric carbonyl 
reductases containing this α-helical extraloop-domain, oligomerization along this interface 
region is prevented because of the disruption of the Q-axis interface. Most interestingly, 3α-
HSD/CR performs dimerization along the P-axis interface (Grimm et al., 2000b). However, 
this type of oligomerization via the P-axis interface can only be found in tetrameric SDRs 
such as for example in 3α/20β-HSD from S. hydrogenans (Ghosh et al., 1994b) (see above).  
 
 
IV.1.3 The Extraloop-Domain of 3α-HSD/CR could be Responsible for the Abnormal 
Oligomerization Pattern in spite of a Complete Set of Typical Structural Mo-
tifs 
3α-HSD/CR from C.testosteroni features all structural elements which are typical for oli-
gomerization along the Q-axis interface. Among these are  α-helix E and α-helix F of each 
subunit forming the so called four helix bundle and the localization of these four helix bundle 
close to the active side of the protein stabilizing the interior of the molecule. Oligomerization 
along the Q-acis interface is described in detail in part I, section II “General features of SDR 
superfamily enzymes”.  
 
Fig. IV-5: „extraloop“-domain in 3-
HSD/CR blocks the formation of a 
tetramer 
Left: The additional -helical subdomain 
(yellow) prevents 3-HSD/CR from dimeri-
zation along the Q-axis interface.  
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In addition to the structural setting for Q-axis oligomerization 3α-HSD/CR is equipped with a 
couple of structural elements typical for P-axis oligomerization, e.g. the antiparallel associa-
tion of β-strand G and α-helix G of each subunit and the carboxyterminal helix αCT.  
 
In 3-HSD/CR there is an insertion of 28 amino acids within the Rossmann fold motif be-
tween strand E and helix F forming a predominantly -helical subdomain (Grimm et al., 
2000b). Additionally the enzyme lacks helix αC and has only a rudimentary strand βC. 
Because of the 28 amino acids insertion (“extraloop”) into the classical Rossmann fold motif 
between strand E and F this mode of dimerization is sterically impossible in 3-HSD/CR 
(Grimm et al., 2000b) (Fig. IV-5). As a consequence, in 3-HSD/CR dimerization takes place 
via a P-axis interface which corresponds to the P-axis interface of 3/20-HSD. The P-axis 
interface is mainly formed by the parallel packing of two αG helices and by side chain-to-
main chain interactions between the βG strands of two neighbouring subunits. In addition, the 
carboxyl-terminal helix αCT of each subunit is packing against the αF helix of the other sub-
unit. The dimerization about a P-axis interface has been discussed as a possible mode of oli-
gomerization in SDRs (Krook et al., 1993b) but has never been observed in a crystal structure 
so far.  
 
IV.2  Combination of in silico Based Approach and Molecular Biology 
Methodology 
To investigate the role and importance of the additional α-helical subdomain on the type of 
oligomerization and its impact on the stability and therefore activity of the protein a combined 
in silico and molecular biological approach has been performed. In this approach the question 
has to be followed if the deletion of this alpha-helical subdomain leads to the formation of a 
homotetramer or even a novel oligomerization mode and if the mutant deleted by this extra-
loop still active. In this combined approach first the structure to be manipulated has to be de-
termined, then as in silico-steps the new amino acid sequence has to be modelled on the basis 
of the 320HSD-pdb-structure, MD-simulations have to be performed and the calculated 
conformations have to be interpreted. The in silico steps are aimed not to destroy the entire 
architecture of the protein by solely deleting the extraloop domain but rather to redesign the 
folding topology as if the protein would originally not have this additional α-helical subdo-
main. 
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IV.3  An In Silico – Approach Provides Insight into the Possible Sterical 
Perturbations after Redesign of the Extraloop-Domain  
IV.4  Molecular Modeling of the SBL and the Redesigned Loop-Region  
3/20-HSD 3-HSD/CR-truncated3-HSD/CR
extraloop

ADH
SBL-ordered
3-HSD/CR
SBL-not ordered
extraloop
3/20-HSD
αEF1
αEF2 αEF3
I
II
 
Fig. IV-6: Overview of mutagenesis approach 
I: Comparison of different members of the SDR Superfamily with respect to their folding pattern and structural 
features regarding the alpha-helical extraloop subdomain. 
II: Approach of redesigning the extraloop domain of 3α-HSD/CR with the corresponding structural feature of 
3α/20β-HSD.   
 
 
To investigate the role of the extraloop in the oligomerization behaviour of 3-HSD/CR a 
mutation-approach was performed to replace the extraloop by the much shorter corresponding 
3/20-HSD loop. This was pursued both in silico (by homology modeling) and in vitro (by 
applying PCR-techniques). The resulting truncated 3-HSD/CR (3-HSD/CR-tr) was theo-
retically analysed by molecular dynamics simulations and experimentally characterized by 
enzymatic methods (IV.5 , p142).  
 
Detailed analysis of a previous 3α-HSD/CR-tr model generated from the templates (PDB 1fjh, 
1a4u, and 2hsd) in a one-step procedure (Hoffmann et al., 2003) revealed some unsatisfactory 
deviations from the primary template, i.e. the wildtype 3α-HSD/CR (1fjh). Therefore, homol-
ogy modeling was repeated by following the two-step procedure described above, which al-
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lowed for a more controlled insertion of the new loops. The top-ranked model obtained from 
this refined approach and its behaviour in the subsequent MD simulation is analyzed herein.  
 
IV.4.1 Modeling of the Crystallographic Unordered Substrate Binding Loop yields 
an One-Chain-Protein as a Basis for Further Simulation Approaches  
As a first step molecular modeling of the structurally unordered substrate binding loop (SBL) 
of 3α-HSD/CR was performed on the basis of the structurally ordered SBL of alcohol dehy-
drogenase of Drosophila lebadonensis (1a4u). Fig. IV-7A shows the structural alignment of 
alcohol dehydrogenase (ADH) as template protein and 3α-HSD/CR. Fig. IV-7B shows the 
TOP-file which defines the different parameters and values of this modeling step. In this ap-
proach the sequence of the unordered SBL of 3α-HSD/CR was structurally aligned to the 
amino acids of the structurally well ordered SBL of ADH to obtain a one-chain protein sub-
unit as unconditional requirement for the further modeling and simulation steps. Modeling of 
the SBL maintains the position of the residual amino acids not to implement unnecessary de-
viations for the residues already structurally well ordered. Ten protein models were generated 
from which the model with the lowest MODELLER target function value was selected. 
This modeling step results in an one-chain protein with the original crystallographic coordi-
nates for all residues except for the ones of the substrate binding loop. Preliminary coordi-
nates for these residues were obtained from the modeling by means of the SBL of ADH.  
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>P1;1a4u
structureX:1a4u:1:A:254:A:alcohole dehydrogenase:::
-MDLTNKNVIFVAALGGIGLDTSRELVKRNLKNFVILDRVE-NPTALAELKAIN
PKVNITFHTYDV--TVPVAESKKLLKKIFDQLKTVDILINGAGIL--------D
DHQIERTIAINFTGLVNTTTAILDFWDKRKGGPGGIIANICSVTGFNAIHQVPV
YSASKAAVVSFTNSLAKLAPITGVTAYSINPGITRTPLVHTFNSWLDVEPRVA-
ELLLSHPTQTSEQCGQNFV---KAIEANKNGAIWKLDLGTLEAIEWTKHWDSHI*
>P1;3hsd+T+SBL
unknown:3hsd+T+SBL: : : : : : : : 
-----MSIIVISGCATGIGAATRKVLEAAGH-QIVGIDIR--------------
----DAEVIADLSTAEGRKQAIADVLAKC--SKGMDGLVLCAGLGP-------Q
TKVLGNVVSVNYFGATELMDAFLPA---LKKGHQPAAVVISSVASLMGLALTSA
YAGSKNALTVAVRKRAAAWGEAGVRLNTIAPGATETPLLQAGLQDPRYGESIAK
FVPPMGRRAEPSEMASVIAFLMSPAASYVHGAQIVIDGGIDAVMRPTQF-----*
INCLUDE
SET OUTPUT_CONTROL = 1 1 1 1
SET ALNFILE               = '../alis/3hsd+T+SBL.pir'
SET KNOWNS                = '1a4u'
SET MD_LEVEL              = 'refine2'
SET SEQUENCE              = '3hsd+T+SBL'
SET ATOM_FILES_DIRECTORY  = '../pdbs'
SET OUTPUT_DIRECTORY      = './'
SET PDB_EXT               = '.pdb'
SET ALIGNMENT_FORMAT = 'PIR'
SET STARTING_MODEL        = 1
SET ENDING_MODEL          = 3
SET DEVIATION             = 4.000000
SET FINAL_MALIGN3D        = 1
CALL ROUTINE              = 'model'
A
B
 
Fig. IV-7: Structural alignment for modelling of SBL 
A: Structural alignment of amino acid sequence of 3α-HSD/CR including the amino acids of the substrate bind-
ing loop (SBL) to the three dimensional structure of alcohol dehydrogenase from Drosophila lebadonensis 
(1a4u). 
B: TOP-file for modeling of the amino acid sequence of 3α-HSD/CR-substrate binding loop to the known struc-
ture of the SBL of alcohol dehydrogenase to obtain a one-chain protein for subsequent modeling steps. 
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IV.4.2 Modeling of the Homologous T-loop Region of 3α/20β-HSD of S.hydrogenans  
into 3α-HSD/CR Generates the Truncated 3α-HSD/CR Protein  
In a second modeling step, the "extraloop" (residues 118-153), which is assumed to prevent 
tetramerization or dimerization along the alternative Q-axis interface, was removed from the 
3α-HSD/CR structure and replaced by an 8-residue loop of 3α/20β-HSD; PDB structure 2hsd 
was used as template for modeling the 3α-HSD/CR-tr structure with this inserted 3α/20β-HSD 
loop.  
Fig. IV-9 shows the structural alignment of the truncated 3α-HSD/CR protein sequence with 
that of 3α20β-HSD which serves as a basis for the modeling step perfomed with the program 
MODELLER 6. The program MODELLER generates 3 different models of the truncated 3α-
HSD/CR which were put into the MD-analysis. Fig. IV-8 shows an overlay of these 3 differ-
ent models generated by MODELLER 6. Expectedly some deviations between the 3 models 
can be observed for the regioni of the inserted shortened extraloop-domain from 3α20β-HSD. 
The orientation of the catalytic residues is nearly the same.  
 
Catalytic triad
Model  1-3Model  1-3 Overall by MODELLER6
Tyr127
Ser114
Lys131
Inserted loop
 
Fig. IV-8: Overlay of the 3 models of 3α-HSD/CR-tr 
This overlay of the 3 models is generated by the modeller 6 program. Some differences can be clearly identified 
in the region of the inserted short loop. The position of the catalytic residues is very simlar in al 3 models. 
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Fig. IV-9: Structural alignment for modelling of extraloop-region 
Structural alignment (A) and TOP-file (B) for modeling of shortened amino acid sequence between βE and αF of 
3α20β-HSD into the truncated pdb-structure of 3α-HSD/CR.  
 
 
 
 
 
 
 
 
 
 
 
 
>P1;2hsd 
structureX:2hsd: 2 :A: 255 :D:3 alpha, 20 beta-hydroxysteroid 
dehydrogenase(holo form:(streptomyces hydrogenans): 2.64:18.80 
NDLSGKTVIITGGARGLGAEAARQAVAAGARVVLADVLDEEGAATARELGDAARYQHLDV 
TIEEDWQRVVA--YAREEFGSVDGLVNNAGISTGMFLETESVERFRKVVEINLTGVFIGM 
KTVIPAMKDAGGGSIVNISSAAGLMGLALTSSYGASKWGVRGLSKLAAVELGTDRIRVNS 
VHPGMTYTPMTAETGIRQGEGNYPNTPMGRVGEPGEIAGAVVKLLSDTSSYVTGAELAVD 
GGWTTGPTVKYVMGQ* 
 
>P1;3hsd_mut 
unknown:3hsd_mut: : : : : : : 0.00: 0.00 
MSI----IVISGCATGIGAATRKVLEAAGHQIVGIDIRDAEVIA--------------DL 
STAEGRKQAIADVLAKCSKG-MDGLVLCAGLGP-------QTKVLGNVVSVNYFGATELM 
DAFLPALKKGHQPAAVVISSVASLMGLALTSAYAGSKNALTVAVRKRAAAWGEAGVRLNT 
IAPGATETPFV------------P--PMGRRAEPSEMASVIAFLMSPAASYVHGAQIVID 
GGIDA---VMRPTQF* 
INCLUDE 
SET OUTPUT_CONTROL = 1 1 1 1 
SET ALNFILE               = '../alis/3hsd+T+SBL.pir' 
SET KNOWNS                = ‘2hsd' 
SET MD_LEVEL              = 'refine2' 
SET SEQUENCE              = '3hsd+T+SBL' 
SET ATOM_FILES_DIRECTORY  = '../pdbs' 
SET OUTPUT_DIRECTORY      = './' 
SET PDB_EXT               = '.pdb' 
SET ALIGNMENT_FORMAT  = 'PIR' 
SET STARTING_MODEL        = 1 
SET ENDING_MODEL          = 3 
SET DEVIATION             = 4.000000 
SET FINAL_MALIGN3D        = 1 
CALL ROUTINE            = 'model' 
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IV.4.3 Molecular Dynamic Simulation of Three Mutant Models in Comparison to the 
Wildtype Gives an Outlook on Their Structural Stability  
Molecular dynamics (MD) is a special form of computer simulation in which all atoms and 
molecules are allowed to interact for a defined period of time under known laws of physics 
and preassigned parameters. As a result of this simulation a view of the motion of the atoms is 
given. Molecular systems generally consist of a vast number of particles and are affected by a 
multitude of physical and chemical parameters. Therefore it is impossible to find the 
properties of such complex systems analytically. Numerical methods are used to circumvent 
this problem. Because of the fact that the most important chemico and physico parameters 
which have an impact on the system of molecules and atoms to be examined are defined in 
the simulation by algorithms MD simulations represent an interface between laboratory 
experiments and theory, and can be understood as a "virtual experiment". 
The objective of a MD simulation is to calculate the temporally process of a molecular system 
in a predefined force field based on a starting configuration by means of Newton’s equation 
of motion. During the simulation the acceleration on all atoms of the system is calculated 
which results in a new position of the atoms at a consecutive point of time. The length of thos 
timeframe has to be chosen correctly to record even motions with the highest frequencies. A 
trajectory is a series of consecutive configurations of the molecule.  
The proteins in this approach were simulated in aqueous solution using a box of explicit water 
molecules and periodic boundary conditions. Fig. IV-10 shows a model of such periodic 
boundary conditions in which a box of water containing the molecule is adjacent to the next 
box of water. After minimization, heat-up to 300 K and initial equilibration, a trajectory of 1 
ns length was sampled and saved at regular intervals of 0.5 ps. 
 
Fig. IV-10: Periodic boundary 
conditions. 
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IV.4.4 Comparative Simulation of the Wildtype Protein as Basis for Validation of 
Observed Structural Deviations. 
To assess the observed root-mean-square deviation (rmsd), the differences between values 
predicted by MD-simulation, for the Cα-atoms of the protein backbone as well as for the all-
atom rmsd comparative molecular dynamic simulations of the wildtype protein were 
performed. To use comparable proteins for this approach the sequence of the structurally 
unordered substrate binding loop (SBL) of 3α-HSD/CR was modelled accordingly to the 
approach for the truncated protein on the basis of the crystallographic well ordered SBL of 
alscohol dehydrogenase (1a4u). All three models of 3α-HSD/CR wildtype derived from the 
last modeling step were put into the simulation (Fig. IV-11). The model with the best score 
was further analyzed and discussed in comparison to the truncated 3α-HSD/CR-tr. Detailed 
analysis of the MD-simulation of the wildtype protein is discussed in the following chapter. 
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Simulation of model 1 – 3 
 
Fig. IV-11: End-conformation of the three models of 3α-HSD/CR wildtype after MD simulation  
 
 
IV.4.5 Comparative Analysis of the Simulated Structure of 3α-HSD/CR-tr and the 
Wildtype Protein Reveals Distinct Hot Spots of Flexibility. 
Overall, the model with the highest score displays significantly higher stability during the 
simulation. After an increase during the first 400 ps, the root-mean-square deviation (rmsd) of 
the Cα atoms from the starting structure oscillates around 2 Å, indicating that the overall fold 
is well maintained. Analyzing the all-atom rmsd on a per-residue basis shows that apart from 
some rather exposed side chains the largest deviations and motions occur in the C-terminal 
area (residues 218-229) and in the substrate binding loop. Especially the latter is not unex-
pected given the experimentally known flexibility of this loop. Somewhat smaller deviations 
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and less pronounced mobility compared to the substrate binding loop are observed for the 
inserted 3α/20β-HSD loop. Most importantly, the distance between the terminal residues of 
this loop (Leu 118 and Ser 125) remains close to the starting value of 13.8 Å and shows a 
simulation average of 14.3 +/- 0.6 Å. As a consequence, no significant changes are also ob-
served with respect to the orientation of the three catalytic residues (Ser 114, Tyr 127, Lys 
131). In fact, their mutual Cα distance in the starting model is perfectly maintained throughout 
the simulation (Fig. IV-12; Fig. IV-14). Moreover, only very small fluctuations are observed 
for the entire catalytic triad, which is in line with the generally proposed structural stability of 
such areas in enzyme binding sites (Luque and Freire, 2000).  
Fig. IV-12: Comparative simulation of 3α-HSD/CR-wildtype protein 
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Although the Cα rmsd and the all-atom rmsd averaged over the trajectory are 0.1 Å smaller 
than in the 3α-HSD/CR-tr simulation, the standard deviations of the rmsd averages (and thus 
the structural fluctuations) are increased by more than a factor of two (0.12 Å for the Cα atoms 
in the mutant, 0.30 Å in the wildtype). This increased flexibility leads also to distortions in the 
active-site, where the catalytic residues occasionally adopt alternative conformations and 
show on average larger mutual distances than in the starting structure (Fig. IV-12; Fig. 
IV-14). Also the average distance between the terminal residues of the extraloop (Ala 118 and 
Leu 153) is slightly widened. In total, 55 Cα atoms in the wildtype MD show standard devia-
tions of the rmsd value larger than 0.65 Å. Among these, there is the entire substrate binding 
loop (which is unresolved in the crystal structure due to its high mobility) and all ten Cα atoms 
with B-factors above 30.00 Å2 in 1fjh. The other residues found to be very flexible in the MD 
show lower B-factors, but are mainly part of the long C-terminal section involved in the dimer 
interface of the 3α-HSD/CR homodimer in crystal structure 1fjh (Fig. IV-13). 
 
Analysis of the all-atom rmsd on a per-residue basis reveals distinct hot spots of flexibility.  
Since the structure was simulated as a monomer (in analogy to the mutant), it is reasonable to 
suggest that the lack of the dimer interface is the main reason for their increased flexibility. 
Interestingly, this higher degree of mobility could also be detrimental for catalytic activity, 
considering the alterations observed at the active site during the MD simulation. In contrast, 
the mutant monomer shows less pronounced flexibility (only 19 Cα atoms show standard de-
viations of the rmsd value larger than 0.65 Å). Apparently, in the absence of the stabilizing 
dimer contact the short 3α/20β-HSD loop of the mutant confers higher stability to the protein 
than the much longer extraloop of the wildtype. 
 
Based on these analyses, the model appears reasonable and suggests that the 3α-HSD/CR-tr 
construct should also be catalytically active. Interestingly, the comparative simulation of the 
3α-HSD/CR wildtype with the modelled substrate binding loop reveals a higher overall flexi-
bility for the wildtype than for the mutant.  
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Fig. IV-13: Positions of the most flexible residues in the simulated WT-structure with the modelled SBL-
loop.    
The simulated monomer is shown in blue ribbons with the SBL (188 - 208) in orange and the extraloop (118 – 
153) in purple. Residues showing Cα-atom-rmsd standard deviations larger than 0.65Å are highlighted in ball-
and-stick representation. To illustrate the relative position of the dimer interface, the simulated WT-monomer 
was superimposed with monomer A of crystal structure 1fjh; in the resulting superposition, monomer B of the 
3α-HSD/CR homodimer is shown as yellow surface.  
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Fig. IV-14: Start and end conformation of the inserted loop and the catalytic residues in 3-HSD/CR-tr, 
model 1 
The distance between the terminal residues of this loop (Leu 118 and Ser 125) remains close to the starting value 
of 13.8Å  and shows a simulation average of 14.3 Å. No significant changes are also observed with respect to the 
orientation of the three catalytic residues (Ser 114, Tyr 127, Lys 131).  
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IV.5  Molecular Biology Approach to Delete the Extraloop Domain 
Yields a Biological Active Protein. 
 
IV.5.1 Overlap Extension PCR-Strategy to Delete Extraloop Domain 
The  cloning of  3-HSD/CR was performed previously (Möbus and Maser, 1998). Based on 
this sequence primers were designed to perform overlap extension PCR. In this overlap exten-
sion PCR the sequence for the additional -helical subdomain was replaced by the sequence 
for the homologous short region of 3/20-HSD (Fig. IV-15). The first PCR with primers 
NdeI-for and PMu10 resulted in a fragment containing the first part of the 3-HSD/CR gene 
and the inserted sequence for the 3/20-HSD-loop. This fragment was used as a primer to-
gether with primer BamHI-rev in a second PCR with vector pK15 as template resulting in a 
690 bp fragment (3-HSD/CR-tr) containing the inserted sequence of the 3/20-HSD-loop. 
Sequencing of the 3-HSD/CR-tr-gene cloned into the pET15b-vector confirmed the correct 
in-frame DNA sequence and the absence of any mutations.  
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Fig. IV-15: PCR-strategy for substitution of the extraloop-domain (Overlap-Extension-PCR) 
The 108 bp-fragment (red) represents the „extraloop“ in the wt-sequence which was replaced by the homologous 
24 bp fragment (green) of 3/20HSD.  
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IV.5.2 Overexpression of the Recombinant and Truncated 3α-HSD/CR Protein  
Cloning and overexpression of the 3-HSD/CR as well as the 3-HSD/CR-tr gene from C. 
testosteroni ATCC 11996 was performed as described in chapter III.2  (page 99). Following 
this approach overexpression resulted in fusion proteins with an N-terminal His tag sequence. 
3α-HSD/CR wildtype protein could be easily detected in the supernatant after the cells were 
harvested and broken. In early experiments 3-HSD/CR-tr could only be found in inclusion 
bodies (Fig. IV-17).   
Inclusion bodies are aggregates of stainable substances, in this case proteins. Bacteria use 
inclusion bodies amongst others to protect themselves from substances which could be 
harmful for them. Another reason to pack protein into inclusion bodies is that the bacteria is 
not able to perform correct folding of the protein expressed with high expression rates within 
the cell. The internal microenvironment (pH, osmolarity) of a prokaryotic cell which is used 
for protein overexpression may differ from that of the original source of the gene. 
Additionally mechanisms for folding a protein may also be absent, and hydrophobic residues 
that normally would remain buried may be exposed and available for interaction with similar 
exposed sites on other ectopic proteins. Processing systems for the cleavage and removal of 
internal peptides would also be absent in bacteria. In addition to the obstructive interactions 
between the overexpressed protein and the the proteins in the cell , the fine controls that may 
keep the concentration of a protein low will also be missing in a prokaryotic cell, and 
overexpression can result in filling a cell with ectopic protein that, even if it were properly 
folded, would precipitate by saturating its environment.  
Protein inclusion bodies are classically thought to contain missfolded protein. However, this 
has recently been contested, as green fluorescent protein will sometimes fluoresce in 
inclusions bodies, which indicates some semblance of the native structure and researchers 
have recover folded protein from inclusion bodies (Przybycien et al., 1994; Tsumoto et al., 
2003; Umetsu et al., 2005).  
To understand if the expression in general was successful and where the overexpressed 
protein can be localized ELIZA was performed.  
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IV.5.3 Enzyme Linked ImmunoSorbent Assay (ELISA) to Detect Soluble Protein 
To perform a distinct localization of soluble protein and overexpressed protein in general 
ELIZA was performed with several samples taken from different steps after the overexpres-
sion. To detect the 3α-HSD/CR-tr an antibody against the entire protein was used. Soluble 
protein should be able to be detected in the supernatant after harvesting the cells. 3α-
HSD/CR-WT could be clearly detected in the supernatant whereas the truncated protein could 
only be found in small amounts in the supernatant. During different cycles of cell wash the 
cells were 3x sonified for 10 sec and ultracentrifugated. In a last step the remaining debris 
was resolubilized in 6M Urea which breaks the inclusion bodies and makes the protein ac-
cessable for the antibody. In spite of the fact that 3α-HSD/CR can be found in increased 
amounts in the supernatant after first round of ultracentrifugation most of the protein seams to 
be located in inclusion body too (Fig. V-2). In contrast to the wildtype protein the truncated 
protein can only be detected in higher amounts in inclusion bodies. Therefore additional 
strategies to renaturate the protein from inclusion bodies as well as to improve protein expres-
sion in terms of solubility have to be developed. 
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Fig. IV-16: Distribution and protein concentration of truncated 3α-HSD/CR 
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sample adsorbtion protein concentration in ng/mg 
total protein diluted 1:100 
protein concentration in 
µg/mg total protein 
Ü.St. WT 1,985 804,42 80,44 
Ü.St. M 0,606 37,52 3,75 
Cell Wash 1 WT 0,345 18,44 1,84 
Cell Wash 1 M 0,237 12,01 1,20 
Cell Wash 2 WT 0,542 32,28 3,23 
Cell Wash 2 M 0,124 5,96 0,60 
Cell Wash 3 WT 0,008 0,38 0,04 
Cell Wash 3 M 0,016 0,77 0,08 
Cell Wash 4 WT 0,982 78,96 7,90 
Cell Wash 4 M 1,788 403,88 40,39 
I.B.sol.WT 1,978 779,59 77,96 
I.B.sol. M 2,026 983,60 98,36 
 
Table IV-1: Protein concentration of 3α-HSd/CR-tr after different steps during protein overexpression  
 
IV.5.4 Refolding of Denatured Protein 
It has been shown that protein folding is an enhanceable process (Rudolph and Lilie, 1996; 
Xie and Wetlaufer, 1996; Gupta et al., 1998) and that insoluble proteins can be refolded 
(Kurucz et al., 1995; Rudolph and Lilie, 1996; Mukhopadhyay, 1997). Most protocols de-
scribe the isolation of insoluble inclusion bodies by centrifugation followed by solubilisation 
under denaturing conditions. The protein is then dialyzed or diluted into a non-denaturating 
buffer where refolding occurs. Because every protein possesses unique folding properties, the 
optimal refolding protocol for any given protein must be empirically determined. Optimal 
refolding conditions can be rapidly determined on a small scale by a matrix approach, in 
which variables such as protein concentration, reducing agent, redox treatment, divalent 
cations, etc., are tested. Once the optimal concentrations are found, they can be applied to a 
larger scale solubilisation with refolding of the target protein. Because of the fact that for 
identifying the critical parameters for refolding not too much parameter should be varied in 
parallel a large number of experiments is required.  
After refolding of the protein all substances used in the approach have to be removed prior to 
activity testing which was ideally done by gentle dialysis against the buffer used for subse-
quent activity testing. To ensure that all approaches have been treated exactly in the same way 
all refolding experiments of a charge of overexpressed protein have been done simultane-
ously.  
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Resuspensation of the inclusion bodies was performed as described in “Materials and Meth-
ods”. The method of dialysis was chosen for refolding the protein as this is a very gentle way 
of changing the conditions for the denatured protein. All refolding approaches were done in 
parallel to use exactly the same stock solutions of the reagents and to avoid degradation (e.g. 
Arginin).  
After refolding all protein solutions solubility was tested by ultracentrifugation followed by 
western blot analysis. To be able to detect also very small amounts of soluble protein the re-
folded samples were tested by HPLC analysis as described in chapter III.11 , page 115.  All 
samples showed insoluble protein aggregates which is a hint that most of the protein is still 
denatured. To enhance refolding the protein concentration was decreased to 0.1mg/ml. After 
dialysis against 50mM Tris buffer and centrifugation the supernatant was again tested for ac-
tivity by HPLC. In the p-Nitrobenzaldehyde as well as in the assay with metyrapone as sub-
strate no protein activity could be detected. This led to the conclusion that the approach to 
refold the truncated 3α-HSD/CR should not be further followed. 
 
 
IV.5.5 Optimized Expression Leads to a Soluble Truncated 3α-HSd/CR Protein. 
As refolding of the truncated protein was not successful optimizing the conditions for protein 
overexpression seemed to be the only approach to produce soluble protein which could be 
used for activity testing by HPLC.  
Several different approaches were performed to optimize the conditions for expression. Based 
on the fact that proper folding of a protein is a time depending process and that to high con-
centrations of overexpressed protein could prevent correct folding the expression temperature 
was decreased to finally RT, the expression time was extended from 4 to up to 12 hours and 
induction of expression by IPTG was decreased by more that a factor of 10. Additionally sev-
eral E.Coli strains were tested for protein expression (see Material and Methods). Among 
these the best results could be identified with the strain BL21(DE3)pLysS (Stratagene). After 
protein expression the supernatant was tested by SDS-PAGE and Western Blot analysis for 
successful protein expression in parallel to the supernatant of wildtype 3α-HSD/CR expres-
sion. Finally Optimizing the conditions for overexpression let to sufficient amounts of soluble 
protein which could be detected by Western Blot analysis (Fig. IV-17). The protein was then 
further purified by Affinity Chromatography.  
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Fig. IV-17: Overexpression of 3-HSD/CR-tr  
3-HSD/CR-tr was initially found only in inclusion bodies (left, lanes 5+6; lanes 8+9 after SDS-treatment). 
Optimized conditions for expression let to soluble 3-HSD/CR-tr which was detected by western blot analysis 
(right). 
 
 
IV.5.6 Affinity Chromatography Yields Purified Protein. 
Affinity Chromatography was performed as described in chapter III.9 , page 111. The recom-
binant 3-HSD/CR and the 3-HSD/CR-tr could be purified in one step using metal chelate 
chromatography, and the purity of the protein was greater than 98% as judged by Coomassie 
staining of SDS-polyacrylamide gels. The molecular mass of the recombinant 3-HSD/CR-tr 
as seen in the SDS gel was identical to the 23.38 kDa predicted from the genomic sequence 
(in comparison to the wt-protein with 26.4 kDa (Maser et al., 2000)).  Previous tests for en-
zymatic activity with steroids and metyrapone as substrates for 3-HSD/CR gave first hints 
for activity of the 3-HSD/CR-tr.  
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IV.5.7 HPLC-Activity Testing Detects Carbonyl Reduction Activity for Truncated 
Protein. 
After purification of the recombinant 3-HSD/CR WT and the 3-HSD/CR-tr protein derived 
from the optimized expression approach HPLC testing was performed to test the overex-
pressed truncated protein in comparison to the also overexpressed wildtype protein. For this 
approach HPLC testing was performed as described in chapter III.11 , page 115.  
Fig. IV-18 shows the results of the HPLC activity testing.  
To define the correct elution time of the used substrate p-nitrobenzaldehyde as well as of the 
product of the reaction both substances were injected into the system together with the same 
purified protein used for the complete reaction samples (Fig. IV-18). As a positive standard 
for the reaction substrate p-nitrobenzaldehyde was injected into the system and an elution 
peak at ~ 10.5 min can be detected. As a positive standard for the reaction product p-
nitrobenzalcohol was also injected into the system and can be detected at ~ 5.7 min. Different 
samples of 3α-HSD/CR wildtype protein as well as the overexpressed and purified 3α-
HSD/CR truncated protein were tested in the HPLC activity test for different incubation 
times. An overview of the tested samples can be found in Table IV-2. 
Fig. IV-18 clearly shows that for the overexpressed and purified truncated 3α-HSD/CR pro-
tein carbonyl reduction activity can be detected. In comparison to the activity of the also 
overexpressed and purified wildtype 3α-HSD/CR protein this enzymatic activity seems to be 
decreased. In further activity testing with the substrate metyrapone no enzymatic activity 
could be detected.  
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Sample Figure Label Retention 
Time 
Positive Standard for reaction substrate 
p-nitrobenzaldehyde 
 
Fig. IV-18 A Peak of pNB-aldeh. 
at ~ 10.5 min 
10.5 min 
Positive Standard for reaction product 
p-nitrobenzalcohol  
 
Fig. IV-18 C pNB-alc. 5.7 min 
Positive Standard for enzymatic reaction 
+ p-nitrobenzaldehyde  
+ incl. WT-protein 
+ incl. NADPH-regenerating 
system 
Fig. IV-18 B Peak of WT pNB-
alc, 15 min incuba-
tion 
5.65 min 
+ p-nitrobenzaldehyde  
+ incl. WT-protein 
+ incl. NADPH-regenerating 
system 
Fig. IV-18 C WT, 5’ inc. 5.65 min 
Negative Standard for enzymatic reaction 
+ p-nitrobenzaldehyde  
+ incl. WT-protein 
- excl. NADPH-regenerating 
system 
Fig. IV-18 C WT - pNBA n.a. 
Enzymatic Reaction with mutated 3α-HSD/CR 
+ p-nitrobenzaldehyde 
+ incl. truncated-protein 
+ incl. NADPH-regenerating 
system 
Fig. IV-18 C M, 5’ inc. 5.63 min 
+ p-nitrobenzaldehyde 
+ incl. truncated-protein 
+ incl. NADPH-regenerating 
system 
Fig. IV-18 C M, 15’ inc. 5.6 min 
Table IV-2: Overview on tested samples for HPLC activity testing 
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Fig. IV-18: HPLC chromatograms of  activity testing
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IV.6  How do the Simulation Data Fit to the Experimental Data? 
This study aimed for answering two different questions with respect to enzymatic characteri-
zation. First, what is the role of the crystallographic determined alpha-helical subdomain and 
its relevance for the catalytic activity of 3α-HSD/CR? And second, has the extraloop domain 
any relevance for the oligomerization behaviour of 3α-HSD/CR? Additionally, from the me-
thodically aspect this study should show if deletions and insertions as comprehensive as in 
this study can be effectively modelled and simulated prior to a molecular biology approach to 
provide an understanding if the planned mutations appears reasonable and if the observed 
effects of the truncation refer to the mutation of the protein or only to a structurally destroyed 
protein. 
The combined in silico and molecular biology approach revealed two different perspectives of 
the characteristics of 3α-HSD/CR.  
 
IV.6.1 First: Homology Modeling and MD Simulation of the Truncated Protein 
Showed, that the Protein is not Particular Instable or Seems to Adopt Untyp-
ical Conformations.  
Simulation of 3α-HSD/CR wildtype as well as the truncated protein provides a first insight 
into the behaviour and the stability of the structural architecture of the truncated protein after 
deletion of the alpha-helical subdomain (extraloop) and the insertion of a shortened loop from 
3α20β-HSD. Different single modeling and simulation steps were necessary to create compa-
rable starting structures. This included the modeling of the substrate binding loop on the basis 
of the SBL from Alcohol dehydrogenase, the modeling of the shortened loop region from 
3α20β-HSD from Streptomyces hydrogenans and the comparative simulation of the wildtype 
structure of 3α-HSD/CR with prior also modeling of the structurally unordered SBL in the 
Wildtype structure. 
All simulation approaches are based on different parameters which have to be defined prior to 
simulation and which all can have critical influence on the outcome of the simulation.  
 
The MD simulation of the truncated protein showed that the orientation of the three catalytic 
residues (Ser 114, Tyr 127, Lys 131) keeps relatively stable during the simulation and their 
mutual Cα distance in the starting model is perfectly maintained throughout the simulation 
(Fig. IV-12; Fig. IV-14).  
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The structural fluctuations within the entire protein as well as between the catalytic residues 
or the domains of the protein, which need distinct flexibility to be biological active, are not 
notably more instable or flexible than in the Wildtype protein. The all-atom rmsd on a per-
residue basis shows that apart from some rather exposed side chains the largest deviations and 
motions occur in the C-terminal area (residues 218-229) and in the substrate binding loop. 
This substrate binding loop (SBL) was expected to show higher flexibility than the rest of the 
protein as this SBL had to be modelled into the structure of 3α-HSD/CR to yield a one-chain 
protein for simulation (cf. chapter IV.4 , page 132). In addition this SBL is responsible for 
substrate binding. Crystallographic studies done by Grimm and coworkers (Grimm et al., 
2000b) also showed that this substrate binding loop becomes only structurally ordered as soon 
as the substrate was bound to the protein and covered by this loop region.  
Fig. IV-12 shows the close position of the alpha helical subdomain in 3α-HSD/CR to the resi-
dues of the catalytic triad. In Fig. IV-14 the close distance of these catalytic residues to the 
inserted loop region can be seen. Only small deviations can be found after the MD simulation 
for the inserted 3α/20β-HSD loop and the distance of between the terminal residues this loop 
region (Leu 118 and Ser 125) remains close to the starting value of of 13.8 Å. But the close 
position of the SBL, the inserted loop region and the catalytic residues Ser 114, Tyr 127, Lys 
131 leads to the assumption that somewhat larger deviations in comparison to the wildtype 
structure can be found in the experimentally determined structure of the truncated 3α-
HSD/CR.  
 
The approach of simulating the wildtype protein whose structure has already been solved 
should serve as a standard for evaluating the observed structural fluctuations in the truncated 
protein. Comparative simulation of the WT-protein even showed that the standard deviations 
of the rmsd averages (and thus the structural fluctuations) are increased by more than a factor 
of two (0.12 Å for the Cα atoms in the mutant, 0.30 Å in the wildtype). This increased flexibil-
ity in the wildtype protein leads also to distortions in the active-site, where the catalytic resi-
dues occasionally adopt alternative conformations and show on average larger mutual dis-
tances than in the starting structure (Fig. IV-12; Fig. IV-14). Therefore the structural fluctua-
tions observed during the MD simulation of the truncated protein seem to be rather small.   
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IV.6.2 Second, the Molecular Biology Approach Served as a Control for the Tenden-
cies Yielded by the in silico Approach.  
Predictions on the structural level investigated by the modeling and simulation approaches 
should be able to be confirmed by molecular biology techniques. The most relevant tendency 
from the in silico approach is, that the truncated protein, which lacks the α-helical subdomain 
(“extraloop”), seems to be structurally stable with the respect to the overall architecture of the 
protein as well as the structural orientation of the catalytic residues.  
With respect to the question on the catalytic activity of 3α-HSD/CR the obvious stability of 
the entire protein and of the catalytic triade could be demonstrated by overexpression, subse-
quent affinity chromatography and western blot analysis. These overexpression experiments 
yielded a soluble protein with a molecular mass which corresponds to a dimerized truncated 
protein. Enzymatic activity could be shown by HPLC analysis for carbonyl reduction activity.  
In comparison to the Wildtype protein, for which all steps were done in parallel, the yield of 
soluble protein was significantly reduced. Only extensive optimization experiments on protein 
expresion yielded amounts of soluble protein which could be further characterized. This de-
crease in solubility could be attributed to the fact, that the in the truncated protein a significant 
number of amino acids were exchanged or deleted in comparison to the wildtype protein. 
In HPLC analysis carbonyl reduction activity could be showed for the truncated protein with 
the substrate p-nitrobenzaldehyde. Here again, carbonyl activity was decreased significantly 
in comparison to the wildtype.  
Redesign of the extraloop-domain in the truncated 3α-HSD/CR protein seems not to destroy 
catalytic activity but leads to a significant decrease in carbonyl reduction activity.  
However, as the correct orientiation of the catalytic residues is critical for enzyme activity the 
decrease in enzyme activity is possible to be caused by small structural deviations in compari-
son to the wildtype protein. This decrease in enzyme activity can be caused by the enzymatic 
truncation of the mutant.  
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IV.6.3 Limitations of the Approach 
First tendencies were obtained by the modeling and simulation approach that the redesign of 
the α-helical subdomain in 3α-HSD/CR on the basis of the corresponding region of 3α20β-
HSD was feasible. Although this investigation is based on in silico data, a general tendency of 
the truncated protein to keep its entire architecture, especially in the biological active catalytic 
residues, can be identified. Particularly the parallel simulation of the three-dimensional struc-
ture of the Wildtype protein served as a suitable tool to assess the validity of the modeling and 
simulation.  
Additionally, the MD simulation of the refined three dimensional structure of the Wildtype 
protein showed, that the structure of a protein, which is described by its pdb-file, is always 
some kind of snapshot with areas of more and areas of less flexibility, depending on its role 
for the biological function of the entire protein. A crystal structure is more than the stable 
conformation, described by the pdb file. Only a closer look in the parameters of this refined 
crystal structure shows which regions of the protein need to be flexible for proper enzymatic 
protein function. Even the refined crystal structure of 3αHSD/CR wildtype protein showed 
regions of higher flexibility in the simulation which appears reasonable as the protein has to 
adapt its 3D architecture to use, e.g., different substances as substrates.  
Therefore the comparative simulation of the wildtype protein showed how difficult the 
evaluation of the structural flexibilities observed in the truncated protein is. 
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V Outlook 
In the present study it was shown that it’s feasible to combine an in silico and a molecular 
biology approach to optimize protein-redesign which aims for a better understanding of struc-
tural features of proteins and their teamwork to enable proper protein function. Especially 
changes to the extent performed in this study, which can be suspected to have significant im-
pact on the structural architecture of a protein, cannot be simply performed by “cut and paste” 
of complete structural domains. Although the overall protein architecture remains stable after 
the deletion of the alpha-helical subdomain and the insertion of the shortened loop from 
3α20β-HSD these data are based only on simulation strategies which cannot replace clear 
crystallographic data after redesign of 3α-HSD/CR. Simulation strategies which use the wild-
type protein for assessment of fluctuations observed during simulation are a must to get a 
feeling of regions within the protein structure which show per se structural flexibility, e.g. to 
adapt on different substrates.  
Therefore, based on the present in silico data and first in vitro characterizations of this study, 
thoroughly enzymatic characterization including complete kinetic data should yield insight 
into the catalytic effects of the redesigned protein. The question should be further investigated 
if the performed changes of the protein have an influence on the kinetic parameters or on the 
use of different substrates of the protein. 
Further enzymatic characterization on the structural level by Dynamic Light Scattering tech-
niques (DLS) together with Size Exclusion Chromatography (SEC) are planned to elucidate 
the oligomerization behaviour after redesign of the original oligomerization interface. 
As a long term goal crystal structure analysis of the mutated protein is planned to investigate, 
if the fraction of dimers in comparison to other forms of oligomerization has eventually 
changed. 
With respect to the role of 3αHSD/CR for the steroid metabolizing pathway as one of the ini-
tiating enzymes of the steroid degradation pathway enabling procaryotes to grow on the ster-
oids, to be resistance towards steroid antibiotics and non-steroid insecticides, further under-
standing of the properties of this enzyme could lead to applications within toxicology or bio-
technology. 
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VI Summary 
On the basis of 3α-HSD/CR from Comamonas testosteroni , which serves as a model system 
for bacterial steroid degradation, the relationship of structural elements, correct protein fold-
ing and proper protein function with respect to its biological function was investigated.  
On the structural level the additional extraloop domain, which is unique in the class of 
dimeric SDR enzymes, was identified as a putative sterical inhibitor of oligomerization via 
the Q-axis interface as the typical oligomerization interface of dimeric SDR enzymes.  Struc-
tural alignments with dimeric and tetrameric members of the SDR superfamily identified the 
α-helical subdomain, called extraloop, as a structural element responsible for deviating oli-
gomerization behaviour.  To investigate the question, which role the additional extraloop do-
main plays in 3α-HSD/CR from C. testosteroni and if this structural feature has a fundamental 
role for protein stability and/or functionality in 3α-HSD/CR a mutated 3α-HSD/CR-protein 
(3α-HSD/CR-tr) had to be established which lacks the extraloop domain. An approach com-
bining “in silico” and “wet chemistry” was performed to redesign a complete loop region in 
3α-HSD/CR by substitution of the extraloop domain by a shortened homologous loop of 
3α/20β-HSD on the basis of two crystallographically determined structures.   
To yield a one-chain protein as basis for Molecular Dynamic simulation the structurally unor-
dered Substrate Binding Loop (SBL) of 3α-HSD/CR was first successfully modelled on the 
basis of the structurally determined SBL of Alcohol Dehydrogenase (ADH) of Drosophila 
Lebadonensis. A second modelling step lead to a pdb-structure of a mutated 3α-HSD/CR pro-
tein in which at the end 36 amino acids of the alpha-helical extraloop-domain were substituted 
by an 8-residue loop of the homologous region of 3α/20β-HSD of S. hydrogenans.  
Molecular Dynamic (MD) Simulation were performed of both, the untruncated wildtype pro-
tein including the re-modelled SBL as well as the truncated protein including the re-modelled 
SBL together with the shortened 8-residue loop from 3α/20β-HSD.  
Analysis of the root-mean-square deviation (rmsd) of the Cα atoms indicated that the overall 
fold of 3α-HSD/CR-tr is well maintained.  
Analysis on a per-residue basis showed that the largest deviations and motions occur in the C-
terminal area and in the substrate binding loop. Especially the latter is not unexpected given 
the experimentally known flexibility of this loop. The inserted 3α/20β-HSD loop shows 
somewhat smaller deviations and less pronounced mobility compared to the substrate binding 
loop. The distance between the terminal residues of the extraloop remains close to the starting 
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value. As a consequence, no significant changes are also observed with respect to the orienta-
tion of the three catalytic residues.  
The comparative simulation of the 3α-HSD/CR wildtype with the modelled substrate binding 
loop reveals a higher overall flexibility for the wildtype than for the mutant. This increased 
flexibility leads also to distortions in the active-site, where the catalytic residues occasionally 
adopt alternative conformations and show on average larger mutual distances than in the start-
ing structure. Simulation of 3α-HSD/CR wildtype as a monomer (in analogy to the mutant) 
and therefore the lack of the dimer interface can be seen as the main reason for their increased 
flexibility. In contrast, the mutant monomer shows less pronounced flexibility. Apparently, in 
the absence of the stabilizing dimer contact the short 3α/20β-HSD loop of the mutant confers 
higher stability to the protein than the much longer extraloop of the wildtype. Based on these 
analyses, the model appears reasonable and suggests that the 3α-HSD/CR-tr construct should 
also be catalytically active. 
The amino acid sequence successfully modelled and simulated in the in silico approach was 
transferred in the molecular biology approach to an active and soluble protein. Overlap exten-
sion PCR yielded the correct DNA sequence coding for the truncated 3α-HSD/CR-tr protein. 
Standard overexpression conditions resulted in high amounts of recombinant protein which 
could be located in inclusion bodies by ELIZA techniques. A broad assay testing well-
established conditions for refolding of denatured proteins didn’t result in renatured recombi-
nant protein. Optimization of conditions for overexpression enabled expression of soluble and 
native truncated 3α-HSD/CR-tr protein which could be detected and clearly identified in 
Western Blot analysis and purified by Affinity Chromatography. Further HPLC characteriza-
tion showed clearly carbonyl reducing activity for truncated 3α-HSD/CR-tr protein which in 
comparison to wildtype protein was significantly reduced.  
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VII Zusammenfassung 
Auf Basis von 3α-HSD/CR von Comamonas testosteroni , das als Modelsystem für den bak-
teriellen Steroidabbau dient, wurde der Zusammenhang von Strukturelementen, korrekter Pro-
teinfaltung und Proteinfunktion bezüglich ihrer biologischen Funktion untersucht. 
Auf struktureller Ebene wurde die zusätzliche Extraloop-Domäne, die einzigartig in der Klas-
se der dimeren SDR Enzyme ist, als als vermeintlicher sterischer Inhibitor einer Oligomerisie-
rung entlang der sonst in dimeren SDRs üblichen Q-Achse identifiziert. Strukturbasierte 
alignments zwischen dimeren und tetrameren Enzymen der SDR Protein-Superfamilie identi-
fizierten die alpha-helikale Untereinheit (extraloop) als das Strukturelement, das für das von 
anderen vergleichbaren SDR Enzymen abweichende Oligomerisierungsverhalten verantwort-
lich zu sein scheint. Um der Frage nachzugehen welche Rolle die zusätzliche extraloop-
Domäne in 3α-HSD/CR spielt und ob dieses Strukturelement eine fundamentale Bedeutung 
für die Proteinstabilität und Funktionalität für das Protein besitzt, wurde ein mutiertes 3α-
HSD/CR-tr Protein generiert, dem diese zusätzliche Untereinheit fehlt. Es wurde ein kombi-
nierter Ansatz aus computerbasierter Modellierung und Simulation sowie molekularbiologi-
schen Methoden verfolgt, der die vollständige extraloop-Region in 3α-HSD/CR durch den 
verkürzten homologen Strukturbereich aus 3α/20β-HSD auf Basis zweier kristallographischer 
Strukturen substituiert.  
Der strukturell ungeordnete Bereich des Substrate Binding Loops (SBL) wurde zuerst erfolg-
reich auf der Basis des strukturell geordneten SBL aus Alkohol Dehydrogenase (ADH) von 
Drosophila Lebadonensis modelliert um eine einkettige Proteinstruktur als Basis für die Mo-
lecular Dynamic (MD) Simulationen zu erhalten. Für die Modellierung der Mutante wurden 
in einem zweiten Modellierungsschritt am Ende 36 Aminosäuren der alpha-helikalen Unter-
einheit (extraloop) durch eine 8 Aminosäuren lange homologe loop-Region der 3α/20β-HSD 
aus S. hydrogenans ersetzt.  
Die Analyse der „root-mean-square deviation” (rmsd) (Wurzel der mittleren quadratischen 
Abweichung) der C-Atome zeigte, dass die Gesamtfaltung der Mutante 3α-HSD/CR-tr wei-
testgehend erhalten bleibt. Die Analyse der rmsd auf Basis der Aminosäure-Reste zeigte, dass 
die größten Abweichungen im Bereich des C-terminalen Endes der Aminosäurekette und im 
Bereich des SBL zu finden sind. Vor allem das Letztere ist zu erwarten, spiegelt dies doch die 
experimentell bekannte und für die biologische Funktion erforderliche Flexibilität dieser Re-
gion wider. Der eingesetzte Loop der 3α/20β-HSD zeigt geringere Abweichungen und eine 
weniger stark ausgeprägte Flexibilät im Vergleich zum SBL. Die Distanz zwischen den ter-
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minalen Resten des eingesetzten Extraloops bleibt im Rahmen der Startwerte.  Daher werden 
ebenfalls keine signifikanten Änderungen in Bezug auf die Orientierung  der biologisch wich-
tigen katalytischen Aminosäuren beobachtet.  
Vergleichssimulation des 3α-HSD/CR Wildtyp-Proteins, das den nachmodellierten SBL trägt, 
zeigte eine höhere Gesamtflexibilität als die Mutante. Diese Flexibilität führte in der Simula-
tion u.a. zu Verzerrungen im Bereich der katalytischen Triarde,  in dem die katalytischen 
Aminosäuren in der Simulation gelegentlich alternative Konformationen einnehmen und im 
Mittel größere gegenseitige Distanzen auftreten als in der Startstruktur vor der Simulation. 
Als Grund für die erhöhte Flexibilität kann die Simulation des 3α-HSD/CR-Wildtyp Proteins 
als Monomer (in Analogie zur Simulation der Mutante) sowie daraus folgernd das Fehlen der 
Dimer-Schnittstelle angesehen werden. Anscheinend ermöglicht der eingesetzte verkürzte 
Loop der 3α/20β-HSD bei einem Fehlen der stabilisierenden Dimer-Schnittstelle eine höhere 
Proteinstabilität als dies der viel längere Extraloop des Wildtyp Proteins tut. Basierend auf 
diesen Analysen erscheint das Modell schlüssig zu sein und lässt erwarten, dass das moleku-
larbiologisch umgesetzte Modell katalytisch aktiv ist. 
Die erfolgreich im computerbasierten Ansatz modellierte und simulierte Aminosäuresequenz 
wurde in den molekularbiologischen Ansatz transferiert und darin in ein lösliches und biolo-
gisch aktives Protein umgesetzt. „Overlap extension PCR“ ermöglichte den Nachbau der 
DNA-Sequenz, die für das mutierte 3α-HSD/CR-tr Protein kodiert. Standardbedingungen für 
Protein-Überexpression ermöglichten zwar die Produktion großer Mengen rekombinanten 
Proteins, das allerdings unlöslich in „inclusion bodies“ durch ELIZA-Techniken lokalisiert 
werden konnte. Ein breit angelegter Ansatz zur Renaturierung des unlöslichen Proteines durch 
etablierte Rückfaltungsbedingungen führte ebenfalls nicht zu löslichem Protein. Erst optimier-
te Bedingungen für die Proteinexpression selber  resultierten in löslichem und nativem re-
kombinantem mutiertem 3α-HSD/CR-tr Protein. Dies konnte anschließend durch Western 
Blot Techniken nachgewiesen sowie durch Affinitätschromatographie aufgereinigt werden. 
HPLC Charakterisierung zeigten eindeutig, dass das mutierte 3α-HSD/CR-tr Protein eine, 
wenn auch im Vergleich zum Wildtyp-Protein reduzierte, Carbonylreduktion-Aktivität be-
sitzt. 
References 161 
VIII References 
Abalain JH, Di Stefano S, Abalain-Colloc ML and Floch HH (1995)  
Cloning, sequencing and expression of Pseudomonas testosteroni gene encoding 3 alpha-
hydroxysteroid dehydrogenase.  
J Steroid Biochem Mol Biol 55:233-238. 
Adams JD, LaVoie EJ and Hoffmann D (1985a)  
On the pharmacokinetics of tobacco-specific N-nitrosamines in Fischer rats.  
Carcinogenesis 6:509-511. 
Adams JD, Lavoie EJ, O'Mara-Adams KJ, Hoffmann D, Carey KD and Marshall MV (1985b)  
Pharmacokinetics of N'-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone in laboratory animals.  
Cancer Lett 28:195-201. 
Adams MD Celniker SE Holt RA Evans CA Gocayne JD Amanatides PG Scherer SE Li PW 
Hoskins RA Galle RF George RA Lewis SE Richards S Ashburner M Henderson SN Sutton 
GG Wortman JR Yandell MD Zhang Q Chen LX Brandon RC Rogers YH Blazej RG 
Champe M Pfeiffer BD Wan KH Doyle C Baxter EG Helt G Nelson CR Gabor GL Abril JF 
Agbayani A An HJ Andrews-Pfannkoch C Baldwin D Ballew RM Basu A Baxendale J Bay-
raktaroglu L Beasley EM Beeson KY Benos PV Berman BP Bhandari D Bolshakov S Bork-
ova D Botchan MR Bouck J Brokstein P Brottier P Burtis KC Busam DA Butler H Cadieu E 
Center A Chandra I Cherry JM Cawley S Dahlke C Davenport LB Davies P de Pablos B Del-
cher A Deng Z Mays AD Dew I Dietz SM Dodson K Doup LE Downes M Dugan-Rocha S 
Dunkov BC Dunn P Durbin KJ Evangelista CC Ferraz C Ferriera S Fleischmann W Fosler C 
Gabrielian AE Garg NS Gelbart WM Glasser K Glodek A Gong F Gorrell JH Gu Z Guan P 
Harris M Harris NL Harvey D Heiman TJ Hernandez JR Houck J Hostin D Houston KA 
Howland TJ Wei MH Ibegwam C Jalali M Kalush F Karpen GH Ke Z Kennison JA Ketchum 
KA Kimmel BE Kodira CD Kraft C Kravitz S Kulp D Lai Z Lasko P Lei Y Levitsky AA Li J 
Li Z Liang Y Lin X Liu X Mattei B McIntosh TC McLeod MP McPherson D Merkulov G 
Milshina NV Mobarry C Morris J Moshrefi A Mount SM Moy M Murphy B Murphy L 
Muzny DM Nelson DL Nelson DR Nelson KA Nixon K Nusskern DR Pacleb JM Palazzolo 
M Pittman GS Pan S Pollard J Puri V Reese MG Reinert K Remington K Saunders RD 
References 162 
Scheeler F Shen H Shue BC Siden-Kiamos I Simpson M Skupski MP Smith T Spier E Sprad-
ling AC Stapleton M Strong R Sun E Svirskas R Tector C Turner R Venter E Wang AH 
Wang X Wang ZY Wassarman DA Weinstock GM Weissenbach J Williams SM WoodageT 
Worley KC Wu D Yang S Yao QA Ye J Yeh RF Zaveri JS Zhan M Zhang G Zhao Q Zheng 
L Zheng XH Zhong FN Zhong W Zhou X Zhu S Zhu X Smith HO Gibbs RA Myers EW 
Rubin GM and Venter JC (2000)  
The genome sequence of Drosophila melanogaster.  
Science 287:2185-2195. 
Agarwal AK, Tusie-Luna MT, Monder C and White PC (1990)  
Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus.  
Mol Endocrinol 4:1827-1832. 
Ahmed NK, Felsted RL and Bachur NR (1978)  
Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers.  
Biochem Pharmacol 27:2713-2719. 
Ahmed NK, Felsted RL and Bachur NR (1979)  
Comparison and characterization of mammalian xenobiotic ketone reductases.  
J Pharmacol Exp Ther 209:12-19. 
Ahmed NK, Felsted RL and Bachur NR (1981)  
Daunorubicin reduction mediated by aldehyde and ketone reductases.  
Xenobiotica 11:131-136. 
Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J and Sidransky D (2000)  
Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-
small cell lung cancer.  
Cancer Res 60:3155-3159. 
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, 
Ohman B and Abrahmsen L (2002)  
Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose 
concentrations in hyperglycaemic mice.  
References 163 
Diabetologia 45:1528-1532. 
Anfinsen CB (1973)  
Principles that govern the folding of protein chains.  
Science 181:223-230. 
Aoki H, Okada T, Mizutani T, Numata Y, Minegishi T and Miyamoto K (1997)  
Identification of two closely related genes, inducible and noninducible carbonyl reductases in 
the rat ovary.  
Biochem Biophys Res Commun 230:518-523. 
Apweiler R, Attwood TK, Bairoch A, Bateman A, Birney E, Biswas M, Bucher P, Cerutti L, 
Corpet F, Croning MD, Durbin R, Falquet L, Fleischmann W, Gouzy J, Hermjakob H, Hulo 
N, Jonassen I, Kahn D, Kanapin A, Karavidopoulou Y, Lopez R, Marx B, Mulder NJ, Oinn 
TM, Pagni M, Servant F, Sigrist CJ and Zdobnov EM (2000)  
InterPro--an integrated documentation resource for protein families, domains and functional 
sites.  
Bioinformatics 16:1145-1150. 
Arda B, Aydemir S, Yamazhan T, Hassan A, Tunger A and Serter D (2003)  
Comamonas testosteroni meningitis in a patient with recurrent cholesteatoma.  
Apmis 111:474-476. 
Atalla A, Breyer-Pfaff U and Maser E (2000)  
Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the to-
bacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human 
liver cytosol.  
Xenobiotica 30:755-769. 
Atalla A and Maser E (1999)  
Carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) in cytosol of mouse liver and lung.  
Toxicology 139:155-166. 
Auerbach G, Herrmann A, Gutlich M, Fischer M, Jacob U, Bacher A and Huber R (1997)  
References 164 
The 1.25 A crystal structure of sepiapterin reductase reveals its binding mode to pterins and 
brain neurotransmitters.  
Embo J 16:7219-7230. 
Aukrust LE, Norum KR and Skalhegg BA (1976)  
Affinity chromatography of 3 alpha-hydroxysteroid dehydrogenase from Pseudomonas testos-
teroni. Use of N,N-dimethylformamide to prevent hydrophobic interactions between the en-
zyme and the ligand.  
Biochim Biophys Acta 438:13-22. 
Ausubel FM, Bren R, Kingston RE, Moore DD, Seidmann JG, Smith JA and Struhl K (1993)  
Current protocols in molecular biology.  
John Wiley & Sons, New York. 
Ax W, Soldan M, Koch L and Maser E (2000)  
Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.  
Biochem Pharmacol 59:293-300. 
Bachur NR (1976)  
Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes.  
Science 193:595-597. 
Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S 
and DuBois RN (2005)  
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.  
J Biol Chem 280:3217-3223. 
Bairoch A and Apweiler R (2000)  
The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000.  
Nucleic Acids Res 28:45-48. 
Baker D and Agard DA (1994)  
Kinetics versus thermodynamics in protein folding.  
Biochemistry 33:7505-7509. 
References 165 
Bates PA, Kelley LA, MacCallum RM and Sternberg MJ (2001)  
Enhancement of protein modeling by human intervention in applying the automatic programs 
3D-JIGSAW and 3D-PSSM.  
Proteins Suppl 5:39-46. 
Belai I, Darvas B, Bauer K and Tag El-Din MH (1995)  
Effects of anti-ecdysteroid azaloe analogues of metyrapone on the larval development of the 
fleshfly, Neobellieria bullata.  
Pestic. Sci. 44:225-232. 
Benach J, Atrian S, Gonzalez-Duarte R and Ladenstein R (1998)  
The refined crystal structure of Drosophila lebanonensis alcohol dehydrogenase at 1.9 A reso-
lution.  
J Mol Biol 282:383-399. 
Benach J, Atrian S, Gonzalez-Duarte R and Ladenstein R (1999)  
The catalytic reaction and inhibition mechanism of Drosophila alcohol dehydrogenase: obser-
vation of an enzyme-bound NAD-ketone adduct at 1.4 A resolution by X-ray crystallography.  
J Mol Biol 289:335-355. 
Beran M, Andersson B, Eksborg S and Ehrsson H (1979)  
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells 
(CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.  
Cancer Chemother Pharmacol 2:19-24. 
Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A and Haak JR (1984)  
Molecular dynamics with coupling to an external bath.  
J.Chem.Phys. 81:3684-3690. 
Birnboim HC and Doly J (1979)  
A rapid alkaline extraction procedure for screening recombinant plasmid DNA.  
Nucleic Acids Res 7:1513-1523. 
Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW and Slone AL (1992)  
References 166 
Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and 
MDL 74156 in NG108-15 neuroblastoma x glioma cells.  
Eur J Pharmacol 219:9-13. 
Bohren KM, Bullock B, Wermuth B and Gabbay KH (1989)  
The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human 
aldehyde and aldose reductases.  
J Biol Chem 264:9547-9551. 
Bohren KM, von Wartburg JP and Wermuth B (1987)  
Kinetics of carbonyl reductase from human brain.  
Biochem J 244:165-171. 
Bohren KM, Wermuth B, Harrison D, Ringe D, Petsko GA and Gabbay KH (1994)  
Expression, crystallization and preliminary crystallographic analysis of human carbonyl re-
ductase.  
J Mol Biol 244:659-664. 
Botella JA, Ulschmid JK, Gruenewald C, Moehle C, Kretzschmar D, Becker K and Schneuw-
ly S (2004)  
The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegenera-
tion.  
Curr Biol 14:782-786. 
Bradford MM (1976)  
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing 
the principle of protein-dye binding.  
Anal Biochem 72:248-254. 
Breyer-Pfaff U, Martin HJ, Ernst M and Maser E (2004)  
Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by 
tissue fractions from human and rat and by enzymes isolated from human liver.  
Drug Metab Dispos 32:915-922. 
Breyer-Pfaff U and Nill K (1999)  
References 167 
Stereoselective high-affinity reduction of ketonic nortriptyline metabolites and of ketotifen by 
aldo-keto reductases from human liver.  
Adv Exp Med Biol 463:473-480. 
Breyer-Pfaff U and Nill K (2000)  
High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortrip-
tyline metabolites by aldo-keto reductases from human liver.  
Biochem Pharmacol 59:249-260. 
Breyer-Pfaff U and Nill K (2004)  
Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human 
liver cytosol.  
J Pharm Pharmacol 56:1601-1606. 
Browne WJ, North AC, Phillips DC, Brew K, Vanaman TC and Hill RL (1969)  
A possible three-dimensional structure of bovine alpha-lactalbumin based on that of hen's 
egg-white lysozyme.  
J Mol Biol 42:65-86. 
Brunmark A, Cadenas E, Segura-Aguilar J, Lind C and Ernster L (1988)  
DT-diaphorase-catalyzed two-electron reduction of various p-benzoquinone- and 1,4-
naphthoquinone epoxides.  
Free Radic Biol Med 5:133-143. 
Buffinton GD, Ollinger K, Brunmark A and Cadenas E (1989)  
DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-
quinone conjugates. Effect of substituents on autoxidation rates.  
Biochem J 257:561-571. 
Cagen LM, Zusman RM and Pisano JJ (1979)  
Formation of 1a, 1b dihomoprostaglandin E2 by rabbit renal intersititial cell cultures.  
Prostaglandins 18:617-621. 
Caldwell J (1989)  
The biochemical pharmacology of fenofibrate.  
References 168 
Cardiology 76 Suppl 1:33-41; discussion 41-34. 
Carmella SG, Akerkar SA, Richie JP, Jr. and Hecht SS (1995)  
Intraindividual and interindividual differences in metabolites of the tobacco-specific lung car-
cinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine.  
Cancer Epidemiol Biomarkers Prev 4:635-642. 
Carmella SG, Borukhova A, Akerkar SA and Hecht SS (1997)  
Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone, a tobacco-specific lung carcinogen.  
Cancer Epidemiol Biomarkers Prev 6:113-120. 
Case DA, Pearlman DA, Caldwell JW, Cheatham III TE, Ross WS, Simmerling CL, Darden 
TA, Merz KM, Stanton RV and Cheng ALea (1999)  
Amber 6. University of California, San Francisco. 
Chang DG and Tai HH (1981)  
Prostaglandin 9-ketoreductase/type II 15-hydroxyprostaglandin dehydrogenase is not a pros-
taglandin specific enzyme.  
Biochem Biophys Res Commun 101:898-904. 
Claessens M, Van Cutsem E, Lasters I and Wodak S (1989)  
Modeling the polypeptide backbone with 'spare parts' from known protein structures.  
Protein Eng 2:335-345. 
Coenye T, Goris J, Spilker T, Vandamme P and LiPuma JJ (2002)  
Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis pa-
tients and description of Inquilinus limosus gen. nov., sp. nov.  
J Clin Microbiol 40:2062-2069. 
Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz Jr KM, Ferguson DM, Spellmayer DC, 
Fox T, Caldwell JW and Kollman PA (1995)  
A second generation force field for the simulation of protein, nucleid acids, and organic mole-
cules.  
J Am Chem Soc 117:5179 - 5197. 
References 169 
Cromlish JA, Yoshimoto CK and Flynn TG (1985)  
Purification and characterization of four NADPH-dependent aldehyde reductases from pig 
brain.  
J Neurochem 44:1477-1484. 
Crouse J and Amorese D (1987)  
Ethanol precipitation: ammonium acetate as an alternative to sodium acetate.  
Focus 9-2:3-5. 
Darden T, York D and Pedersen L (1993)  
Particle mesh Ewald -An N.log(N) method for Ewald sums in large systems.  
J Chem Phys 98:10089 - 10092. 
Darvas B, Belai I, Fonagy A, Kulcsar P and Tag El-Din MH (1991)  
Lethal disturbances in larval development of Neobellieria bullata caused by metyrapone deri-
vates.  
Pestic. Sci. 32:133-139. 
Dawson TM and Dawson VL (2003)  
Molecular pathways of neurodegeneration in Parkinson's disease.  
Science 302:819-822. 
Dayton HE and Inturrisi CE (1976)  
The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.  
Drug Metab Dispos 4:474-478. 
Dessypris EN, Brenner DE and Hande KR (1986)  
Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in 
vitro.  
Cancer Treat Rep 70:487-490. 
Dinner AR, Sali A and Karplus M (1996)  
The folding mechanism of larger model proteins: role of native structure.  
Proc Natl Acad Sci U S A 93:8356-8361. 
References 170 
Doorn JA, Maser E, Blum A, Claffey DJ and Petersen DR (2004)  
Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal.  
Biochemistry 43:13106-13114. 
Duax WL, Ghosh D and Pletnev V (2000)  
Steroid dehydrogenase structures, mechanism of action, and disease.  
Vitam Horm 58:121-148. 
Duplomb L, Lee Y, Wang MY, Park BH, Takaishi K, Agarwal AK and Unger RH (2004)  
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with tro-
glitazone.  
Biochem Biophys Res Commun 313:594-599. 
Ellis EM (2002)  
Microbial aldo-keto reductases.  
FEMS Microbiol Lett 216:123-131. 
Ellis EM and Hayes JD (1995)  
Substrate specificity of an aflatoxin-metabolizing aldehyde reductase.  
Biochem J 312 ( Pt 2):535-541. 
Ensor CM and Tai HH (1991)  
Site-directed mutagenesis of the conserved tyrosine 151 of human placental NAD(+)-
dependent 15-hydroxyprostaglandin dehydrogenase yields a catalytically inactive enzyme.  
Biochem Biophys Res Commun 176:840-845. 
Espey LL, Yoshioka S, Russell D, Ujioka T, Vladu B, Skelsey M, Fujii S, Okamura H and 
Richards JS (2000)  
Characterization of ovarian carbonyl reductase gene expression during ovulation in the go-
nadotropin-primed immature Rat.  
Biol Reprod 62:390-397. 
Esterbauer H, Cheeseman KH, Dianzani MU, Poli G and Slater TF (1982)  
Separation and characterization of the aldehydic products of lipid peroxidation stimulated by 
ADP-Fe2+ in rat liver microsomes.  
References 171 
Biochem J 208:129-140. 
Faber K (1998)  
Biotransformations in organic chemistry.  
in: 2nd Edition. Springer-verlag. Berlin. ( 
Felsted RL and Bachur NR (1980)  
Mammalian carbonyl reductases.  
Drug Metab Rev 11:1-60. 
Felsted RL and Bachur NR (1982)  
Human liver daunorubicin reductases.  
Prog Clin Biol Res 114:291-305. 
Fischer SM, Klein-Szanto AJ, Adams LM and Slaga TJ (1985)  
The first stage and complete promoting activity of retinoic acid but not the analog RO-10-
9359.  
Carcinogenesis 6:575-578. 
Floch HH, Abalain JH, Di Stefano S, Carre JL and Abalain-Colloc ML (1995)  
[Cloning of genes coding for 3-alpha-hydroxysteroid dehydrogenase and for (3-17)-beta-
hydroxysteroid dehydrogenase from Pseudomonas testosteroni].  
C R Seances Soc Biol Fil 189:705-712. 
Flynn TG and Green NC (1993)  
The aldo-keto reductases: an overview.  
Adv Exp Med Biol 328:251-257. 
Ford G and Ellis EM (2001)  
Three aldo-keto reductases of the yeast Saccharomyces cerevisiae.  
Chem Biol Interact 130-132:685-698. 
Ford G and Ellis EM (2002)  
Characterization of Ypr1p from Saccharomyces cerevisiae as a 2-methylbutyraldehyde reduc-
tase.  
References 172 
Yeast 19:1087-1096. 
Forrest GL, Akman S, Krutzik S, Paxton RJ, Sparkes RS, Doroshow J, Felsted RL, Glover 
CJ, Mohandas T and Bachur NR (1990)  
Induction of a human carbonyl reductase gene located on chromosome 21.  
Biochim Biophys Acta 1048:149-155. 
Forrest GL and Gonzalez B (2000)  
Carbonyl reductase.  
Chem Biol Interact 129:21-40. 
Fujii J, Iuchi Y and Okada F (2005)  
Fundamental roles of reactive oxygen species and protective mechanisms in the female repro-
ductive system.  
Reprod Biol Endocrinol 3:43. 
Gersl V, Mazurova Y, Bajgar J, Melka M, Hrdina R and Palicka V (1996)  
Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochino-
line: comparison with daunorubicin in rabbits.  
Arch Toxicol 70:645-651. 
Gessner T, Vaughan LA, Beehler BC, Bartels CJ and Baker RM (1990)  
Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells.  
Cancer Res 50:3921-3927. 
Ghosh D, Erman M, Pangborn W, Duax WL and Baker ME (1992)  
Inhibition of Streptomyces hydrogenans 3 alpha,20 beta-hydroxysteroid dehydrogenase by 
licorice-derived compounds and crystallization of an enzyme-cofactor-inhibitor complex.  
J Steroid Biochem Mol Biol 42:849-853. 
Ghosh D, Erman M, Pangborn W, Duax WL, Nakajin S, Ohno S and Shinoda M (1993)  
Crystallization and preliminary X-ray diffraction studies of a mammalian steroid dehydro-
genase.  
J Steroid Biochem Mol Biol 46:103-104. 
References 173 
Ghosh D, Erman M, Wawrzak Z, Duax WL and Pangborn W (1994a)  
Mechanism of inhibition of 3 alpha, 20 beta-hydroxysteroid dehydrogenase by a licorice-
derived steroidal inhibitor.  
Structure 2:973-980. 
Ghosh D, Pletnev VZ, Zhu DW, Wawrzak Z, Duax WL, Pangborn W, Labrie F and Lin SX 
(1995)  
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution.  
Structure 3:503-513. 
Ghosh D, Sawicki M, Pletnev V, Erman M, Ohno S, Nakajin S and Duax WL (2001)  
Porcine carbonyl reductase. structural basis for a functional monomer in short chain dehydro-
genases/reductases.  
J Biol Chem 276:18457-18463. 
Ghosh D, Wawrzak Z, Weeks CM, Duax WL and Erman M (1994b)  
The refined three-dimensional structure of 3 alpha,20 beta-hydroxysteroid dehydrogenase and 
possible roles of the residues conserved in short-chain dehydrogenases.  
Structure 2:629-640. 
Ghosh D, Weeks CM, Grochulski P, Duax WL, Erman M, Rimsay RL and Orr JC (1991)  
Three-dimensional structure of holo 3 alpha,20 beta-hydroxysteroid dehydrogenase: a mem-
ber of a short-chain dehydrogenase family.  
Proc Natl Acad Sci U S A 88:10064-10068. 
Gonzalez B, Sapra A, Rivera H, Kaplan WD, Yam B and Forrest GL (1995)  
Cloning and expression of the cDNA encoding rabbit liver carbonyl reductase.  
Gene 154:297-298. 
Grimm C, Maser E, Mobus E, Klebe G, Reuter K and Ficner R (2000a)  
The crystal structure of 3alpha -hydroxysteroid dehydrogenase/carbonyl reductase from Co-
mamonas testosteroni shows a novel oligomerization pattern within the short chain dehydro-
genase/reductase family.  
J Biol Chem 275:41333-41339. 
References 174 
Grimm C, Maser E, Möbus E, Klebe G, Reuter K and Ficner R (2000b)  
The crystal structure of 3alpha -hydroxysteroid dehydrogenase/carbonyl reductase from Co-
mamonas testosteroni shows a novel oligomerization pattern within the short chain dehydro-
genase/reductase family.  
J Biol Chem 275:41333-41339. 
Guan G, Tanaka M, Todo T, Young G, Yoshikuni M and Nagahama Y (1999)  
Cloning and expression of two carbonyl reductase-like 20beta-hydroxysteroid dehydrogenase 
cDNAs in ovarian follicles of rainbow trout (Oncorhynchus mykiss).  
Biochem Biophys Res Commun 255:123-128. 
Guda C, Lu S, Scheeff ED, Bourne PE and Shindyalov IN (2004)  
CE-MC: a multiple protein structure alignment server.  
Nucleic Acids Res 32:W100-103. 
Guda C, Pal LR and Shindyalov IN (2006)  
DMAPS: a database of multiple alignments for protein structures.  
Nucleic Acids Res 34:D273-276. 
Guda C, Scheeff ED, Bourne PE and Shindyalov IN (2001)  
A new algorithm for the alignment of multiple protein structures using Monte Carlo optimiza-
tion.  
Pac Symp Biocomput:275-286. 
Gunsteren v, WF and Berendsen H (1990)  
Computer simulation of molecular dynamics: methodology, applications, and perspectives in 
chemistry.  
Angew Chem Int. Ed. Engl 29:992-1023. 
Gupta P, Hall CK and Voegler AC (1998)  
Effect of denaturant and protein concentrations upon protein refolding and aggregation: a 
simple lattice model.  
Protein Sci 7:2642-2652. 
Habrych M, Rodriguez S and Stewart JD (2002)  
References 175 
Purification and identification of an Escherichia coli beta-keto ester reductase as 2,5-diketo-
D-gluconate reductase YqhE.  
Biotechnol Prog 18:257-261. 
Hara A, Hasebe K, Hayashibara M, Matsuura K, Nakayama T and Sawada H (1986a)  
Dihydrodiol dehydrogenases in guinea pig liver.  
Biochem Pharmacol 35:4005-4012. 
Hara A, Nakayama T, Deyashiki Y, Kariya K and Sawada H (1986b)  
Carbonyl reductase of dog liver: purification, properties, and kinetic mechanism.  
Arch Biochem Biophys 244:238-247. 
Hara A, Oritani H, Deyashiki Y, Nakayama T and Sawada H (1992)  
Activation of carbonyl reductase from pig lung by fatty acids.  
Arch Biochem Biophys 292:548-554. 
Hara A, Usui S, Hayashibara M, Horiuchi T, Nakayama T and Sawada H (1987)  
Microsomal carbonyl reductase in rat liver. Sex difference, hormonal regulation, and charac-
terization.  
Prog Clin Biol Res 232:401-414. 
Hara A, Yamamoto H, Deyashiki Y, Nakayama T, Oritani H and Sawada H (1991)  
Aldehyde dismutation catalyzed by pulmonary carbonyl reductase: kinetic studies of chloral 
hydrate metabolism to trichloroacetic acid and trichloroethanol.  
Biochim Biophys Acta 1075:61-67. 
Hartl FU, Pfanner N, Nicholson DW and Neupert W (1989)  
Mitochondrial protein import.  
Biochim Biophys Acta 988:1-45. 
Havel TF and Snow ME (1991)  
A new method for building protein conformations from sequence alignments with homo-
logues of known structure.  
J Mol Biol 217:1-7. 
References 176 
Hayashi H, Fujii Y, Watanabe K, Urade Y and Hayaishi O (1989)  
Enzymatic conversion of prostaglandin H2 to prostaglandin F2 alpha by aldehyde reductase 
from human liver.  
Prog Clin Biol Res 290:365-379. 
Hecht SS (1994)  
Metabolic activation and detoxification of tobacco-specific nitrosamines--a model for cancer 
prevention strategies.  
Drug Metab Rev 26:373-390. 
Hecht SS (1996)  
Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen.  
Crit Rev Toxicol 26:163-181. 
Hecht SS (1998)  
Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines.  
Chem Res Toxicol 11:559-603. 
Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD and Hoffmann D (1993)  
A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke.  
N Engl J Med 329:1543-1546. 
Heredia VV, Cooper WC, Kruger RG, Jin Y and Penning TM (2004)  
Alanine scanning mutagenesis of the testosterone binding site of rat 3 alpha-hydroxysteroid 
dehydrogenase demonstrates contact residues influence the rate-determining step.  
Biochemistry 43:5832-5841. 
Higuchi T, Imamura Y and Otagiri M (1993)  
Kinetic studies on the reduction of acetohexamide catalyzed by carbonyl reductase from rab-
bit kidney.  
Biochim Biophys Acta 1158:23-28. 
Hoffmann D, Lavoie EJ and Hecht SS (1985)  
Nicotine: a precursor for carcinogens.  
References 177 
Cancer Lett 26:67-75. 
Hoffmann F, Sotriffer C, Evers A, Xiong G and Maser E (2006)  
Understanding oligomerization in 3 -hydroxysteroid dehydro-genase /carbonyl reductase from 
Comamonas testosteroni: an in silico approach and evidence for an active protein.  
J. Biotechnol. 129:131-139. 
Hoffmann F, Xiong G, Sotriffer C, Reuter K and Maser E (2003)  
Structural aspects of oligomerization in 3alpha-hydroxysteroid dehydrogenase from Coma-
monas testosteroni: Redesign of an "extraloop"-domain on the basis of 3alpha/20beta-HSD.  
Medimond, Bologna. 
Hyndman D, Bauman DR, Heredia VV and Penning TM (2003)  
The aldo-keto reductase superfamily homepage.  
Chem Biol Interact 143-144:621-631. 
Iino T, Tabata M, Takikawa S, Sawada H, Shintaku H, Ishikura S and Hara A (2003)  
Tetrahydrobiopterin is synthesized from 6-pyruvoyl-tetrahydropterin by the human aldo-keto 
reductase AKR1 family members.  
Arch Biochem Biophys 416:180-187. 
Iino T, Takikawa SI, Yamamoto T and Sawada H (2000)  
The enzyme that synthesizes tetrahydrobiopterin from 6-pyruvoyl-tetrahydropterin in the 
lemon mutant silkworm consists of two carbonyl reductases.  
Arch Biochem Biophys 373:442-446. 
Ikeda M, Hattori H and Ohmori S (1984)  
Properties of NADPH-dependent carbonyl reductases in rat liver cytosol.  
Biochem Pharmacol 33:3957-3961. 
Imamura Y, Higuchi T, Nozaki Y, Sugino E, Hibino S and Otagiri M (1993)  
Purification and properties of carbonyl reductase from rabbit kidney.  
Arch Biochem Biophys 300:570-576. 
Imamura Y, Migita T, Anraku M and Otagiri M (1999a)  
References 178 
Inhibition of rabbit heart carbonyl reductase by fatty acids.  
Biol Pharm Bull 22:731-733. 
Imamura Y, Migita T, Otagiri M, Choshi T and Hibino S (1999b)  
Purification and catalytic properties of a tetrameric carbonyl reductase from rabbit heart.  
J Biochem (Tokyo) 125:41-47. 
Inazu N and Fujii T (1997)  
Pre- and post-ovulatory changes in carbonyl reductase in ovarian follicles and corpora lutea in 
rats.  
Res Commun Mol Pathol Pharmacol 98:325-334. 
Inazu N, Inaba N, Satoh T and Fujii T (1992a)  
Human chorionic gonadotropin causes an estrogen-mediated induction of rat ovarian carbonyl 
reductase.  
Life Sci 51:817-822. 
Inazu N, Ruepp B, Wirth H and Wermuth B (1992b)  
Carbonyl reductase from human testis: purification and comparison with carbonyl reductase 
from human brain and rat testis.  
Biochim Biophys Acta 1116:50-56. 
Inazu N and Satoh T (1994)  
Activation by human chorionic gonadotropin of ovarian carbonyl reductase in mature rats 
exposed in vivo to estrogens.  
Biochem Pharmacol 47:1489-1496. 
Iwata N, Inazu N and Satoh T (1989)  
The purification and properties of NADPH-dependent carbonyl reductases from rat ovary.  
J Biochem (Tokyo) 105:556-564. 
Iwata N, Inazu N and Satoh T (1990a)  
Immunological and enzymological localization of carbonyl reductase in ovary and liver of 
various species.  
J Biochem (Tokyo) 107:209-212. 
References 179 
Iwata N, Inazu N, Takeo S and Satoh T (1990b)  
Carbonyl reductases from rat testis and vas deferens. Purification, properties and localization.  
Eur J Biochem 193:75-81. 
Jarabak J, Luncsford A and Berkowitz D (1983)  
Substrate specificity of three prostaglandin dehydrogenases.  
Prostaglandins 26:849-868. 
Jez JM, Bennett MJ, Schlegel BP, Lewis M and Penning TM (1997a)  
Comparative anatomy of the aldo-keto reductase superfamily.  
Biochem J 326 ( Pt 3):625-636. 
Jez JM, Flynn TG and Penning TM (1997b)  
A new nomenclature for the aldo-keto reductase superfamily.  
Biochem Pharmacol 54:639-647. 
Jones TA and Thirup S (1986)  
Using known substructures in protein model building and crystallography.  
Embo J 5:819-822. 
Jorgensen WL, Chandrasekhar J, Madura JP, Impey RW and Klein ML (1983)  
Comparison of simple poteintial functions for simulating liquid water.  
J.Chem.Phys. 79:926-935. 
Jornvall H, Hoog JO and Persson B (1999)  
SDR and MDR: completed genome sequences show these protein families to be large, of old 
origin, and of complex nature.  
FEBS Lett 445:261-264. 
Jornvall H, Persson B, Krook M, Atrian S, Gonzalez-Duarte R, Jeffery J and Ghosh D (1995)  
Short-chain dehydrogenases/reductases (SDR).  
Biochemistry 34:6003-6013. 
Jörnvall H, Persson B, Krook M, Atrian S, Gonzalez-Duarte R, Jeffery J and Ghosh D (1995)  
Short-chain dehydrogenases/reductases (SDR).  
References 180 
Biochemistry 34:6003-6013. 
Jornvall H, Persson M and Jeffery J (1981)  
Alcohol and polyol dehydrogenases are both divided into two protein types, and structural 
properties cross-relate the different enzyme activities within each type.  
Proc Natl Acad Sci U S A 78:4226-4230. 
Kallberg Y, Oppermann U, Jornvall H and Persson B (2002a)  
Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters 
common to human, animal, and plant genomes.  
Protein Sci 11:636-641. 
Kallberg Y, Oppermann U, Jörnvall H and Persson B (2002b)  
Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters 
common to human, animal, and plant genomes.  
Protein Sci 11:636-641. 
Kallberg Y and Persson B (1999)  
KIND-a non-redundant protein database.  
Bioinformatics 15:260-261. 
Karplus K, Barrett C and Hughey R (1998)  
Hidden Markov models for detecting remote protein homologies.  
Bioinformatics 14:846-856. 
Karplus K, Karchin R, Shackelford G and Hughey R (2005)  
Calibrating E-values for hidden Markov models using reverse-sequence null models.  
Bioinformatics 21:4107-4115. 
Karplus M and Petsko GA (1990)  
Molecular dynamics simulations in biology.  
Nature 347:631-639. 
Kita K, Fukura T, Nakase KI, Okamoto K, Yanase H, Kataoka M and Shimizu S (1999)  
References 181 
Cloning, overexpression, and mutagenesis of the Sporobolomyces salmonicolor AKU4429 
gene encoding a new aldehyde reductase, which catalyzes the stereoselective reduction of 
ethyl 4-chloro-3-oxobutanoate to ethyl (S)-4-chloro-3-hydroxybutanoate.  
Appl Environ Microbiol 65:5207-5211. 
Klapper MH (1971)  
On the nature of the protein interior.  
Biochim Biophys Acta 229:557-566. 
Koehl P and Levitt M (1999)  
A brighter future for protein structure prediction.  
Nat Struct Biol 6:108-111. 
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, 
Brown R, Edwards CR, Seckl JR and Mullins JJ (1997)  
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-
inducible responses and resist hyperglycemia on obesity or stress.  
Proc Natl Acad Sci U S A 94:14924-14929. 
Krook M, Ghosh D, Duax W and Jornvall H (1993a)  
Three-dimensional model of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase and 
relationships to the NADP(+)-dependent enzyme (carbonyl reductase).  
FEBS Lett 322:139-142. 
Krook M, Ghosh D, Duax W and Jörnvall H (1993b)  
Three-dimensional model of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase and 
relationships to the NADP(+)-dependent enzyme (carbonyl reductase).  
FEBS Lett 322:139-142. 
Krook M, Ghosh D, Stromberg R, Carlquist M and Jornvall H (1993c)  
Carboxyethyllysine in a protein: native carbonyl reductase/NADP(+)-dependent prostaglandin 
dehydrogenase.  
Proc Natl Acad Sci U S A 90:502-506. 
Krozowski Z (1992)  
References 182 
11 beta-hydroxysteroid dehydrogenase and the short-chain alcohol dehydrogenase (SCAD) 
superfamily.  
Mol Cell Endocrinol 84:C25-31. 
Kurucz I, Titus JA, Jost CR and Segal DM (1995)  
Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv pro-
teins from bacterial inclusion bodies.  
Mol Immunol 32:1443-1452. 
Kyhse-Andersen J (1984)  
Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of 
proteins from polyacrylamide to nitrocellulose.  
J Biochem Biophys Methods 10:203-209. 
Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R and Belanger A (1997)  
The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology.  
Steroids 62:148-158. 
Laemmli UK (1970)  
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.  
Nature 227:680-685. 
Lakhman SS, Ghosh D and Blanco JG (2005)  
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).  
Drug Metab Dispos 33:254-257. 
Lee SC and Levine L (1974a)  
Prostaglandin metabolism. I. Cytoplasmic reduced nicotinamide adenine dinucleotide phos-
phate-dependent and microsomal reduced nicotinamide adenine dinucleotide-dependent pros-
taglandin E 9-ketoreductase activities in monkey and pigeon tissues.  
J Biol Chem 249:1369-1375. 
Lee SC and Levine L (1974b)  
Purification and properties of chicken heart prostaglandin delta13-reductase.  
Biochem Biophys Res Commun 61:14-21. 
References 183 
Levinthal C (1968)  
Are there pathways for ptotein folding?  
C J Chim  Phys 65:44-45. 
Levitt M (1992)  
Accurate modeling of protein conformation by automatic segment matching.  
J Mol Biol 226:507-533. 
Li KX, Obeyesekere VR, Krozowski ZS and Ferrari P (1997)  
Oxoreductase and dehydrogenase activities of the human and rat 11beta-hydroxysteroid de-
hydrogenase type 2 enzyme.  
Endocrinology 138:2948-2952. 
Lin D, Lee HG, Liu Q, Perry G, Smith MA and Sayre LM (2005)  
4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-
nonenal.  
Chem Res Toxicol 18:1219-1231. 
Lind C, Cadenas E, Hochstein P and Ernster L (1990)  
DT-diaphorase: purification, properties, and function.  
Methods Enzymol 186:287-301. 
Lind C, Hochstein P and Ernster L (1982)  
DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and su-
peroxide radical formation.  
Arch Biochem Biophys 216:178-185. 
Luque I and Freire E (2000)  
Structural stability of binding sites: consequences for binding affinity and allosteric effects.  
Proteins Suppl 4:63-71. 
Marcus PI and Talalay P (1956)  
Induction and purification of alpha- and beta-hydroxysteroid dehydrogenases.  
J Biol Chem 218:661-674. 
References 184 
Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F and Sali A (2000)  
Comparative protein structure modeling of genes and genomes.  
Annu Rev Biophys Biomol Struct 29:291-325. 
Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S and Maser E (2006)  
Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of 
xenobiotics.  
Drug Metab Dispos 34:464-470. 
Maser E (1993)  
The purification and properties of a novel carbonyl reducing enzyme from mouse liver micro-
somes.  
Adv Exp Med Biol 328:339-350. 
Maser E (1995)  
Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of 
several hydroxysteroid dehydrogenases.  
Biochem Pharmacol 49:421-440. 
Maser E (1997)  
Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the inci-
dence of tobacco smoke-related cancer?  
Trends Pharmacol Sci 18:270-275. 
Maser E (1998)  
11Beta-hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-
specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone in mouse lung micro-
somes.  
Cancer Res 58:2996-3003. 
Maser E (2004)  
Significance of reductases in the detoxification of the tobacco-specific carcinogen NNK.  
Trends Pharmacol Sci 25:235-237. 
Maser E and Bannenberg G (1994a)  
References 185 
11 beta-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl 
compounds.  
Biochem Pharmacol 47:1805-1812. 
Maser E and Bannenberg G (1994b)  
The purification of 11 beta-hydroxysteroid dehydrogenase from mouse liver microsomes.  
J Steroid Biochem Mol Biol 48:257-263. 
Maser E, Friebertshauser J and Mangoura SA (1994)  
Ontogenic pattern of carbonyl reductase activity of 11 beta-hydroxysteroid dehydrogenase in 
mouse liver and kidney.  
Xenobiotica 24:109-117. 
Maser E, Friebertshauser J and Volker B (2003)  
Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid 
dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxi-
fication of a tobacco-derived carcinogen.  
Chem Biol Interact 143-144:435-448. 
Maser E, Hoffmann JG, Friebertshauser J and Netter KJ (1992)  
High carbonyl reductase activity in adrenal gland and ovary emphasizes its role in carbonyl 
compound detoxication.  
Toxicology 74:45-56. 
Maser E, Möbus E and Xiong G (2000)  
Functional expression, purification, and characterization of 3alpha- hydroxysteroid dehydro-
genase/carbonyl reductase from Comamonas testosteroni.  
Biochem Biophys Res Commun 272:622-628. 
Maser E and Oppermann UC (1995)  
Molecular cloning and sequencing of mouse hepatic 11 beta-hydroxysteroid dehydro-
genase/carbonyl reductase. A member of the short chain dehydrogenase superfamily.  
Adv Exp Med Biol 372:211-221. 
Maser E and Oppermann UC (1997)  
References 186 
Role of type-1 11beta-hydroxysteroid dehydrogenase in detoxification processes.  
Eur J Biochem 249:365-369. 
Maser E, Richter E and Friebertshauser J (1996)  
The identification of 11 beta-hydroxysteroid dehydrogenase as carbonyl reductase of the to-
bacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.  
Eur J Biochem 238:484-489. 
Maser E, Volker B and Friebertshauser J (2002)  
11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme 
cooperativity support its postulated role as glucocorticoid reductase.  
Biochemistry 41:2459-2465. 
Maser E, Wsol V and Martin HJ (2006)  
11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characteriza-
tion as carbonyl reductase of xenobiotics.  
Mol Cell Endocrinol 248:34-37. 
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR and Flier JS (2001)  
A transgenic model of visceral obesity and the metabolic syndrome.  
Science 294:2166-2170. 
Matsuda T, Harada T, Nakajima N, Itoh T and Nakamura K (2000)  
Two classes of enzymes of opposite stereochemistry in an organism: one for fluorinated and 
another for nonfluorinated substrates.  
J Org Chem 65:157-163. 
Matsunaga T, Shintani S and Hara A (2006)  
Multiplicity of mammalian reductases for xenobiotic carbonyl compounds.  
Drug Metab Pharmacokinet 21:1-18. 
Matsuura K, Bunai Y, Ohya I, Hara A, Nakanishi M and Sawada H (1994)  
Ultrastructural localization of carbonyl reductase in mouse lung.  
Histochem J 26:311-316. 
References 187 
Matsuura K, Hara A, Sawada H, Bunai Y and Ohya I (1990)  
Localization of pulmonary carbonyl reductase in guinea pig and mouse: enzyme histochemi-
cal and immunohistochemical studies.  
J Histochem Cytochem 38:217-223. 
Matsuura K, Naganeo F, Hara A, Nakayama T, Nakagawa M and Sawada H (1989)  
Pulmonary carbonyl reductase: metabolism of carbonyl products in lipid peroxidation.  
Prog Clin Biol Res 290:335-349. 
Matsuura K, Nakayama T, Nakagawa M, Hara A and Sawada H (1988)  
Kinetic mechanism of pulmonary carbonyl reductase.  
Biochem J 252:17-22. 
McGrath T and Center MS (1987)  
Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein.  
Biochem Biophys Res Commun 145:1171-1176. 
Meger M, Meger-Kossien I, Dietrich M, Tricker AR, Scherer G and Adlkofer F (1996)  
Metabolites of 4-(N-methylnitrosamino)-1-(3-pyridyl)-1-butanone in urine of smokers.  
Eur J Cancer Prev 5 Suppl 1:121-124. 
Melka M (1993)  
Oracin-preclinical summary report of the research Institute for Pharmacy and Biochemis-
try.:Prague, Czech Republic. 
Michel-Briand Y (1969)  
[Relationship between the structure of a steroid and the inducing effect on 3 alpha-
hydroxysteroid: NAD oxidoreductase of Pseudomonas testosteroni].  
Eur J Biochem 10:132-139. 
Michel-Briand Y and Roux J (1969)  
[Role of the composition of the culture medium in the delay of appearance of the 3 alpha-
hydroxysteroid enzyme: NAD-oxidoreductase (EC I.I.I.50) of Pseudomonas testoteroni. 
(Catabolic repression phenomenon)].  
Ann Inst Pasteur (Paris) 116:448-473. 
References 188 
Miko M, Krepelka J and Melka M (1991)  
Effects of benfluron and its two metabolites on respiratory processes in P388 murine leuke-
mia and Ehrlich ascites cells.  
Biochem Pharmacol 42 Suppl:S214-216. 
Miko M, Poturnajova M and Soucek R (2002)  
Cytotoxicity and mode of action of the potential cytostatic drug oracin.  
Neoplasma 49:167-171. 
Möbus E, Jahn M, Schmid R, Jahn D and Maser E (1997)  
Testosterone-regulated expression of enzymes involved in steroid and aromatic hydrocarbon 
catabolism in Comamonas testosteroni.  
J Bacteriol 179:5951-5955. 
Mobus E and Maser E (1998)  
Molecular cloning, overexpression, and characterization of steroid-inducible 3alpha-
hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. A novel 
member of the short-chain dehydrogenase/reductase superfamily.  
J Biol Chem 273:30888-30896. 
Möbus E and Maser E (1998)  
Molecular cloning, overexpression, and characterization of steroid- inducible 3alpha-
hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. A novel 
member of the short-chain dehydrogenase/reductase superfamily.  
J Biol Chem 273:30888-30896. 
Monder C and Shackleton CH (1984)  
11 beta-Hydroxysteroid dehydrogenase: fact or fancy?  
Steroids 44:383-417. 
Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D and Edwards CR (1989)  
Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in 
vitro studies.  
Endocrinology 125:1046-1053. 
References 189 
Monder C and White PC (1993)  
11 beta-hydroxysteroid dehydrogenase.  
Vitam Horm 47:187-271. 
Monks TJ, Hanzlik RP, Cohen GM, Ross D and Graham DG (1992)  
Quinone chemistry and toxicity.  
Toxicol Appl Pharmacol 112:2-16. 
Moore CC, Mellon SH, Murai J, Siiteri PK and Miller WL (1993)  
Structure and function of the hepatic form of 11 beta-hydroxysteroid dehydrogenase in the 
squirrel monkey, an animal model of glucocorticoid resistance.  
Endocrinology 133:368-375. 
Mukhopadhyay A (1997)  
Inclusion bodies and purification of proteins in biologically active forms.  
Adv Biochem Eng Biotechnol 56:61-109. 
Nadkarni DV and Sayre LM (1995)  
Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal.  
Chem Res Toxicol 8:284-291. 
Nakajin S, Tamura F, Takase N and Toyoshima S (1997)  
Carbonyl reductase activity exhibited by pig testicular 20 beta-hydroxysteroid dehydrogenase.  
Biol Pharm Bull 20:1215-1218. 
Nakanishi M, Deyashiki Y, Nakayama T, Sato K and Hara A (1993)  
Cloning and sequence analysis of a cDNA encoding tetrameric carbonyl reductase of pig 
lung.  
Biochem Biophys Res Commun 194:1311-1316. 
Nakanishi M, Deyashiki Y, Ohshima K and Hara A (1995)  
Cloning, expression and tissue distribution of mouse tetrameric carbonyl reductase. Identity 
with an adipocyte 27-kDa protein.  
Eur J Biochem 228:381-387. 
References 190 
Nakayama T, Hara A and Sawada H (1982)  
Purification and characterization of a novel pyrazole-sensitive carbonyl reductase in guinea 
pig lung.  
Arch Biochem Biophys 217:564-573. 
Nakayama T, Hara A, Yashiro K and Sawada H (1985)  
Reductases for carbonyl compounds in human liver.  
Biochem Pharmacol 34:107-117. 
Nakayama T, Yashiro K, Inoue Y, Matsuura K, Ichikawa H, Hara A and Sawada H (1986)  
Characterization of pulmonary carbonyl reductase of mouse and guinea pig.  
Biochim Biophys Acta 882:220-227. 
Neupert W, Hartl FU, Craig EA and Pfanner N (1990)  
How do polypeptides cross the mitochondrial membranes?  
Cell 63:447-450. 
Norrander J, Kempe T and Messing J (1983)  
Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis.  
Gene 26:101-106. 
O'Brien PJ (1991)  
Molecular mechanisms of quinone cytotoxicity.  
Chem Biol Interact 80:1-41. 
Ogata K, Arakawa M, Kasahara T, Shioiri-Nakano K and Hiraoka K (1983)  
Detection of toxoplasma membrane antigens transferred from SDS-polyacrylamide gel to 
nitrocellulose with monoclonal antibody and avidin-biotin, peroxidase anti-peroxidase and 
immunoperoxidase methods.  
J Immunol Methods 65:75-82. 
Oh JW, Lee HB, Kim CR, Yum MK, Koh YJ, Moon SJ, Kang JO and Park IK (1999)  
Analysis of induced sputum to examine the effects of inhaled corticosteroid on airway in-
flammation in children with asthma.  
Ann Allergy Asthma Immunol 82:491-496. 
References 191 
Ohara H, Miyabe Y, Deyashiki Y, Matsuura K and Hara A (1995)  
Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde 
reductase of human liver.  
Biochem Pharmacol 50:221-227. 
Ohno S, Nakajin S and Shinoda M (1991)  
20 beta-hydroxysteroid dehydrogenase of neonatal pig testis: 3 alpha/beta-hydroxysteroid 
dehydrogenase activities catalyzed by highly purified enzyme.  
J Steroid Biochem Mol Biol 38:787-794. 
Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL and Reeves RH (2003)  
Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl 
reductase 1.  
Cancer Res 63:6602-6606. 
Oppermann CT, Netter KJ and Maser E (1993)  
Carbonyl reduction by 3 alpha-HSD from Comamonas testosteroni--new properties and its 
relationship to the SCAD family.  
Adv Exp Med Biol 328:379-390. 
Oppermann UC, Belai I and Maser E (1996)  
Antibiotic resistance and enhanced insecticide catabolism as consequences of steroid induc-
tion in the gram-negative bacterium Comamonas testosteroni.  
J Steroid Biochem Mol Biol 58:217-223. 
Oppermann UC and Maser E (1996)  
Characterization of a 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase from the 
gram-negative bacterium Comamonas testosteroni.  
Eur J Biochem 241:744-749. 
Oppermann UC and Maser E (2000)  
Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reduc-
tases and dehydrogenases in xenobiotic phase I reactions.  
Toxicology 144:71-81. 
References 192 
Oppermann UC, Maser E, Mangoura SA and Netter KJ (1991)  
Heterogeneity of carbonyl reduction in subcellular fractions and different organs in rodents.  
Biochem Pharmacol 42 Suppl:S189-195. 
Oppermann UC, Nagel G, Belai I, Bueld JE, Genti-Raimondi S, Koolman J, Netter KJ and 
Maser E (1998)  
Carbonyl reduction of an anti-insect agent imidazole analogue of metyrapone in soil bacteria, 
invertebrate and vertebrate species.  
Chem Biol Interact 114:211-224. 
Oppermann UC, Netter KJ and Maser E (1995)  
Cloning and primary structure of murine 11 beta-hydroxysteroid dehydrogenase/microsomal 
carbonyl reductase.  
Eur J Biochem 227:202-208. 
Oritani H, Deyashiki Y, Nakayama T, Hara A, Sawada H, Matsuura K, Bunai Y and Ohya I 
(1992)  
Purification and characterization of pig lung carbonyl reductase.  
Arch Biochem Biophys 292:539-547. 
Ota T Suzuki Y Nishikawa T Otsuki T Sugiyama T Irie R Wakamatsu A Hayashi K Sato H 
Nagai K Kimura K Makita H Sekine M Obayashi M Nishi T Shibahara T Tanaka T Ishii S 
Yamamoto J Saito K Kawai Y Isono Y Nakamura Y Nagahari K Murakami K Yasuda T 
Iwayanagi T Wagatsuma M Shiratori A Sudo H Hosoiri T Kaku Y Kodaira H Kondo H Su-
gawara M Takahashi M Kanda K Yokoi T Furuya T Kikkawa E Omura Y Abe K Kamihara K 
Katsuta N Sato K Tanikawa M Yamazaki M Ninomiya K Ishibashi T Yamashita H Murakawa 
K Fujimori K Tanai H Kimata M Watanabe M Hiraoka S Chiba Y Ishida S Ono Y Takiguchi 
S Watanabe S Yosida M Hotuta T Kusano J Kanehori K Takahashi-Fujii A Hara H Tanase 
TO Nomura Y Togiya S Komai F Hara R Takeuchi K Arita M Imose N Musashino K Yuuki 
H Oshima A Sasaki N Aotsuka S Yoshikawa Y Matsunawa H Ichihara T Shiohata N Sano S 
Moriya S Momiyama H Satoh N Takami S Terashima Y Suzuki O Nakagawa S Senoh A 
Mizoguchi H Goto Y Shimizu F Wakebe H Hishigaki H Watanabe T Sugiyama A Takemoto 
M Kawakami B Watanabe K Kumagai A Itakura S Fukuzumi Y Fujimori Y Komiyama M 
Tashiro H Tanigami A Fujiwara T Ono T Yamada K Fujii Y Ozaki K Hirao M Ohmori Y 
References 193 
Kawabata A Hikiji T Kobatake N Inagaki H Ikema Y Okamoto S Okitani R Kawakami T 
Noguchi S Itoh T Shigeta K Senba T Matsumura K Nakajima Y Mizuno T Morinaga M Sa-
saki M Togashi T Oyama M Hata H Komatsu T Mizushima-Sugano J Satoh T Shirai Y Taka-
hashi Y Nakagawa K Okumura K Nagase T Nomura N Kikuchi H Masuho Y Yamashita R 
Nakai K Yada T Ohara O Isogai T and Sugano S (2004)  
Complete sequencing and characterization of 21,243 full-length human cDNAs.  
Nat Genet 36:40-45. 
Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE and Young RC (1980)  
Inhibition of human ovarian cancer colony formation by adriamycin and its major metabo-
lites.  
Cancer Res 40:4109-4112. 
Pal L and Basu G (1999)  
Novel protein structural motifs containing two-turn and longer 3(10)-helices.  
Protein Eng 12:811-814. 
Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P and Cantelli-Forti G (1999)  
Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes.  
Cancer Lett 145:35-42. 
Park YS, Heizmann CW, Wermuth B, Levine RA, Steinerstauch P, Guzman J and Blau N 
(1991)  
Human carbonyl and aldose reductases: new catalytic functions in tetrahydrobiopterin biosyn-
thesis.  
Biochem Biophys Res Commun 175:738-744. 
Penning TM (1997)  
Molecular endocrinology of hydroxysteroid dehydrogenases.  
Endocr Rev 18:281-305. 
Penning TM (2005)  
AKR1B10: A New diagnostic marker of Non-Small Cell Lung Carcinoma in Smokers.  
Clinical Cancer Research 11:1687-1690. 
References 194 
Penning TM, Bennett MJ, Smith-Hoog S, Schlegel BP, Jez JM and Lewis M (1997)  
Structure and function of 3 alpha-hydroxysteroid dehydrogenase.  
Steroids 62:101-111. 
Penning TM, Mukharji I, Barrows S and Talalay P (1984)  
Purification and properties of a 3 alpha-hydroxysteroid dehydrogenase of rat liver cytosol and 
its inhibition by anti-inflammatory drugs.  
Biochem J 222:601-611. 
Penning TM, Pawlowski JE, Schlegel BP, Jez JM, Lin HK, Hoog SS, Bennett MJ and Lewis 
M (1996)  
Mammalian 3 alpha-hydroxysteroid dehydrogenases.  
Steroids 61:508-523. 
Persson B, Kallberg Y, Oppermann U and Jörnvall H (2003)  
Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs).  
Chem Biol Interact 143-144:271-278. 
Persson B, Krook M and Jornvall H (1991)  
Characteristics of short-chain alcohol dehydrogenases and related enzymes.  
Eur J Biochem 200:537-543. 
Peters J, Minuth T and Kula MR (1993)  
A novel NADH-dependent carbonyl reductase with an extremely broad substrate range from 
Candida parapsilosis: purification and characterization.  
Enzyme Microb Technol 15:950-958. 
Pfanner N, Hartl FU and Neupert W (1988)  
Import of proteins into mitochondria: a multi-step process.  
Eur J Biochem 175:205-212. 
Pfanner N, Ostermann J, Rassow J, Hartl FU and Neupert W (1990a)  
Stress proteins and mitochondrial protein import.  
Antonie Van Leeuwenhoek 58:191-193. 
References 195 
Pfanner N, Rassow J, Guiard B, Sollner T, Hartl FU and Neupert W (1990b)  
Energy requirements for unfolding and membrane translocation of precursor proteins during 
import into mitochondria.  
J Biol Chem 265:16324-16329. 
Pietruszko R and Chen FF (1976)  
Aldehyde reductase from rat liver is a 3 alpha-hydroxysteroid dehydrogenase.  
Biochem Pharmacol 25:2721-2725. 
Propper D and Maser E (1997)  
Carbonyl reduction of daunorubicin in rabbit liver and heart.  
Pharmacol Toxicol 80:240-245. 
Przybycien TM, Dunn JP, Valax P and Georgiou G (1994)  
Secondary structure characterization of beta-lactamase inclusion bodies.  
Protein Eng 7:131-136. 
Puranen T, Poutanen M, Ghosh D, Vihko P and Vihko R (1997)  
Characterization of structural and functional properties of human 17 beta-hydroxysteroid de-
hydrogenase type 1 using recombinant enzymes and site-directed mutagenesis.  
Mol Endocrinol 11:77-86. 
Quinkler M, Kosmale B, Bahr V, Oelkers W and Diederich S (1997)  
Evidence for isoforms of 11 beta-hydroxysteroid dehydrogenase in the liver and kidney of the 
guinea pig.  
J Endocrinol 153:291-298. 
Ramachandran C, Yuan ZK, Huang XL and Krishan A (1993)  
Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi 
gene expression.  
Biochem Pharmacol 45:743-751. 
Ratnam K, Ma H and Penning TM (1999)  
The arginine 276 anchor for NADP(H) dictates fluorescence kinetic transients in 3 alpha-
hydroxysteroid dehydrogenase, a representative aldo-keto reductase.  
References 196 
Biochemistry 38:7856-7864. 
Reidenberg MM (2000)  
Environmental inhibition of 11beta-hydroxysteroid dehydrogenase.  
Toxicology 144:107-111. 
Rekka EA, Soldan M, Belai I, Netter KJ and Maser E (1996)  
Biotransformation and detoxification of insecticidal metyrapone analogues by carbonyl reduc-
tion in the human liver.  
Xenobiotica 26:1221-1229. 
Revie D, Smith DW and Yee TW (1988)  
Kinetic analysis for optimization of DNA ligation reactions.  
Nucleic Acids Res 16:10301-10321. 
Ris MM and von Wartburg JP (1973)  
Heterogenity of NADPH-dependent aldehyde reductase from human and rat brain.  
Eur J Biochem 37(1):69-77. 
Roberts S (1997)  
Preparative Biotrransformations.  
Wiley & Sons, Chichester - New York. 
Rosemond MJ and Walsh JS (2004)  
Human carbonyl reduction pathways and a strategy for their study in vitro.  
Drug Metab Rev 36:335-361. 
Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT and Gibson NW (1993)  
DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mito-
mycin C.  
Cancer Metastasis Rev 12:83-101. 
Rossmann MG, Liljas A, Bränden CI and Banaszal LJ (1975)  
in: in "The Enzymes". ( 
References 197 
Rudolph R and Lilie H (1996)  
In vitro folding of inclusion body proteins.  
Faseb J 10:49-56. 
Ryckaert JP, Ciccotti G and Berendsen HJC (1977)  
NUmerical integration of the Cartesian equations of motion of a system with constrains: mo-
lecular dynamics of n-alkanes.  
J.Comp.Phys. 23:327-341. 
Sali A (1995a)  
Comparative protein modeling by satisfaction of spatial restraints.  
Mol Med Today 1:270-277. 
Sali A (1995b)  
Modeling mutations and homologous proteins.  
Curr Opin Biotechnol 6:437-451. 
Sali A and Blundell TL (1993)  
Comparative protein modeling by satisfaction of spatial restraints.  
J Mol Biol 234:779-815. 
Sambrook J, Fritsch EF and Maniatis T (1989)  
Molecular Cloning. A laboratory manual.  
Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 
Sanchez R and Sali A (1998)  
Large-scale protein structure modeling of the Saccharomyces cerevisiae genome.  
Proc Natl Acad Sci U S A 95:13597-13602. 
Sawada H and Hara A (1979)  
The presence of two NADPH-linked aromatic aldehyde-ketone reductases different from al-
dehyde reductase in rabbit liver.  
Biochem Pharmacol 28:1089-1094. 
Sawada H, Hara A, Kato F and Nakayama T (1979)  
References 198 
Purification and properties of reductases for aromatic aldehydes and ketones from guinea pig 
liver.  
J Biochem (Tokyo) 86:871-881. 
Sawada H, Hara A, Nakayama T and Kato F (1980)  
Reductases for aromatic aldehydes and ketones from rabbit liver. Purification and characteri-
zation.  
J Biochem (Tokyo) 87:1153-1165. 
Sawada H, Hara A, Nakayama T, Nakagawa M, Inoue Y, Hasebe K and Zhang YP (1988)  
Mouse liver dihydrodiol dehydrogenases. Identity of the predominant and a minor form with 
17 beta-hydroxysteroid dehydrogenase and aldehyde reductase.  
Biochem Pharmacol 37:453-458. 
Sayre LM, Smith MA and Perry G (2001)  
Chemistry and biochemistry of oxidative stress in neurodegenerative disease.  
Curr Med Chem 8:721-738. 
Schieber A, Frank RW and Ghisla S (1992)  
Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. 
Identity with human carbonyl reductase.  
Eur J Biochem 206:491-502. 
Schieber A and Ghisla S (1992)  
Prostaglandin 9-ketoreductase from pig and human kidney: purification, properties and iden-
tity with human carbonyl reductase.  
Eicosanoids 5 Suppl:S37-38. 
Schott B and Robert J (1989)  
Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in 
culture.  
Biochem Pharmacol 38:4069-4074. 
Schwartz AG, Yang P and Swanson GM (1996)  
Familial risk of lung cancer among nonsmokers and their relatives.  
References 199 
Am J Epidemiol 144:554-562. 
Sciotti M and Wermuth B (2001)  
Coenzyme specificity of human monomeric carbonyl reductase: contribution of Lys-15, Ala-
37 and Arg-38.  
Chem Biol Interact 130-132:871-878. 
Sciotti MA, Nakajin S, Wermuth B and Baker ME (2000)  
Mutation of threonine-241 to proline eliminates autocatalytic modification of human carbonyl 
reductase.  
Biochem J 350 Pt 1:89-92. 
Seckl JR (1997)  
11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid ac-
tion?  
Front Neuroendocrinol 18:49-99. 
Sgraja T, Ulschmid J, Becker K, Schneuwly S, Klebe G, Reuter K and Heine A (2004)  
Structural insights into the neuroprotective-acting carbonyl reductase Sniffer of Drosophila 
melanogaster.  
J Mol Biol 342:1613-1624. 
Shapiro HK (1998)  
Carbonyl-trapping therapeutic strategies.  
Am J Ther 5:323-353. 
Shikita M and Talalay P (1979)  
Preparation of highly purified 3 alpha- and 3 beta-hydroxysteroid dehydrogenases from Pseu-
domonas sp.  
Anal Biochem 95:286-292. 
Skalhegg BA (1975)  
3Alpha-hydroxysteroid dehydrogenase from Pseudomonas testosteroni: kinetic properties 
with NAD and its thionicotinamide analogue.  
Eur J Biochem 50:603-609. 
References 200 
Skalova L, Nobilis M, Szotakova B, Kondrova E, Savlik M, Wsol V, Pichard-Garcia L and 
Maser E (2002)  
Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in 
human in vitro.  
Biochem Pharmacol 64:297-305. 
Smolen A and Anderson AD (1976)  
Partial purification and characterization of a reduced nicotinamide adenine dinucleotide phos-
phate-linked aldehyde reductase from heart.  
Biochem Pharmacol 25:317-323. 
Soldan M, Nagel G, Losekam M, Ernst M and Maser E (1999)  
Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-
hydroxysteroid dehydrogenase 1 in human lung.  
Cancer Lett 145:49-56. 
Soldan M, Netter K and Maser E (1996a)  
Enzymatic detoxification of daunorubicin as supplementary mechanism to multidrug resis-
tance. .  
Exp Toxic Path 48 (Suppl.II):370-376. 
Soldan M, Netter KJ and Maser E (1996b)  
Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resis-
tant pancreas carcinoma cells.  
Biochem Pharmacol 51:117-123. 
Somers WS, Stahl ML and Sullivan FX (1998)  
GDP-fucose synthetase from Escherichia coli: structure of a unique member of the short-
chain dehydrogenase/reductase family that catalyzes two distinct reactions at the same active 
site.  
Structure 6:1601-1612. 
Srinivasan S, March CJ and Sudarsanam S (1993)  
An automated method for modeling proteins on known templates using distance geometry.  
References 201 
Protein Sci 2:277-289. 
Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC and Whorwood 
CB (1996)  
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 
beta-hydroxysteroid dehydrogenase type 2 gene.  
Lancet 347:88-91. 
Stewart PM, Murry BA and Mason JI (1994)  
Type 2 11 beta-hydroxysteroid dehydrogenase in human fetal tissues.  
J Clin Endocrinol Metab 78:1529-1532. 
Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, 
Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, 
Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, 
Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, 
Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquel-
lano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, 
Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, 
Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, 
Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouf-
fard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood 
J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch 
A, Schein JE, Jones SJ and Marra MA (2002)  
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA se-
quences.  
Proc Natl Acad Sci U S A 99:16899-16903. 
Suzuki K, Ueda S, Sugiyama M and Imamura S (1993)  
Cloning and expression of a Pseudomonas 3 alpha-hydroxysteroid dehydrogenase-encoding 
gene in Escherichia coli.  
Gene 130:137-140. 
Sweet F and Samant BR (1980)  
References 202 
Bifunctional enzyme activity at the same active site: study of 3 alpha and 20 beta activity by 
affinity alkylation of 3 alpha, 20 beta-hydroxysteroid dehydrogenase with 17-
(bromoacetoxy)steroids.  
Biochemistry 19:978-986. 
Szotakova B, Wsol V, Treitjnar F, Skalova L and Kvasnickova E (1996)  
Studies on the metabolism of the potential cytostatic drug oracin. Species differences. .  
Exp. Toxic. Pathol. 48 Suppl. II:377-388. 
Szweda LI, Uchida K, Tsai L and Stadtman ER (1993)  
Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Selective modi-
fication of an active-site lysine.  
J Biol Chem 268:3342-3347. 
Tajima K, Hashizaki M, Yamamoto K, Narimatsu S and Mizutani T (1999)  
Purification and some properties of two enzymes from rat liver cytosol that catalyze carbonyl 
reduction of 6-tert-butyl-2, 3-epoxy-5-cyclohexene-1,4-dione, a metabolite of 3-tert-butyl-4-
hydroxyanisole.  
Arch Biochem Biophys 361:207-214. 
Talalay P, Dobson MM and Tapley DF (1952)  
Oxidative degradation of testosterone by adaptive enzymes.  
Nature 170:620-621. 
Tamaoka J, Ha DM and Komagata K (1987)  
Reclassification of pseudomonas acidovorans den Dooren de Jong 1926 and Pseudomonas 
testosteroni Marcus and Talaly 1956 as Comamonas acidovorans comb. nov. and Comamonas 
testosteroni comb. nov., with an amended decription of genus comamonas.  
Int.J.Syst. Bacteriol. 37:52-59. 
Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlin-
game AL, Trautman JK, Shokat KM and Adams CL (2005)  
An unbiased cell morphology-based screen for new, biologically active small molecules.  
PLoS Biol 3:e128. 
References 203 
Tanaka M, Ohno S, Adachi S, Nakajin S, Shinoda M and Nagahama Y (1992)  
Pig testicular 20 beta-hydroxysteroid dehydrogenase exhibits carbonyl reductase-like struc-
ture and activity. cDNA cloning of pig testicular 20 beta-hydroxysteroid dehydrogenase.  
J Biol Chem 267:13451-13455. 
Tanaka N, Nonaka T, Nakanishi M, Deyashiki Y and Hara A (1995)  
Crystallization of mouse lung carbonyl reductase complexed with NADPH and analysis of 
symmetry of its tetrameric molecule.  
J Biochem (Tokyo) 118:871-873. 
Tanaka N, Nonaka T, Nakanishi M, Deyashiki Y, Hara A and Mitsui Y (1996a)  
Crystal structure of the ternary complex of mouse lung carbonyl reductase at 1.8 A resolution: 
the structural origin of coenzyme specificity in the short-chain dehydrogenase/reductase fam-
ily.  
Structure 4:33-45. 
Tanaka N, Nonaka T, Tanabe T, Yoshimoto T, Tsuru D and Mitsui Y (1996b)  
Crystal structures of the binary and ternary complexes of 7 alpha-hydroxysteroid dehydro-
genase from Escherichia coli.  
Biochemistry 35:7715-7730. 
Terada T, Sugihara Y, Nakamura K, Mizobuchi H and Maeda M (2003)  
Further characterization of Chinese hamster carbonyl reductases (CHCRs).  
Chem Biol Interact 143-144:373-381. 
Terada T, Sugihara Y, Nakamura K, Sato R, Sakuma S, Fujimoto Y, Fujita T, Inazu N and 
Maeda M (2001)  
Characterization of multiple Chinese hamster carbonyl reductases.  
Chem Biol Interact 130-132:847-861. 
Thibault ST, Singer MA, Miyazaki WY, Milash B, Dompe NA, Singh CM, Buchholz R, 
Demsky M, Fawcett R, Francis-Lang HL, Ryner L, Cheung LM, Chong A, Erickson C, Fisher 
WW, Greer K, Hartouni SR, Howie E, Jakkula L, Joo D, Killpack K, Laufer A, Mazzotta J, 
References 204 
Smith RD, Stevens LM, Stuber C, Tan LR, Ventura R, Woo A, Zakrajsek I, Zhao L, Chen F, 
Swimmer C, Kopczynski C, Duyk G, Winberg ML and Margolis J (2004)  
A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac.  
Nat Genet 36:283-287. 
Toffoli G, Simone F, Gigante M and Boiocchi M (1994)  
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in mul-
tidrug resistant LoVo cell lines.  
Biochem Pharmacol 48:1871-1881. 
Towbin H, Staehelin T and Gordon J (1979)  
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: proce-
dure and some applications.  
Proc Natl Acad Sci U S A 76:4350-4354. 
Tropschug M, Nicholson DW, Hartl FU, Kohler H, Pfanner N, Wachter E and Neupert W 
(1988)  
Cyclosporin A-binding protein (cyclophilin) of Neurospora crassa. One gene codes for both 
the cytosolic and mitochondrial forms.  
J Biol Chem 263:14433-14440. 
Tsigelny I and Baker ME (1995a)  
Structures important in mammalian 11 beta- and 17 beta-hydroxysteroid dehydrogenases.  
J Steroid Biochem Mol Biol 55:589-600. 
Tsigelny I and Baker ME (1995b)  
Structures stabilizing the dimer interface on human 11 beta-hydroxysteroid dehydrogenase 
types 1 and 2 and human 15-hydroxyprostaglandin dehydrogenase and their homologs.  
Biochem Biophys Res Commun 217:859-868. 
Tsumoto K, Umetsu M, Kumagai I, Ejima D and Arakawa T (2003)  
Solubilization of active green fluorescent protein from insoluble particles by guanidine and 
arginine.  
Biochem Biophys Res Commun 312:1383-1386. 
References 205 
Umetsu M, Tsumoto K, Nitta S, Adschiri T, Ejima D, Arakawa T and Kumagai I (2005)  
Nondenaturing solubilization of beta2 microglobulin from inclusion bodies by L-arginine.  
Biochem Biophys Res Commun 328:189-197. 
Upadhyaya P, Kenney PM, Hochalter JB, Wang M and Hecht SS (1999)  
Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enanti-
omers and metabolites in the A/J mouse.  
Carcinogenesis 20:1577-1582. 
Usami N, Ishikura S, Abe H, Nagano M, Uebuchi M, Kuniyasu A, Otagiri M, Nakayama H, 
Imamura Y and Hara A (2003)  
Cloning, expression and tissue distribution of a tetrameric form of pig carbonyl reductase.  
Chem Biol Interact 143-144:353-361. 
Valentino R, Tommaselli AP, Savastano S, Stewart PM, Ghiggi MR, Galletti F, Mariniello P, 
Lombardi G and Edwards CR (1995)  
Alcohol inhibits 11-beta-hydroxysteroid dehydrogenase activity in rat kidney and liver.  
Horm Res 43:176-180. 
Varughese KI, Skinner MM, Whiteley JM, Matthews DA and Xuong NH (1992)  
Crystal structure of rat liver dihydropteridine reductase.  
Proc Natl Acad Sci U S A 89:6080-6084. 
Wada M, Kataoka M, Kawabata H, Yasohara Y, Kizaki N, Hasegawa J and Shimizu S (1998)  
Purification and characterization of NADPH-dependent carbonyl reductase, involved in 
stereoselective reduction of ethyl 4-chloro-3-oxobutanoate, from Candida magnoliae.  
Biosci Biotechnol Biochem 62:280-285. 
Waksman SA (1961)  
The Actinomycetes.  
Williams and Wilkins Co, Baltimore. 
Watanabe K, Sugawara C, Ono A, Fukuzumi Y, Itakura S, Yamazaki M, Tashiro H, Osoe-
gawa K, Soeda E and Nomura T (1998)  
References 206 
Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human 
chromosome 21q22.2.  
Genomics 52:95-100. 
Wermuth B (1981)  
Purification and properties of an NADPH-dependent carbonyl reductase from human brain. 
Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.  
J Biol Chem 256:1206-1213. 
Wermuth B (1982)  
Human carbonyl reductases.  
Prog Clin Biol Res 114:261-274. 
Wermuth B (1985)  
Aldo-keto reductases.  
Prog Clin Biol Res 174:209-230. 
Wermuth B (1995)  
Expression of human and rat carbonyl reductase in E. coli. Comparison of the recombinant 
enzymes.  
Adv Exp Med Biol 372:203-209. 
Wermuth B, Bohren KM and Ernst E (1993)  
Autocatalytic modification of human carbonyl reductase by 2-oxocarboxylic acids.  
FEBS Lett 335:151-154. 
Wermuth B, Bohren KM, Heinemann G, von Wartburg JP and Gabbay KH (1988)  
Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid se-
quence of the encoded protein.  
J Biol Chem 263:16185-16188. 
Wermuth B, Burgisser H, Bohren K and von Wartburg JP (1982)  
Purification and characterization of human-brain aldose reductase.  
Eur J Biochem 127:279-284. 
References 207 
Wermuth B, Mader-Heinemann G and Ernst E (1995)  
Cloning and expression of carbonyl reductase from rat testis.  
Eur J Biochem 228:473-479. 
Wermuth B, Platts KL, Seidel A and Oesch F (1986)  
Carbonyl reductase provides the enzymatic basis of quinone detoxication in man.  
Biochem Pharmacol 35:1277-1282. 
Willems A, de Vos P and de Lay J (1992)  
The Prokaryotes, a Handbook on the Biology of Bacteria, Ecophysiology, Isolation, Identifi-
cation an Applications.  
Balows A, Trueper, H.G., Dworkin, M. ed)Springer Verlag, Berlin. 
Wilmot CM and Thornton JM (1988)  
Analysis and prediction of the different types of beta-turn in proteins.  
J Mol Biol 203:221-232. 
Winberg JO, Brendskag MK, Sylte I, Lindstad RI and McKinley-McKee JS (1999)  
The catalytic triad in Drosophila alcohol dehydrogenase: pH, temperature and molecular 
modeling studies.  
J Mol Biol 294:601-616. 
Wirth H and Wermuth B (1992)  
Immunohistochemical localization of carbonyl reductase in human tissues.  
J Histochem Cytochem 40:1857-1863. 
Wirth HP and Wermuth B (1985)  
Immunochemical characterization of aldo-keto reductases from human tissues.  
FEBS Lett 187:280-282. 
Wsol V, Kvasnickova E, Szotakova B and Hais IM (1996)  
High-performance liquid chromatographic assay for the separation and characterization of 
metabolites of the potential cytostatic drug oracine.  
J Chromatogr B Biomed Appl 681:169-175. 
References 208 
Wsol V, Skalova L, Szotakova B, Trejtnar F and Kvasnickova E (1999)  
Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.  
Chirality 11:505-509. 
Wsol V, Szotakova B, Kvasnickova E and Fell AF (1998)  
High-performance liquid chromatography study of stereospecific microsomal enzymes cata-
lysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.  
J Chromatogr A 797:197-201. 
Wsol V, Szotakova B, Skalova L, Cepkova H and Kvasnickova E (2000)  
The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver micro-
somes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-
dihydrooracin to oracin.  
Enantiomer 5:263-270. 
Wsol V, Szotakova B, Skalova L and Maser E (2003)  
Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse 
liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.  
Chem Biol Interact 143-144:459-468. 
Wsol V, Szotakova B, Skalova L and Maser E (2004)  
The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl 
reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.  
Toxicology 197:253-261. 
Xie Y and Wetlaufer DB (1996)  
Control of aggregation in protein refolding: the temperature-leap tactic.  
Protein Sci 5:517-523. 
Yamano S, Nakamoto N and Toki S (1999)  
Purification and characterization of rat liver naloxone reductase that is identical to 3alpha-
hydroxysteroid dehydrogenase.  
Xenobiotica 29:917-930. 
Yesair DW, Thayer PS, McNitt S and Teague K (1980)  
References 209 
Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro 
and in vivo.  
Eur J Cancer 16:901-907. 
Yokota H, Yuasa A and Sato R (1992)  
Topological disposition of UDP-glucuronyltransferase in rat liver microsomes.  
J Biochem (Tokyo) 112:192-196. 
Yum DY, Lee BY and Pan JG (1999a)  
Identification of the yqhE and yafB genes encoding two 2, 5-diketo-D-gluconate reductases in 
Escherichia coli.  
Appl Environ Microbiol 65:3341-3346. 
Yum MK, Kim NS, Oh JW, Kim CR, Lee JW, Kim SK, Noh CI, Choi JY and Yun YS 
(1999b)  
Non-linear cardiac dynamics and morning dip: an unsound circadian rhythm.  
Clin Physiol 19:56-67. 
Zelinski T, Peters J and Kula MR (1994)  
Purification and characterization of a novel carbonyl reductase isolated from Rhodococcus 
erythropolis.  
J Biotechnol 33:283-292. 
 
 
 
Figures/Tables 210 
IX Figure/Table List: 
Part I: 
 
Fig. I-1: Multiplicity of enzymes involved in carbonyl reduction ............................................. 8 
Table II-1: Features of the five families within the SDR superfamily according to 
Persson and coworkers (Kallberg et al., 2002b; Persson et al., 2003). ................... 16 
Fig. II-1: Multiple sequence alignments of some well-known members of the SDR 
superfamily .............................................................................................................. 18 
Fig. II-2: Folding topology of 3α-HSD/CR from C. testosteroni. ........................................... 19 
Fig. II-3: Reaction mechanism and catalytic triade exemplified by 3α/20β-HSD from S. 
hydrogenans............................................................................................................. 20 
Fig. II-4: Typical Rossmann fold of SDR enzymes exemplified by 3α-HSD/CR from C. 
testosteroni............................................................................................................... 25 
Fig. III-1: Evolutionary tree of carbonyl-reducing enzymes from different species ............... 28 
Fig. III-2: In vivo reaction of 11-HSD 1 and 11-HSD 2 ...................................................... 43 
Fig. IV-1: Biosynthetic pathways from 6-pyruvoyltetrahydropterin (PPH4) to 
tetrahydrobiopterin (BH4) ....................................................................................... 50 
Fig. IV-2: Scheme on the metabolic inactivation of the lipid peroxidation product 4-
oxonon-2-enal . ........................................................................................................ 52 
Fig. IV-3: Role of 11β-HSD1 and CBR1 in quinone detoxification........................................ 55 
Table IV-1: Multiplicity of carbonyl substrates....................................................................... 57 
Fig. IV-4: Scheme of daunorubicin carbonyl reduction........................................................... 59 
Fig. IV-5: The metabolic activation and inactivation of  4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK)..................................................................................... 63 
 
Part II: 
 
 
Fig. I-1: Typical Rossmann fold of SDR enzymes exemplified by 3α-HSD/CR from C. 
testosteroni............................................................................................................... 75 
Fig. III-1: ELISA for detection of 3α-HSD/CR during overexpression................................. 111 
Table III-1: Refolding screen of denatured protein................................................................ 113 
Fig. III-2: PEG-concentration of renaturation solution.......................................................... 114 
Fig. IV-1: Overview of oligomerization behaviour of SDR enzymes ................................... 120 
Figures/Tables 211 
Fig. IV-2: Structural alignment of 4 members of the SDR superfamily ................................ 121 
Fig. IV-3: Structural alignment of the SDR enzymes 3-HSD/CR, 3/20-HSD and 
ADH....................................................................................................................... 123 
Fig. IV-4: Structural elements involved in folding topology as in 3α-HSD/CR from C. 
testosteroni............................................................................................................. 127 
Fig. IV-5: „extraloop“-domain in 3-HSD/CR blocks the formation of a tetramer .............. 130 
Fig. IV-6: Overview of mutagenesis approach ...................................................................... 132 
Fig. IV-7: Structural alignment for modelling of SBL........................................................... 134 
Fig. IV-8: Overlay of the 3 models of 3α-HSD/CR-tr ........................................................... 135 
Fig. IV-9: Structural alignment for modelling of extraloop-region ....................................... 136 
Fig. IV-10: Periodic boundary conditions.............................................................................. 137 
Fig. IV-11: End-conformation of the three models of 3α-HSD/CR wildtype after MD 
simulation .............................................................................................................. 138 
Fig. IV-12: Comparative simulation of 3α-HSD/CR-wildtype protein ................................. 139 
Fig. IV-13: Positions of the most flexible residues in the simulated WT-structure with 
the modelled SBL-loop.......................................................................................... 141 
Fig. IV-14: Start and end conformation of the inserted loop and the catalytic residues in 
3-HSD/CR-tr, model 1 ........................................................................................ 141 
Fig. IV-15: PCR-strategy for substitution of the extraloop-domain (Overlap-Extension-
PCR) ...................................................................................................................... 143 
Fig. IV-16: Distribution and protein concentration of truncated 3α-HSD/CR....................... 145 
Table IV-1: Protein concentration of 3α-HSd/CR-tr after different steps during protein 
overexpression ....................................................................................................... 146 
Fig. IV-17: Overexpression of 3-HSD/CR-tr ...................................................................... 148 
Table IV-2: Overview on tested samples for HPLC activity testing...................................... 150 
Fig. IV-18: HPLC chromatograms of  activity testing........................................................... 151 
 
 
 
 
 
 
Die vorliegende Arbeit wurde auf Anregung von Herrn Prof. Dr. E. Maser am 
Institut für Pharmakologie und Toxikologie Fachbereichs Medizin der 
Philipps-Universität Marburg in der Zeit von April 2001 bis Juni 2006 
durchgeführt. 
 
Mein herzlicher Dank gilt: 
 Herrn Prof. Dr. E. Maser für die interessante Aufgabenstellung, jegliche 
Freiheit beim Entwickeln neuer Ideen sowie konstruktiven 
Diskussionen, die immer neu Begeisterung wecken und motivieren 
konnten 
 Herrn Prof. Dr. G. Klebe für die Möglichkeit, in seinem Arbeitskreis die 
Modellierungen und Simulationen durchführen zu können sowie alle 
Möglichkeiten des Kristall-Labores uneingeschränkt nutzen zu können. 
 Frau Prof. Dr. M. Löffler sowie Herrn Prof. Dr. K. H. Röhm für die 
Möglichkeit, einen Großteil der molekularbiologischen Arbeit in ihrem 
Labor durchzuführen, für die herzliche Aufnahme und das tolle 
Arbeitsklima 
 Herrn Prof. Dr. Christoph Sotriffer für seine umfassende Hilfe bei den 
Molekular-Dynamik Simulationen, seine vielen Tipps sowie die sehr 
angenehme Zusammenarbeit 
 Herrn Christian Sohn für seine Hilfe bei unzähligen 
Kristallisationsansätzen und seine endlose Geduld.  
 Dem gesamten Arbeitskreis Prof. Maser für die tolle Zusammenarbeit, 
die angenehme Atmosphäre sowie die vielen  konstruktiven 
Diskussionen 
 Herrn Dr. Guangming Xiong für seine Hilfe bei der Herstellung der 
Mutanten und seine nicht enden wollende Fülle von Tipps und Tricks, 
die ein drohendes Scheitern des Ansatzes immer wieder verhinderten 
 Dr. Kurt M. Bohren, Houston USA, für die Bereitstellung von 
Carbonyl-Reduktase Kristallen 
 Herrn Prof. Dr. R. Rudolph am Institut für Biotechnologie der Martin-
Luther-Universität Halle-Wittenberg für die Unterstützung bei den 
Experimenten zur Rückfaltung von Proteinen  
 Dem Graduiertenkolleg „Proteinfunktion auf atomarer Ebene“ der 
DFG für die finanzielle Unterstützung  
 Meiner Frau Frauke für ihre unerschöpfliche Toleranz, Geduld und 
immer neue Motivation und Ermunterung! 
 
 
 
 
 
 
Erklärung 
 
 
 
Ich versichere, dass ich meine Dissertation 
 
„Carbonyl Reductases and Pluripotent Hydroxysteroid Dehydrogenases of the Short-
Chain Dehydrogenase/Reductase Superfamily:  
Structural aspects of oligomerization in 3-Hydroxysteroid dehydrogenase /carbonyl 
reductase from Comamonas testosteroni: New approaches for efficient protein design” 
 
selbständig ohne unerlaubte Hilfe angefertigt und mich dabei keiner anderen 
als der von mir ausdrücklich bezeichneten Quellen bedient habe. 
 
Die Dissertation wurde in der jetzigen oder einer ähnlichen Form noch bei 
keiner anderen Hochschule eingereicht und hat noch keinen sonstigen 
Prüfungszwecken gedient. 
 
 
 
 
Aachen, im April 2009 
Frank Hoffmann 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lebenslauf 
 
Geburtstag: 20. August 1973   
 
Geburtsort: Siegen 
 
August 1984 – Juni 1993 Fürst Johann Moritz Gymnasium Siegen 
Abschluss: Allgemeine Hochschulreife 
  
Oktober 1994 – April 
1999 
Studium der Biologie an der Philipps-Universität 
Marburg 
Schwerpunkte: Molekulargenetik molekulare 
Entwicklungsbiologie, Immunologie 
Abschluss: „sehr gut“ 
 
Mai 1999 – Mai 2000 Diplomarbeit bei Prof. Dr. R. Renkawitz-Pohl  in 
molekularer Entwicklungsbiologie, Abschluss: 
„sehr gut“ 
 
Juni 2000 – März 2001 Forschungspraktikum Prof. Dr. Gerhard Klebe, 
Institut für Pharmazeutische Chemie, Philipps-
Universität Marburg  
Schwerpunkt: „Wirkstoffdesign“ und „Molecular 
Modeling“  
 
04/2001 – Juli 2006 Promotion bei Prof. Dr. E. Maser, Pharmakologie 
und Toxikologie, Marburg 
„Carbonyl Reductases and Pluripotent Hydroxysteroid 
Dehydrogenases of the Short-Chain 
Dehydrogenase/Reductase Superfamily:  
Structural Aspects of Oligomerization in 3-
Hydroxysteroid Dehydrogenase /Carbonyl Reductase 
from Comamonas testosteroni: New Approaches for 
efficient Protein Design” 
 
August 2006 – heute  Tätigkeit als „Regulatory Affairs Manager“, 
Grünenthal GmbH, Aachen 
  
 
 
    
   
